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Abstract 
 
 
Colorectal cancer is the second most common cancer in women and third in men, 
accounting for 9.7 % of all cancers incidence globally, with about 814,000 cases in men 
and 664,000 cases in women. Colorectal cancer is a disease of ageing where more than 
90% occurs in individuals at least 50 years old. For instance, the incidence is 50 times 
greater in sixty to eighty year olds than in forty year olds or younger. From 1997 to 
2004, overall incidence and death due to colorectal cancer decreased by 2.6% and 4.7% 
respectively. Adjuvant chemotherapy and radiotherapy remain cornerstones in the 
management of colorectal cancer, in terms of disease-free survival and overall survival 
benefit.  
Oxaliplatin is a platinum-based anticancer drug used typically in combination with 
folinic acid and 5-fluorouracil in the treatment against colorectal cancer. However, 
numerous side effects such as nausea and vomiting, gastrointestinal toxicity, anaemia, 
immunodeficiency, ototoxicity, nephrotoxicity, and neurotoxicity are associated with 
concurrent uses of oxaliplatin. The side effects can be decreased by lowering the dose 
of oxaliplatin. Phytochemicals that can act as antioxidants have been used by people in 
treatment against cancer throughout human history because of their low toxicity and the 
ease in availability. Besides providing protection against cancer, they are also found to 
kill cancer cells. From numerous in vitro and in vivo preclinical studies, it is now 
established fact that chemopreventive agents could boost the activity of anticancer 
drugs and thus improve treatment outcome. In this study, four phytochemicals 
resveratrol, thymoquinone, capsaicin and quercetin were applied to four human 
colorectal cancer cell lines HT-29, Caco-2, Lim-1215 and Lim-2405 in combination 
with two platinum drugs cisplatin and oxaliplatin using three sequences of 
 XII 
administration (0/0 h, 0/4 h and 4/0 h). The activity of the compounds alone and in 
combination were determined using MTT reduction assay. Combination index was used 
as a measure of combined drug action. Studies on cellular accumulation, 
platinumDNA binding, DNA damage and proteomics were carried out to obtain 
mechanistic insights. 
 
The results show that in HT-29 cell line all sequences of administration produced 
antagonism at lower concentration (ED50). In Caco-2 cell line, bolus combination of 
cisplatin with resveratrol is found to produce moderate synergistic effect at all 
concentrations. In Lim-2405 cell line, combination of cisplatin with quercetin was 
found to produce  most synergistic outcome. As applied to oxaliplatin, its combination 
with quercetin was found to produce most synergistic outcomes in Caco-2 cell line. 
Combination of oxaliplatin and capsaicin was most synergistic in Lim-2405 cell line.  
 
Results on PtDNA binding showed that synergistic effect was associated with higher 
platinumDNA binding. DNA-damage study did not provide any clarity. In proteomics 
study, at least 16 proteins belonging to different functional groupings were found to 
undergo changes in expression as a result of treatment with synergistic combinations. 
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Chapter One 
 
1  Introduction 
 
1.1 Overview of Cancer  
 
Cancer is the most dreaded disease of recent time all over the world. It was detected first in the 
skulls and bones of Egyptian and Peruvian mummies embalmed as far back as 3000 BC 
(Dehghani et al., 2015). The word ‘cancer’ is used to represent a group of diseases that occur 
when abnormal cells multiply in an uncontrolled way and invade the surrounding tissues 
causing further damage (Sarkar, 2015). It is induced by DNA mutations that may be the result 
of exposure to or ingestion of carcinogenic substances and environmental mutagens (Dehghani 
et al., 2015). The World Health Organisation has stated that cancer causes more deaths than 
coronary heart diseases and stroke (Ferlay et al., 2015).  
To date 200 different types of cancer have been identified, but this study will focus on 
colorectal cancer (CRC). CRC kills almost 700,000 people each year making it the world’s 
fourth most deadly cancer (Brody, 2015). In Australia, cancer represents a greater burden of 
incidence with CRC making up 12.9% of all new cases in both sexes (Young et al., 2015). It is 
also second in order in regard to incidence after prostate cancer, and is  the second leading 
cause of mortality after lung cancers (Young et al., 2015). A brief description of the status, 
epidemiology and treatment of CRC; and of the roles of tumour active platinum and plant 
derived compounds on treatment, are given in this chapter. 
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1.2 Types of Cancer 
 
There are many kinds of cancer, but all originate from the transformation of normal cells and 
can be broadly classified into three categories: carcinoma, sarcoma and leukaemia/lymphoma 
(Young et al., 2015).  
Carcinoma: This cancer arises in skin, the lining of the internal organs and glands. 
Approximately ninety percent of cancer belongs to this group. Carcinoma can metastasise 
(spreading to other organs) either through the bloodstream or the lymphatic fluid. This includes 
the mouth, skin, nose, lungs, gastrointestinal tract, throat, and glands, (for instance, thyroid and 
breasts).  
Sarcoma: This is a cancer of connective tissues such as muscle and bone, and is rare in humans. 
Sarcoma can be formed in surrounding tissues, including the liver, kidneys, bladder, spleen and 
lungs (Alschuler and Gazella, 2012). 
Leukaemia: This type of cancer arises from blood forming cells and bone marrow. Leukaemia 
is not a solid tumour but, replaces healthy white blood cells with the abnormal white blood 
cells that circulate through the blood stream. It constitutes eight percent of human cancer 
(Cooper, 1993). 
Lymphoma: This type of cancer is found in the nodes and glands of the lymphatic system. 
Lymph nodes act as a filtering medium for the body system, removing impurities and toxins. 
Lymphoma present as solid tumours resulting from abnormal white blood cells. The most 
common forms of lymphomatic cancer are Hodgkin’s and non-Hodgkin’s lymphoma.  
Myeloma: This type of tumour usually originates in the plasma cells, and is rare (Alschuler and 
Gazella, 2012). In view of its metastatic potential, there are two categorisations of this cancer; 
adenomas or benign tumours, where neoplastic development stays clustered like a single mass; 
and adenocarcinoma or malignant tumours, when a tumour shows invasiveness and metastasis 
(Ravindran et al., 2009). 
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1.3 Epidemiology of Cancer 
 
The epidemiology of cancer involves looking at cancer trends in a given population and current 
interventions available (Cameron and Roder, 2014). In Australia, over 120,700 new cases of 
cancer were identified in 2014, mainly prostate, breast, bowel and female lung cancers 
(Cameron and Roder, 2014). This growth has a linear correlation with increasing rates of risk 
factors such as being overweight, having sedentary lifestyle and having poor socioeconomic 
status (Cameron and Roder, 2014).  
Furthermore, cancer is one of the major public health issues globally and is considered as the 
second leading causes of mortality. The International Agency for Research on Cancer (IARC) 
reported that the burden and incidence of cancer are expected to rise rapidly ,specifically in 
low/middle-income countries (Torre et al., 2016).  
According to GLOBOCAN, 14.1 million people were diagnosed with cancer and 8.2 million 
deaths due to cancer occurred in 2012. By 2025 it is expected that more than 20 million people 
will be diagnosed with this chronic disease (Alam and Sharaf-Eldin, 2016). In developed 
countries, the percentage of new cases is expected to increase from 56% in 2008 up to more 
than 60% in 2030 (Jemal et al., 2010). The most common cancer in term of death is lung cancer 
(19.4%, 1.6 million deaths) and 12.9%, 1.8 million new cases), followed by breast cancer, 
which accounts for 1.7 million cases. Third is colorectal cancer followed by prostate cancer, 
stomach cancer and liver cancer (figure1.1, below) (Ferlay et al., 2015).  At present over 60% 
of all cancer cases occur in Asia, Central and South America and Africa (Stewart and Wild, 
2016). 
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Figure 1.1Numbers of Estimated new cases for both developed and less developed countries 
worldwide, 2012. (Ferlay et al., 2015). 
1.4 Hallmarks of Cancer  
 
Although each type of cancer is unique and exhibits a definite set of behaviours and growth 
characteristics, all cancers share a group of common characteristics that are known as 
‘hallmarks’. Hanahan and Weinberg described six hallmarks of cancer: sustained proliferation 
in signalling, evasion of growth suppressors, resistance to cell death, immortality in replication, 
induction of angiogenesis, and activation of invasion and metastasis (Hanahan and Weinberg, 
2011, Menyhárt et al., 2016). 
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Expansion of cancer cell populations is determined not only by the rate of cell proliferation but 
also by the rate of cell death. Apoptosis is the main cause of cell death, and so  agents that 
induce apoptosis, could be the most promising candidate for  treatment against cancer 
(Ravindran et al., 2009). The following subsections will discuss cell proliferation/death and 
other significant features of cancer such as cell cycles, oxidative stress, and cellular 
detoxification.  
1.4.1Cell proliferation and cell death  
 
Human body is composed of about 1014 cells and about 1012 cells die or are shed in the normal 
course of each day and must be replaced to sustain life. Cell proliferation is the process by 
which cells grow and divide to substitute lost cells. This is a highly regulated activity in normal 
process so that the total number of cells composing all organs and tissues in the body remains 
essentially unchanged (Blows, 2006, Pollock and Doroshow, 2004). 
Most normal cells cease their proliferation during the adulthood of human being and do not 
proliferate until they are stimulated to divide to replenish dead cells. Loss in control of 
regulation of the cell cycle may lead to excess proliferation of cells and consequently results 
into abnormal cell numbers. Cancer cells originate from a single that has abnormal regulation; 
when it divides, the abnormal regulation is carried on to the daughter cells, and again to the 
progenitors and so on (Kearney and Richardson, 2006, Nevitijon and Sowers, 2000).  
1.4.1.1 Cell cycle and cancer 
 
A series of stages through which eukaryotic cells actively divide into daughter cells, is 
collectively called the cell cycle. It consists of two gap phases (G1 and G2); one synthesis 
phase(S) in which the genetic material is doubled; and one mitotic phase (M), in which mitosis 
reorganises the genetic material and the cell divides (Cooper, 2000). Figure 1.2 pictorially 
describes the outlook of this highly regulated process.  
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Figure 1.2: Different phases of cell cycle in eukaryotes 
 
The cell cycle has some ‘check points’ at which the cell stops progression through the cycle 
until it can be assured that an earlier process such as DNA replication or mitosis, is 
accomplished (Hartwell and Weinert, 1989). These checkpoints appear close to the end of G1, 
at the transition of G2/M, and during metaphase.  
The G1 checkpoint controls whether all settings are favourable for cell division to proceed and 
checks the suitability of eukaryotic cells to transition from the G1 phase to enter into S phase 
(DNA synthesis). Cell size, nutrients, growth factors and DNA damage are checked at this 
point (Bartek et al., 1996).  
At the G2 checkpoint, cell size and DNA replication are checked to allow for the repair of any 
breaks in the DNA. This checkpoint inhibits the progression of mitosis until DNA replication 
is completed. Arrest in the cell cycle is caused by the P53 protein (a tumor suppressor gene) in 
the G1 and G2 phases (Passalaris et al., 1999). If the damage to the genome is extensive and 
cannot be repaired, P 53 can also activate genes that code for apoptosis, or cell death. 
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Last is the assembly checkpoint, which checks for chromosome attachment to the spindle. In 
order for chromosome separation to take place all the chromosomes need to be attached by 
kinetochore microtubules of both polar ends of the cell and optimum tension must be placed 
on the kinetochore pairs to ensure equal and appropriate chromosome segregation. The 
checkpoint controls senses when the mitotic spindle undergoes inappropriate assembly and 
then prevents the activation of the APC polyubiquitination system (Skaar and Pagano, 2009). 
This system normally leads to the progression of the anaphase (Steuerwald et al., 2001). 
Cyclin dependent kinase (CDK) complexes like CDK4/6-Cyclin D and CDK2-Cyclin E, act 
together to release inhibition of a dynamic transcription complex that contains the 
retinoblastoma protein (Rb) and E2F. Protein kinase-B/Akt phosphorylate forkhead box 
protein (FoxO1/3) thereby allow cell survival and proliferation in presence of growth factors. 
A variety of stimuli activate checkpoint control, including transforming growth factor beta 
(TGF-β), replicative senescence, DNA damage, and growth factor withdrawal. These stimuli 
act through transcription factors to induce particular members of the Kip/Cip or INK4 families 
of CDK inhibitors (Besson et al., 2008).  
Abnormalities in cell cycle checkpoint control may cause freedom of growth regulating signals. 
Common reasons for the onset of cancer include either the aberrant expression of cyclins, or 
the downregulation of CKIs (Funk, 2006). Cyclin D1/CKD4/6 complexes are considered as 
therapeutic targets for developing new anticancer drugs because of the invariant deregulation 
of this checkpoint  in human tumours (Musgrove et al., 2011).  
1.4.1.2 Cell death and cancer 
 
Programmed cell death maintains an equilibrium between growth and death of normal cells 
and can be categorised as apoptosis, autophagy and programmed necrosis. Apoptotic cell death 
is seen to have characteristics such as shrinkage, fragmentation, condensation and, membrane 
blebbing and adhesion loss (extracellular matrix) (Nishida et al., 2008). Figure 1.3 provides a 
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schematic of the extrinsic and intrinsic pathways of apoptosis. Autophagy is an evolutionarily 
preserved catabolism which starts with the production of autophagosomes, double membrane-
bound structures surrounding cytoplasmic macromolecules and organelles, destined for 
recycling (Liu et al., 2011). The literature suggests that autophagic cells usually commit suicide 
by inducing cell death and thus coping with excessive stress,  which is different from apoptosis 
and programmed cell death (Eisenberg-Lerner et al., 2009). Necrosis involves cell swelling 
followed by organelle dysfunction and cell lysis (Leist and Jäättelä, 2001). This is how 
programmed cell death play vital role in maintaining homoeostasis and eliminating impaired 
cells, which has a great impact on malignant tissues (Bialik et al., 2010). 
In the 1970s, Kerr et al. related apoptosis to elimination of cancerous cells, hyperplasia and 
progression of tumour (Kerr et al., 1972). Later, resistance to programmed cell death was found 
to play vital role in carcinogenesis. The mechanisms by which evasion of apoptosis occurs are 
related to disruption of equilibrium between pro- and anti-apoptotic proteins, reduction in 
caspase function and impairment in death receptor signalling. Every deficiency in apoptotic 
signalling pathways can be a target for cancer treatment. Compounds which restore the 
apoptotic cell death towards normality have the potential to kill malignant cells which depend 
on these defects to stay alive. Recent discoveries throughout the globe have opened new 
horizon into potential new classes of anticancer agents (Wong, 2011). 
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Figure 1.3: Mechanism of apoptotic cell death (Haupt et al., 2003) 
Oblimersen sodium, sodium butyrate, depsipetide, fenretinide, flavipirodol, gossypol, HA14-1 
, ABT-737, GX15-070, ABT-263,  and BH3 mimetics are the examples of drugs that target  the 
Bcl-2 family of proteins (Abou-Nassar and Brown, 2010, Kang and Reynolds, 2009, Oltersdorf 
et al., 2005, Albershardt et al., 2011). CP-31398, nutlins and Phikan083 have been investigated 
to target P53 (Boeckler et al., 2008, Rippin et al., 2002, Shangary and Wang, 2009). 
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1.4.2Cancer and Oxidative Stress 
 
Life without oxygen is impossible, and it is indispensable for the production of energy in the 
mitochondria of eukaryotic cells during respiration. Most of the oxidative metabolic products, 
reactive oxygen species (ROS), are beneficial; but can be destructive as well when 
concentration increases (Sosa et al., 2013). Favourable effects of ROS involve physiological 
roles in defence mechanisms against infectious agents, the induction of mitogenic responses 
and functioningin a number of cellular signalling systems(Valko et al., 2006). At high 
concentrations of ROS, homeostatic balance between prooxidant and antioxidant gets disturbed 
and this impairment is called ‘oxidative stress’ that causes damage to various cellular 
components including cell mebrane, proteins and nucleic acids (Poli et al., 2004). Although the 
antioxidant defence system counteracts oxidative damage from ROS, oxidative stress plays a 
vital role in the progress of age-dependent diseases including cancer, arteriosclerosis, 
rheumatoid arthritis, neurological disorders and other conditions (Halliwell and Gutteridge, 
2015). 
Mechanisms through which oxidative stress promotes tumour development can be classified 
into four biological processes : (i) cellular proliferation (e.g. extracellular-regulated kinase 1/2 
(ERK1/2) activation and ligand independent RTK activation), (ii) evasion of apoptosis (e.g., 
Src, NF-κB and phosphatidylinositol-3 kinase (PI3K)/Akt activation), (iii) tissue invasion and 
metastasis (e.g., metalloproteinase (MMP) secretion into the extracellular matrix (ECM), Met 
overexpression, and Rho-Rac interaction; and (iv) angiogenesis (e.g., the release of vascular 
endothelial growth factor (VEGF) and angiopoietin) (Sosa et al., 2013). 
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1.5 Colorectal Cancer 
 
Colorectal cancer (CRC) is a multifactorial disease that occurs in the rectum and colon. The 
colon has four parts (ascending, descending, sigmoid and the transverse colon) but the most 
CRC arises in the sigmoid colon. CRC is the second most common cancer in women and the 
third in men, accounting for 9.7 % of all cancers incidents globally, with around 814,000 cases 
in men and 664,000 cases in women (Aran et al., 2016b). CRC is a disease of ageing; more 
than 90% cases occur in individuals 50 years or older, and the incidence is 50 times greater in 
60- to 79-year-olds than in people younger than 40.5 From 1997 to 2004, the overall incidence 
decreased by 2.6% and death by 4.7% (Espey et al., 2007). 
1.5.1 Stages of CRC 
 
One of the most important factors in deciding on a treatment strategy for CRC is identifying 
the stage of the cancer. British pathologist Cuthbert Dukes classified colorectal cancer staging 
in 1932, on the basis of anatomical features. He divided CRC by the the extent of the tumour’s 
spread, with Group A standing for CRC growth is to the rectum wall only; Group B for the 
invasion of the CRC into the wall of the bowel but no lymphatic metastases, and Group C for 
metastasised CRC  involving lymph nodes (Dukes, 1932). Later the American Joint Committee 
on Cancer (AJCC) introduced the TNM system, based on three key pieces of information : 
growth of the primary tumour (T), its spread to regional lymph nodes (N); and its 
metastasisation to other organs of the body (M). Numbers or letters after T, N, or M indicate 
more detailed information about each of these factors (O’Connell et al., 2004).the seventh 
edition of the staging for colon cancer (Table 1.1) was published by AJCC in 2010 and is now 
adopted by the clinicians throughout the world (Labianca et al., 2010).  
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Table 1.1: Staging of colorectal cancer (Arena and Bilchik, 2013) 
 
1.5.2 Aetiology of CRC 
 
Although there is no specific cause for CRC, various factors are found to be associated with 
the prevalence of colorectal cancer. The major risk factors include age, sex, heredity, lifestyle, 
alcohol, smoking, diabetes, physical activity, obesity and bowel diseases (Aran et al., 2016a). 
Some of these factors are described in the following sections. 
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1.5.2.1 Age  
 
Although colorectal cancer may occur at any age, the possibility of having the disease may 
markedly increases in older age (Wei et al., 2017). Approximately 90 percent of all colorectal 
cancers occur in people fifty years or older of age. The incidence of CRC in people aged  60 - 
79 years is 50% higher than those of age group below 40 years (Haggar and Boushey, 2009).  
However, recently in young people, there has been a significant increase in colorectal cancer 
(Karanikas and Esebidis, 2016). 
1.5.2.2   Gender 
The incidence rate of CRC is higher in men  than  in women, but the survival rate is higher in 
women than in men in many countries (Oberoi, 2014). This may be due to the protecting effect 
of endogenous female sex hormones (Majek et al., 2013). 
1.5.2.2  Heridity 
 
Almost 30% percent of patients with CRC have a family history of the disese, and around 5% 
of cases are associated with inherited mutations in cancer predisposing genes (Brosens et al., 
2015). Lynch syndrome, or hereditary nonpolyposis colorectal cancer (HNPCC), is an 
autosomal, dominant, inherited syndrome, occurring in colorectal cancer that accounts for 
around 3 to 4 % of the all CRC (Lynch and Shaw, 2013). The most important genes that cause 
mutations in DNA mismatch repair (MMR) are mutL homolog 1 (MLH1) positioned on 
chromosome 3p21.3; mutS homolog 2 (MSH2) ; postmeiotic mutS homolog 6 (MSH6); mutL 
homolog 3 (MLH3) positioned on chromosome 2p21, postmeiotic segregation increased 1 
(PMS1); and segregation increased 2 (PMS2) located on chromosome 7p22(Lynch and Shaw, 
2013, Silva et al., 2009). However among these mutations around 90% of LS syndrome 
mutation is due to Germline aberrations in MSH2 and MLH1 genes. (Calvert and Frucht, 2002).  
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Familial adenomatous polyposis (FAP) is another autosomal, dominant, inherited disorder that 
results from germline mutation of the APC (adenomatous polyposis coli) gene, and accounts 
for 1% of total CRC cases. Unless treated, the lifetime risk of CRC in FAP is nearly 100% 
(Dalavi et al., 2015).  Another gene which discovered recently, called MUTYH gene, also plays 
a significant role in increasing colonic adenomatous polyposis(Vasen et al., 2008). Figure 1.4 
describes the common phenotypes and genotype involved in the heredity of colorectal cancer. 
 
Figure 1.4: Phenotypes and genotypes in CRC [adapted from (Lynch and Shaw, 2013)] 
 
1.5.2.3 Smoking 
 
Various studies have found that smoking increases the incidence of colorectal cancer by 20% 
to 60% (Hannan et al., 2009, Drew et al., 2016). The mortality rate of CRC has been found to 
increase with active smoking (Hou et al., 2014). The mechanism described  is that carcinogens 
from tobacco reach the mucosa of the colorectal through the circulatory system, and may lead 
to the altering or damage expression of cancer-related genes (Giovannucci, 2001).  
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1.5.2.4 Consumption of alcohol 
 
Numerous studies have revealed a linear dose-dependent relationship between alcohol intake 
and CRC(Klarich et al., 2015). Recent meta-analysis shows that alcohol drinking has a direct 
association with increased mortality in CRC (Cai et al., 2014). Infact, the oxidized 
metabolites of alcohol acetaldehyde act as carcinogens after the consumption of alcohol. 
Alcohol is converted to acetaldehyde by alcohol dehydrogenase (ADH) in the liver, then is 
rapidly oxidized to acetate by aldehyde dehydrogenase (ALDH) enzymes (Bongaerts et al., 
2011).  
1.5.2.6 Inflammatory bowel disease (IBD) 
People suffering from inflammatory bowel disease (either Crohn’s disease or/and ulcerative 
colitis) have an increased risk of developing CRC (Burr et al., 2017). The positive correlation 
between IBD and CRC was suggested in the 1920s and later supported by epidemiologic 
studies (Adami et al., 2016). The link between IBD and CRC is not due to common risk factors, 
but rather from chronic inflammation and other mechanisms that encourage malignant 
transformation in the  mucosa of the colon (Adami et al., 2016).  
1.5.2.5 Diet and obesity  
 
It is evident that western dietary patterns (more red meat, less fiber and vegetables) are 
associated with an increased risk of CRC compared to a prudent diet (rich in fruits and 
vegetables), as has been found in systematic reviews and meta-analysis (Magalhães et al., 2012, 
Mehta et al., 2017). Nutrition and diet are estimated to explain  30%–50% of the incidence of 
colorectal cancer globally (Vargas and Thompson, 2012). The fiber present in food usually acts 
to protect against CRC by increasing the bulk and transit rate, which leads to minimising 
carcinogen exposure in the diet. A fiber rich diet also gives protection against CRC by 
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modifying the excretion of faecal bile salt, reducing colon pH and adsorbing carcinogens 
(Hague et al., 1996).  
The incidence of CRC rises upwards with increased body mass index (Font-Burgada et al., 
2016). Obese people are more (7-60 % greater) prone to suffer from CRC than non-obese 
people (Nakajima et al., 2010). Meta-analysis also shows a 5% increase in CRC incidence per 
inch of above-normal waist circumference (Wiseman, 2008). Insulin is known to be the main 
biochemical mediator between colon cancer and obesity. There is strong evidence from human 
and animal studies that cancer incidence is promoted by excessive concentrations of insulin as 
well as by insulin like growth factors (IGFs) acting through the insulin/IGF axis (Bardou et al., 
2013). 
1.6  Management of Colorectal Cancer  
 
1.6.1Diagnosis of Colorectal Cancer 
 
Colorectal cancer is charaterized by changes in bowel habit, such as diarrhoea, constipation or 
abnormal consistency in the stool, blood in the stool, or abdominal cramps. Usually CRC is 
diagnosed through colonoscopy, sigmoidoscopy, double contrast barium enema, or both lower 
endoscopy and barium enema(Vega et al., 2015). The gold standard diagnostic tool for 
suspected colorectal cancer is colonoscopy, which has shown better sensitivity and specificity 
than barium enema (Leslie and Steele, 2002). Colonoscopy allows the physician to look inside 
the entire rectum and colon while the patient is asleep. If colorectal cancer is found, a complete 
diagnosis is followed by complete blood count, biopsy,  molecular testing of the  tumour, 
computed tomography, ultrasound, chest x-ray and positron emission tomography.  
1.6.2Treatment of colorectal cancer 
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The first therapeutic approach for treatment of colon cancer is surgery (Viswanath et al., 2016), 
but adjuvant chemotherapy and radiotherapy are cornerstones in the management of colorectal 
cancer, in terms of disease-free survival and overall survival benefit (Labianca et al., 1997). 
Standard adjuvant chemotherapy is represented by fluorouracil plus levamisole and/or calcium 
folinate (folinic acid). In many instances oxaliplatin is also used to treat patients (Wolpin and 
Mayer, 2008). Other strategies are represented by monoclonal antibodies (mAb), and by portal 
vein fluorouracil, alone or in combination with systemic therapy (Viswanath et al., 2016). In 
rectal cancer, the best results have been obtained with a combination of radiotherapy and 
chemotherapy. 
1.7   Chemotherapeutic Drugs Used in 
Colorectal Cancer 
 
Treatment of cancer using an anticancer agent or with a combination of such agents into a 
standardized treatment regimen is known as chemotherapy. Contrasting to surgery and 
radiation which act in the vicinity, chemotherapy acts through the system by targeting cancer 
cells wherever they have metastasised. For metastasised cancer, chemotherapy is still the main 
treatment in advanced stages (Kerr et al., 2016). Chemotherapy is usually included into cancer 
treatment regimen in combination with surgery or radiation or both, based on the stage and 
recurrence of cancer. Depending on the dose,the nature of the drugs and the patient's condition, 
chemotherapy may comprise  a single drug or be used in combination with others via 
intraperitoneal, intravenous and oral administration.  
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1.7.15-fluorouracil (5-FU) 
 
5-fluorouracil (Figure 1.5) is a prodrug that becomes active after cellular metabolism and 
inhibits thymidylate synthase, impairing DNA synthesis largely in the S phase. Metabolites of 
5-FU can be falsely incorporated into RNA and DNA, interfering with the normal protein 
production necessary for cell growth. After administration of 5-FU intravenous bolus, 10-15% 
of patients have at least a 50% reduction in the volume of their disease, as defined by a product 
of bidimensional perpendicular measurements on CT or ultrasound scan (Nicum et al., 2000). 
 
Figure 1.5: Structure of 5-flurouracil 
1.7.2 Infusional 5-fluorouracil 
 
Due to the short half-life of 5-FU (8-14 minutes), the argument for infusional therapy is that a 
higher proportion of susceptible cells will enter the sensitive S-phase than with bolus 
administration. Trials in advanced colorectal cancer have shown a response rate of 30% for 
infusions compared with 14% for bolus therapy, with a small improvement in median survival 
(Blijham, 1991). 
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1.7.3 Biomodulation of 5-fluorouracil 
 
To increase their efficacy against colorectal cancer, various drugs have been tried in 
combination with  5-fluorouracil including as methotrexate, cisplatin, N-(phosphonacetyl)-L-
aspartic acid, thymidine, interferon, leucovorin/folinic acid, oxaliplatin and irinotecan 
(Moertel, 1994, Goyle and Maraveyas, 2006, Reynolds et al., 2016). However, high doses of 
cisplatin, N-(phosphonacetyl)-L-aspartic acid, thymidine and interferon do not show any 
benefit in combination with 5-FU.  
 
1.7.3.1  Leucovorin (folinic acid) 
 
Leucovorin (Figure 1.6) is a vitamer for folic acid, and has the full vitamin activity of this 
vitamin. It increases thymidylate synthase inhibition, thus depleting cellular thymidine and 
inducing apoptosis. In combination with 5-FU and methotrexate it has a synergistic effect in 
colorectal cancer (Keshava et al., 1998, Delfino and Petrelli, 1994). Meta-analysis, it has been 
found that 5-FU and folinic acid comboinations have double the response rate than 5-FU alone 
(Delfino and Petrelli, 1994). 
 
Figure 1.6: Chemical structure of Leucovorin 
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1.7.3.2  Irinotecan 
 
Irinotecan (Figure 1.7) is a semisynthetic analogue of the natural alkaloid camptothecin, and 
acts by inhibiting the topoisomerase I enzyme during DNA synthesis. It has been included in 
the treatment regimen FOLFIRI with infusional 5-FU and leucovorin. In a study of patients 
after 5FU failure, 1-year survival with irinotecan increased 36.2% and the drug enhanced 
quality of life and reduced tumour-related symptoms(Cunningham et al., 1998). FOLFIRI has 
been proven as efficacious treatment of metastatic CRC, with overall survival times of 
approximately two years (Gustavsson et al., 2015). 
 
Figure 1.7: chemical structure of Irinotecan 
1.7.3.3  Oxaliplatin 
 
Oxaliplatin (Figure 1.8) is a platinum based alkylating agent, and typically used with folinic 
acid and 5-fluorouracil in a combination known as FOLFOX. In clinical studies, oxaliplatin by 
itself has modest activity against advanced colorectal cancer (Becouarn et al., 1998). Phase II 
trials in patients with advanced 5FU-resistant colorectal cancer showed a response rate of only 
10% with oxaliplatin alone, but 46% with FOLFOX (de Gramont et al., 1997). FOLFOX is 
currently considered as the most effective treatment of CRC in an adjuvant setting (Onesti et 
al., 2016). 
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Figure 1.8: Chemical structure of oxaliplatin 
Since the present project focuses on the combination of platinum drugs and selected 
phytochemicals against colorectal cancer, the following sections will deal with the mentioned 
topic. 
1.8 Platinum-based Chemotherapy 
 
The platinum-based drugs cisplatin, carboplatin and oxaliplatin are among the most widely 
used chemotherapeutics prescribed for 50–70% of all cancer patients and with more than US$2 
billion sales every year (Alam and Huq, 2016). The serendipitous discovery of cisplatin was 
the key fact that triggered the interest in platinum(II)- and other metal containing compounds 
as potential anticancer drugs.  
1.8.1 First generation platinum drug: cisplatin 
 
Cisplatin is called the ‘penicillin of cancer’ because it is one of the oldest anticancer drugs 
widely used against lung, ovarian, bladder, testicular, head and neck, oesophageal, gastric, 
mesothalioma, and pancreatic cancers as a first-line chemotherapy (Ullah and Ben-Jonathan, 
2017). Becaude of its high success rate, cisplatin is indicated as a palliative therapy to be 
employed against metastatic testicular tumours. Geometrically, it is a square planar molecule 
having platinum(II) in the centre, which is covalently bound loosely to two chlorides (known 
as leaving groups) and two tightly bound ammonia ligands (known as the carrier groups) in a 
cis-configuration. 
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1.8.1.1 Mechanism of action of cisplatin 
 
Cisplatin is usually administered to the patients through intravenous route. As it is neutral by 
nature, it can easily diffuse into cells by passive diffusion (Sherman et al., 1985, Sedletska et 
al., 2005). However, it can enter into the cells by active transport as well (Byfield and Calabro-
Jones, 1981). Several transporters, including the Na+, K+-ATPase, copper transporter-1 
(CTR1) and organic cationic transporters SLC22 family of proteins have been implicated in 
facilitating the entry of cisplatin into the cells (Basu and Krishnamurthy, 2010).  
Cisplatin is a relatively inert molecule, but its aquated species are highly reactive. Thus the 
conversion of cisplatin into its hydrolysed products [Pt(NH3)2Cl(OH2)]
+ and 
[Pt(NH3)2(OH2)2]
2+ is the key factor for activation (Wang and Lippard, 2005). Low chloride 
concentration inside the cell (4 mM) compared to the blood stream (100 mM) facilitates the 
aquation process after entry into the cells. However, before binding with DNA, about 90% of 
cisplatin molecules are deactivated as a result of binding with albumin, glutathione and other 
plasma proteins that contain the thiol group (Cepeda et al., 2007). 
Even though only about 1% of administered cisplatin molecules successfully bind with DNA, 
cytotoxicity of cisplatin is believed to due to its interaction with nucleophilic N7 positions of 
guanine and adenine in DNA to form various crosslinks (Eastman, 1987). Binding to the N7 
position of guanine is more preferable to that of adenine, because of the formation of a more 
stable hydrogen bond between a coordinated water molecule and G-O6. Cisplatin can form 
both monofunctional and bifunctional DNA adducts, but the monofunctional adducts are 
preferred during the initial DNA-binding step. Monofunctional adducts of cisplatin can distort 
DNA, reduce thermal stability and disturb stacking interactions due to local loss in winding 
(Brabec et al., 1992, Brabec et al., 1994, Bursova et al., 2005). Monofunctional adducts can 
evolve into bifunctional ones. Once bifubctinal adducts are formed, DNA would be further 
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distorted locally that would involve bending and unwinding as applied to the double helix 
(Trimmer and Essigmann, 1998). 
Different types of bifunctional adducts can be formed from cisplatin-DNA binding, such as 
1,2-intrastrand d(GpG) adduct; 1,2-intrastrand d(ApG) adduct; interstrand adducts linking the 
two strands of DNA double helix and intrastrand 1,3-d(GpXpG) adducts between purines 
separated by one or more intervening bases (Bose, 2002). There is also evidence of the 
formation of protein–DNA cross-links through the coordination of cisplatin with protein and 
nucleobases (Ho et al., 2003). Figure 1.9 describes different types of binding modes of 
cisplatin-DNA binding.    
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Figure 1.9: Different modes of binding of cisplatin with DNA [Adapted from (Pizarro and 
Sadler, 2009)] 
There is controversy among scientists as to which of the various platinum–DNA adducts might 
be the more biologically significant in relation to the cytotoxicity of cisplatin. However, 
evidence from previous studies strongly favours intra-strand adducts as being the lesions 
responsible for the cytotoxic action (Pinto and Lippard, 1985). It may be noted that over 60% 
of the adducts formed by cisplatin belong to the categories:  1,2-d(GpG) intrastrand cross-links 
while about 20% belongs to d(ApG) intrastrand crosslink. These adducts activate various 
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signal-transduction pathways; for example, those involved in DNA-damage recognition and 
repair, cell-cycle arrest, and apoptosis or necrosis. 
1.8.1.2 Signal transduction pathways responsible for cisplatin 
induced cell death 
 
Cytotoxicity mediated by cisplatin is directly proportional to the amount of cisplatin bound to 
DNA (Prestayko, 2013). It is believed that cisplatin induces cell death mainly by apoptosis and 
to some extent by necrosis(Gonzalez et al., 2001). Apoptosis is likely started or progressed 
immediately after recognition of DNA damage by more than twenty individual candidate 
proteins. These proteins are induced by interstrand/intrastrand bifunctional and monofunctional 
adducts (Bellon et al., 1991). Among these damage recognition proteins, the most prominent 
ones are HMG1 and HMG2 proteins, hMSH2 or hMutSα component of  MMR complex, the 
transcriptional factor ‘TATA binding protein’ (TBP) and human RNA polymerase I 
transcription ‘upstream binding factor’ abbreviated as hUBF (Donahue et al., 1990, Chaney 
and Vaisman, 1999, Fink et al., 1998). However, either a single protein or combinations may 
be responsible for sensing the damage (Siddik, 2003). 
Each of the damage recognition proteins may activate one or more signalling pathways, and 
thus DNA damage leads towards multiple biological effects. At the same time, both cell-
survival and cell-death signals are activated following cisplatin exposure. The relative strength 
of signals is integrated downstream to determine the ultimate fate of the cell: survival or death. 
The pathways involved in cisplatin-induced cytotoxicity are summarised in Figure 1.10. 
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Figure 1.10: Pathways involved in cisplatin-induced cell death (Siddik, 2003) 
1.8.2 Second generation platinum drug 
 
Although cisplatin was discovered serendipitously, the ensuing discovery of newer platinum 
complexes that have been approved for clinical use relied less on serendipity and more on 
systematic, targeted investigations. Over the three decades, many platinum-based drugs have 
entered clinical trials but only two (oxaliplatin and carboplatin) received worldwide approval 
for clinical practice, and another three (heptaplatin, lobaplatin and nedaplatin) received limited 
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approval for clinical use. Currently, there are four drugs, satraplatin, picoplatin, Lipoplatin™ 
and ProLindac™ that are in the various phases of clinical trial. However, no new platinum drug 
has come into  phase –III clinical trials since 1999 (Wheate et al., 2010). 
1.8.3 Restrictions of platinum compounds 
 
Chemotherapy drugs such as cisplatin, carboplatin and oxaliplatin are widely used for the 
management of many types of cancer, including colorectal, breast cancer, ovarian, and lung; 
but numerous side effects are associated with concurrent uses of platinum drugs, and limit their 
uses side effects include nausea and vomiting, fatigue, weight change, gastrointestinal toxicity, 
dyspepsia, hair loss, anaemia, immunodeficiency, ototoxicity, nephrotoxicity, rashes, 
haemophilia and neurotoxicity (Santabarbara et al., 2016). Figure 1.11 depicts the major side 
effects of platinum drugs. 
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Figure 1.11: Major side effects of platinum drugs (Rabik and Dolan, 2007) 
The main obstacle to treatment with platinum drugs is drug resistance, which is known as the 
reduction in effectiveness of a chemotherapeutic drug in the treatment of certain types of cancer 
(Nichols and Bae, 2012, Hartmann and Lipp, 2003, Li et al., 2016). Resistance to 
chemotherapeutics can be categorised as intrinsic or acquired. Intrinsic resistance refers to 
those cases where the bulk of the tumour cells inherently possess some special characteristics 
that confer them resistant towards chemotherapy and render it ineffective.  Whereas, acquired 
drug resistance is developed after receiving treatment to which the tumour cells were initially 
sensitive but become resistant later, as a result of mutations or various adaptive responses 
including elevated expression of the therapeutic target and activation of alternative 
compensatory signalling pathways (Holohan et al., 2013).  
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A number of pathways are believed to lead  to resistance to platinum drugs , such as  decreased 
platinum accumulation, DNA damage repair, inhibition of cell death (apoptosis)  and 
intracellular inactivation of drugs (Housman et al., 2014, Ohmichi et al., 2005). The different 
mechanisms involved in cisplatin resistance are portrayed in figure 1.12.   
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Figure 1.12: Possible mechanism of resistance to cisplatin (Galluzzi et al., 2014)  
Note: CDDP= Cisplatin; CTR1= copper transporter 1; MRP2= multidrug resistance-
associated protein 2; UPR= unfolded protein response. CDDP aquation is depicted in red 
1.9  Phytochemicals in cancer 
 
Phytochemicals are mainly obtained from vegetables and fruits and can be classified into  
families: flavonoids, isoflavones, alkaloids, organosulfur compounds, isothiocyanates, 
phytosterols and capsaicinoids (Prasad et al., 2016). Phytochemicals have been used against 
cancer throughout history because of their safety, low toxicity and availability. The 
antineoplastic activity of phytochemicals can be credited to their strong antioxidant properties, 
and they thus occupy a vital place in cancer chemotherapy (Yoon et al., 2012).  
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Phytochemicals have the ability to divert the abnormal signalling pathways that lead towards 
cancer and act synergistically with radiotherapy and chemotherapy (Da Silva et al., 2016). They 
can block several premalignant stages, such as initiation and promotion of multistep 
carcinogenesis. Moreover, they can arrest or delay the progression and development of 
precancerous cells into tumours (Surh, 2003). Dietary phytochemicals hinder DNA changes by 
favouring the clearance of carcinogens and by acting instantly on DNA modifications. 
Phytochemicals can also block the growth of cancer cells by targeting prompt mechanisms 
related to proliferation of cells. Figure 1.13 shows the different ways phytochemicals can act 
against colorectal cancer (Ricciardiello et al., 2011).  
From numerous in vitro and in vivo preclinical studies, it is now a established fact that 
chemopreventive agents could boost the activity of anticancer drugs and thus improve 
treatment outcomes (Sarkar, 2007). Based on their mode of action, a few phytochemicals, 
namely resveratrol, thymoquinone, capsaicin and quercetin, were selected for this study to first 
test for activity against colorectal cancer cell lines, and then to combine with two platinum 
drugs, cisplatin and oxaliplatin, to improve cancer treatment. 
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Figure 1.13: Mechanism of phytochemicals against colorectal cancer (Ricciardiello et al., 
2011) 
1.9.1 Resveratrol 
 
Resveratrol is a non-flavonoid polyphenol (3,4,5-trihydroxystilbene) belonging to the 
phytoalexin family and mainly obtained from a variety of fruits and vegetables including 
blueberries, red grapes, pistachios, and peanuts (Vallianou et al., 2015). Resveratrol possesses 
cardioprotective, antiaging, hepatoprotective, neuroprotective, antiasthmatic, anti-
inflammatory, anti-platelet, antidiabetic activities; but its antitumour activity was unknown 
until Pezzuto and co-workers reported on it in 1997 (Goswami and Das, 2009, Pandey and Rizvi, 
2011). 
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Figure 1.14: Chemical structure of Resveratrol and major sources 
Chemosensitisation of tumour cells by resveratrol comes from its ability to modify multiple 
cell-signalling molecules such as cell survival proteins, drug transporters, the signalling 
pathways of the NF-κB and STAT3, and cell proliferative proteins(Varoni et al., 2016).A 
combination of resveratrol with  5-FU, doxorubicin and other phytochemicals exerts a 
synergistic effect using different pathways (Gupta et al., 2011, Singh et al., 2013). The 
anticancer action of resveratrol has also been described through the induction of protein kinase 
C (PKC)-delta, c-Jun N-terminal kinase (JNK), downstream matrix metalloproteinase-9 
(MMP-9) via phorbol myristate acetate (PMA)(Goswami and Das, 2009, Schaafsma et al., 
2016). Furthermore, resveratrol decreases the level of glutathione by augmenting the 
expression of glutathione peroxidase (GPx) and glutathione-S-transferase (GST) (Hu et al., 
2007). 
1.9.2 Thymoquinone 
 
Thymoquinone (2-isopropyl-5-methylbenzo-1, 4-quinone)  is usually obtained from the seed 
oil of Nigella sativa from the Ranunculaceae family (Gali-Muhtasib et al., 2006). The seed of 
Nigella sativa is also known as black seed and is commonly used in the Middle East as the seed 
of blessing (Schneider-Stock et al., 2014). Approximately 15 new compounds have been 
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identified from black seed, of which the major compounds are dithymoquinone, thymol, 
thymoquinone and thymohydroquinone (Malik et al., 2016).  
 
  
Figure 1.15: Chemical structure of thymoquinone and its source 
Thymoquinone has antioxidant, antiproliferative, anti-mutagenic, anti-metastatic, anti-
angiogenic and pro-apoptotic effects against different kinds of cancer cells (Majdalawieh and 
Fayyad, 2016). Intraperitoneal administration of thymoquinone markedly reduces the volume 
of human colon cancer, gastric cancer and breast cancer cells (Kundu et al., 2014). It 
significantly reduced the growth of squamous and fibrosarcoma (FsaR) cell carcinomas in a 
mouse xenograft model via intratumoral injection (Kundu et al., 2014). The action 
mechanism of its antitumour activity of thymoquinone has been reported as working through 
S/G2 cell cycle arrest, p53 mediated apoptosis through down-regulation of cyclin E and 
upregulation of p21. Moreover, thymoquinone displayed an essential role in inhibiting the 
production of prostaglandin as well as COX2 expression in allergic airway inflammation 
(Malik et al., 2016, Rahmani et al., 2014). A very recent review found that NF-κB, p53, 
STAT3, PPARγ, PI3K/AKT and MAPK signalling pathways are among the most significant 
pathways through which thymoquinone exhibits its antitumour action (Majdalawieh et al., 
2017). 
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1.9.3Capsaicin 
 
Capsaicin (trans-8-methyl-N-Vanilyl-6-nonenamide) is generally found in various capsicum 
species of the Solanaceae family (Oyagbemi et al., 2010). Capsaicin has been used to treat many 
peripheral painful conditions including rheumatoid arthritis, diabetic neuropathy, post-herpetic 
neuralgia and post-mastectomy pain syndrome since its discovery in 1919 (Surh and Lee, 
1996). Capsaicin can also be used topically to treat psoriasis by the inhibition of some 
erythematogenic chemicals (Agrawal et al., 2015). Several studies have reported that capsaicin has 
chemoreceptive and chemopreventive effects, despite its irritant properties (Deorukhkar et al., 
2007). It reduces the growth of human leukemic cells, prostate, nasopharyngeal, hepatic and gastric 
carcinoma cells in vitro by inducing cell apoptosis and cell cycle arrest (Cao et al., 2015).  
 
  
Figure 1.16: Chemical structure of capsaicin and major sources 
The anticancer mechanism of capsaicin has been attributed to cell cycle arrest at the  G2/M phase 
and stimulation of caspase 9, 3 and poly-(ADP-ribose) polymerase in KB human cancer cells (Lin 
et al., 2013). Activation of the Peroxisome proliferator-activated receptor gamma (PPAR-γ) by 
capsaicin leads to disruption of the  mitochondrial trans membrane, resulting in apoptotic cell death 
in HT-29 human colon cancer cell lines (Kim et al., 2004). Treatment with low-concentration 
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treatment of capsaicin in CRC cells, enhances the production of ROS, which leads to over 
expression of MMP-2 and MMP-9 in addition to the activation of the STAT-3 and Akt/mTOR 
signalling pathway (Yang et al., 2012). It has also been reported that capsaicin inhibits the 
downstream of VEGF-induced KDR / FIK-1 signalling by activating p125 FAK tyrosine 
phosphorylation and p38 mitogen-activated protein kinase (Oyagbemi et al., 2010). A combination 
study of capsaicin with pirarubicin produces a synergistic outcome by activating TRPV1(Clark and 
Lee, 2016). Similarly, capsaicin chemotherapy sensitises stomach carcinoma cells to 5-FU and 
inhibits proliferation (Kismali et al., 2014). 
1.9.4Quercetin 
 
Quercetin is a natural flavonoid (3,3′,4′,5,7- pentahydroxy-flavone) found in many vegetables, 
fruits, beverages and seeds such as wine , apple and tea (Nair et al., 2006). It possesses 
antioxidant, anti-inflammatory, antihypertensive, antithrombotic, antiviral and anti-
proliferative effects (Serban et al., 2016, Maalik et al., 2014). Quercetin is well known as strong 
antioxidant because of its capability to scavenge free radicals and bind transitional metallic 
ions. This is why it can block lipid peroxidation and exert a protective effect in the reperfusion 
ischemic tissue damage and atherosclerosis (Baghel et al., 2012). The anti-inflammatory effects 
of quercetin are thought due to the inhibition of lipoxygenase (LOX) and cyclooxygenase 
(COX) enzymes, in addition to the reduction of the of COX transcription. Moreover, quercetin 
is also reported to inhibit CYP450, which plays a major role in the stimulation of many 
suspected human carcinogens (Joshi et al., 2011). 
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Figure 1.17: Chemical structure of Quercetin and major sources 
Quercetin exhibits several anticancer properties, such as cell signalling, pro-apoptotic, anti-
proliferative and anti-oxidant effects, and growth suppression (Brito et al., 2015). It has been 
shown to increase cellular reactive oxidative stress (ROS), which then increases tumour 
suppressor proteins and induces cell death through the mitochondrial pathway. Quercetin can 
cause apoptosis in cancer cells via the death domain pathways: Bcl-2, survivin, and XIAP 
inhibition (Vargas and Burd, 2010). It is also found to reduce β-catenin/Tcf transcriptional 
activity, and to induce G2/M cell-cycle arrest by decreasing the gene expression of cyclin D1 
and survivin in SW480 colon cancer cells(Pan et al., 2011). The combination of quercetin with 
chemotherapeutics such as cisplatin and doxorubicin, as well as phytochemicals like ellagic 
acid, resveratrol and luteolin derivatives produces synergistic outcomes (Srivastava et al., 
2016a).  
1.10 Justification of the present research 
 
More than third of total cancer patients diagnosed yearly are found to have colorectal cancer, 
which is the third largest cause of death among cancer patients. Although chemotherapy is the 
mainstream treatment for metastasised CRC, it has a major limitation in relation to non-
selectivity (Anitha et al., 2014); and moreover, colon cancer is found to develop resistance to 
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the existing drugs (5-FU, Oxaliplatin). The activity of a chemotheraputic drug in cancer 
treatment could be improved with the right combination strategy, either using another chemo 
drugs or other nontoxic phytochemicals (Du et al., 2006, Huq et al., 2014, Fujiki et al., 2015). 
As phytochemicals often exert their antitumour activity using mechanisms different from those 
of platinum drugs, it is rational to think that platinum drugs in binary combinations with plant-
derived tumour active compounds might exhibit enhanced antitumour activity. Such a 
synergistic approach to treatment might also reduce the adverse effects produced by 
chemotherapies, because of smaller doses would be required. 
1.11 Aims of present research 
 
It is evident from the literature review that many phytochemicals have been investigated in 
combination with platinum drugs in search of synergistic activity against ovarian, pancreatic, 
breast, skin, and other types of cancer. So far, though, very little has been done with regard to 
colorectal cancer. This study aims to examine sequenced combinations of platinum drugs and 
selected phytochemicals towards synergistic outcomes that can overcome drug resistance. 
The specific objectives are: 
 to quantify anticancer activity of platinums (cisplatin and oxaliplatin) and selected 
phytochemicals (resveratrol, thymoquinone, capsaicin and quercetin) against HT-29, 
Caco-2, Lim-1215 and Lim-2405 human colorectal cancer cell lines 
 to determine combined drug action associated with sequenced binary combinations of 
platinum drugs and selected phytochemicals 
 to determine the nature of platinum-DNA interaction 
 to quantify intracellular platinum accumulation and Pt‒DNA binding level 
 to investigate changes in protein expression following drug treatments  
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Chapter Two  
2 Materials and methods 
2.1 Preamble 
 
This research is focused on identifying sequenced binary combined action of platinum drugs 
(oxaliplatin and cisplatin) with selected phytochemicals (resveratrol, thymoquinone, capsaicin 
and quercetin) in human colorectal tumour models (HT-29, Caco-2, Lim-1215 and Lim-2405 
cell lines) with the objective of overcoming platinum resistance and minimizing the adverse 
effects. Previous researchers from our Cancer Research Group in the Discipline of Biomedical 
Science, the University of Sydney conducted a similar type of work against ovarian cancer 
models. In this project, the work has been extended against colorectal cancer models.  
To identify the basis of combined drug action, different mechanistic approaches including 
damage to cellular DNA, cellular drug accumulation, the level of drug-DNA binding and 
proteomic studies were also carried out.  
 
The methods and procedures used in this research strictly follow the standard operating 
practices developed in the host laboratory and because of commonness of research in terms 
of drug discovery and therapy, the procedures would be largely the same for all the past 
and present researchers in the host laboratory. Accordingly the methods are placed in 
Appendices. 
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2.2  Platinum drugs and phytochemicals 
 
In the beginning of the study, cisplatin was synthesized on the basis of modified Dhara method 
(Dhara, 1970) using potassium tetrachloroplatinate (K2PtCl4) as a starting material. The details 
of the procedure are given in Appendix 1. Oxaliplatin and all selected phytochemicals 
(resveratrol, thymoquinone, capsaicin and quercetin) were purchased from Sigma-Aldrich, 
Australia.   
2.2.1 Materials for synthesis of cisplatin 
 
The reagents used during synthesis of cisplatin are listed in Table 2.1 and reaction scheme is 
shown in figure 2.1. 
Table 2.1: Reagents used for synthesis of cisplatin 
 
 
 
Figure 2.1:  Reaction scheme of cisplatin Synthesis 
2.2.2 Preparation of stock solutions 
 
Solvents used to dissolve platinum drugs and phytochemicals were chosen depending on their 
solubility. To make 1 mM of the 5 mL solution, platinum drugs were dissolved firstly in DMF 
followed by mQ water (ratio 1:4). For the phytochemicals, quercetin was dissolved in ethanol 
whereas resveratrol, thymoquinone and capsaicin were dissolved in 1 ml DMF and the final 
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volume was made up to 5 mL by adding mQ water to get the desired concentration as shown 
in Table 2.2. All the stock solutions were sterilized by filtering through 0.22 µm membrane 
filter, aliquoted into several five mL tubes and stored at -20 C until used.  
 
Table 2.2: Preparation of drug samples 
Drugs Formula 
Weight 
1mM (g/5mL) 10 mM 
(g/5mL) 
Solvent 
Cisplatin 300 0.00150 - DMF and water 
Oxaliplatin 397.27 0.00199 - DMF and water 
Resveratrol 228.2 0.00114 - DMF and water 
Thymoquinone 164.2 0.00082 - DMF and water 
Capsaicin 305.42 - 0.00153 DMF and water 
Quercetin 302.24 - 0.00151 Ethanol 
2.3 Colorectal cancer cell lines  
 
Four human colorectal cancer cell lines were used in the present study, i.e. HT-29, Caco-2, 
Lim-1215 and Lim-2405. Among the cell lines, Caco-2 and HT-29 cells were obtained as a 
generous gift from Dr. Mu Yao, Department of Endocrinology, The University of Sydney, 
Australia. Lim-1215 (ECACC 10092301) and Lim-2405 (ECACC 12062003) cells were 
purchased from Cell Bank Australia.  
2.4 Materials for cell culture and 
cytotoxicity assay  
 
The chemicals and instruments used during cytotoxicity assay of single drugs and combination 
study are listed in Table 2.3. 
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Table 2.3: Chemicals and instruments for single and combined drug action assay 
 
2.4.1 Preparation of Cell culture medium 
 
Fetal calf serum (10%) in RPMI 1640 was used as a medium for cell culture of all four 
colorectal cell lines.  During preparation of 500 mL of this medium, 50 mL of fetal calf serum 
was mixed with 450 mL of RPMI 1640 and then 0.25 mL of NaOH was added. 
2.4.2 Preparation of Phosphate buffer saline 
 
4.8 g of PBS powder was dissolved in 450 mL of mQ water in a clean 500 mL volumetric flask 
through gentle stirring. The pH of the solution was adjusted to 7.4 by adding 1 M hydrochloric 
acid (HCl). The final volume of the solution was made up to 500 mL by adding mQ water and 
sterilized using membrane filters (0.22 µm) and kept at 4C until used. 
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2.4.3 Preparation of Trypsin-EDTA solution 
 
10 mL of 0.5% (w/v) Trypsin-EDTA solution was added to 80 mL of PBS in 100 mL 
volumetric flask. The pH of the solution was adjusted to 7.2 to 8.0 by adding 1 M HCl. The 
final volume of the solution was made up to 100 mL with PBS and then sterilised through 
membrane filtration (0.22 μm filter) and stored at 4C until used. 
2.4.4 Subculture technique 
 
Sub culturing is a technique where saturated cells are divided from one culture vessel to 
generate anew culture vessels. Firstly, the previous medium in the Corning® cell culture flask 
containing the cancer cells was drained, and PBS is added for rinsing. Then trypsin solution 
was added for detachment and then the flask was placed in the CO2 incubator at 37
oC. Fresh 
medium was added to the flask and cell suspensions were then separated into new cell culture 
flasks and incubated for growing in CO2 incubator at 37
oC. The cells were then counted and 
seeded to the quantity to make required concentration before assay. 
2.4.5  Cell count and seeding 
 
TC10TM automated cell counter (Version 1.129, BIO-RAD, Australia) was used for counting 
the cells. In an Eppendorf tube, 10 μL of trypan blue dye (BIO-RAD, Australia) and 10 μL of 
cell suspension were mixed thoroughly. Then 10 μL of the mixture was applied to each 
chamber of the slide followed by cell count using the counter.  
For cell viability (MTT) assay, 96 well plates were used. Concentration of cells was about 5 x 
105 cells/mL. Each well of 96 well plates was seeded with 100 μL of cell suspension and then 
incubated at 37°C in 5% CO2 incubator overnight. 
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2.4.6 Addition of drugs into cells 
 
Five folds serial dilution of the drug solutions were made in 10% FCS/RPMI 1640 medium. 
Then 100 μL of drugs were added to equal volumes of cell culture medium in triplicate wells 
and left to incubate in the CO2 incubator for 72 h at 37
oC in a humidified atmosphere. The 
control wells were treated with additional 100 μL of medium only. 
2.5  MTT reduction assay 
 
MTT (3-[4,5-dimethylthiazol-2yl]-2,5-diphenyl tetrazolium bromide) reduction assay is a 
colorimetric assay which is commonly used in cell culture laboratories to detect living cells in 
a quantitative manner (Mosmann, 1983). 0.5 g of MTT powder was weighed and dissolved in 
500 mL of serum free-RPMI-1640 medium to get the concentration of 1 mg/mL. The solution 
was then sterilized by filtering through 0.45 µM membrane filter.  
After 72 h of incubation 96 well plates were removed from the incubator followed by drainage 
of the medium. Then to each well, was added 50 μL of MTT solution. The plates were kept 
again for four hours in the same CO2 incubator. After incubation was completed, solution of 
MTT was drained followed by addition of 150 μL of DMSO to each well. Purple colour made 
by formazan indicated the presence of living cells. Absorbance in terms of optical density (OD) 
was measured at 595 nm using iMarkTM Bio-Rad Microplate Reader Version 1.04.02E. The 
survival cell fraction was calculated (Mosmann, 1983) as follows: 
Optical density of platinum drug/phytochemical-treated cells 
Optical density of untreated cells 
2.6 IC50 evaluations 
 
For the determination of IC50 values, dose response curves were drawn with percentage of 
living cells along the y axis and drug concentration along the x axis. The drug concentration 
required to cause 50% cell kill (IC50 value) applying to HT-29, Caco-2, Lim-1215 and Lim-
 71 
2405 cell lines was then calculated from the curve. For each drug concentration, at least three 
independent experiments were done. 
2.7 Drug combination studies 
 
Following determination of the IC50 values of platinum drugs and phytochemicals, studies on 
drug combination were conducted to measure synergism, additiveness or antagonism. The 
combination effect is determined from combination indices and dose response curves. Dose 
response curves display visual representation of combined drug action but gives only 
qualitative measure. On the other side, combination indices provide more of a quantitative 
measure for the same.  
Four human colorectal cancer cell lines (HT-29, Caco-2, LIM-1215 and LIM-2405) were used 
for combination studies. Drugs were added in three different sequences namely bolus addition 
or 0/0 h where both of combined drugs added simultaneously at the same time; 0/4 h sequence 
where platinum drug added first and phytochemical after four hours; and 4/0 h sequence where 
phytochemical added first and platinum drug after 4 hours. Calcusyn software was used for the 
quantitative analysis of the results obtained from combination studies in terms of combination 
index (CI) (Chou and Talalay, 1984).  
2.7.1 Addition of drugs into cells 
 
During combination studies, 5 x 104 cells/mL were seeded into 96 well culture plates in 
RPMI-1640 medium and incubated for overnight. After 24 hours of seeding, three different 
concentrations of compounds were added either alone or in combination (Figure 2.2). 50 μL 
of cisplatin/oxaliplatin and 50 μL of phytochemical (Res/TQ/Cap/Quer) were added in 
triplicate wells according to their sequence of administrations and incubated for 72 h in 5% 
CO2 incubator. 
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 1 2 3 4 5 6 7 8 9 10 11 12  
A Cis-1 Res (1) TQ (1) Cis + TQ (4/0)-1 A 
B Cis-2 Res (2) TQ (2) Cis + TQ (4/0)-2 B 
C Cis-3 Res (3) TQ (3) Cis + TQ (4/0)-3 C 
D Cis + Res  (0/4)-1 Cis +Res  (0/0)-1 Cis + TQ (0/0)-1 Cis + TQ (0/4)-1 D 
E Cis + Res (0/4)-2 Cis +Res (0/0)-2 Cis + TQ (0/0)-2 Cis + TQ (0/4)-2 E 
F Cis + Res (0/4)-3 Cis +Res (0/0)-3 Cis + TQ (0/0)-3 Cis + TQ (0/4)-3 F 
G Cis + Res  (4/0)-1 Cis + Res (4/0)-3 Blank G 
H Cis + Res (4/0)-2   H 
 1 2 3 4 5 6 7 8 9 10 11 12  
Figure 2.2: A representative plan for addition of drugs corresponding to the combination of Cis, 
Res and TQ using three different sequences of administration 
Dose response curves and IC50 values obtained from treatment with the single drug were used 
as a guideline to generate the plan for combination studies shown in Table 2.4. A series of 5 
folds dilution of the drugs were made with IC50 as the midpoint. 
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Table 2.4: Summary of final concentrations of platinum drugs and phytochemicals 
Drug Concentration 
series 
HT-29 Caco-2 Lim-1215 Lim-2405 
Cis 1 1.11 4.16 1.20 0.85 
2 5.54 20.82 5.99 4.26 
3 27.68 104.08 29.97 21.32 
 
Oxa 
1 0.22 0.19 0.20 0.23 
2 1.08 0.97 1.00 1.15 
3 5.39 4.84 5.00 5.76 
 
Res 
1 7.59 6.49 12.72 8.16 
2 37.97 32.46 63.74 40.8 
3 189.84 162.28 318.7 204 
 
TQ 
1 1.92 1.06 2.56 2.08 
2 9.62 5.30 12.8 10.04 
3 48.12 26.52 64 52 
 
Cap 
1 9.30 12.06 14.70 12 
2 46.48 60.30 73.52 60 
3 232.40 301.52 367.60 300 
 
Quer 
1 8.10 15.01 10.53 4.55 
2 40.52 75.03 52.64 22.77 
3 202.60 375.16 263.20 113.84 
 
2.7.2 Combination Index calculation 
 
Chou and Talalay derived the following equation to determine the combination index (CI) 
(Chou and Talalay, 1984) for binary combinations.  
 
                DA                   DB      
CI =     +        
                DAp      DBp 
 
DA and DB indicate doses of A and B to achieve p% inhibition when present in combination. 
(Dp)A and (Dp)B denote doses of compounds A and B to achieve the same level of inhibition 
when present alone.  Dp can be calculated as follows. 
Dp = Dm[fd/(1-fd)]
1/m 
In the above equation, Dp indicates dose of the drug, Dm stands for median-effect dose, fd stands 
for killed cell fraction, fl is the living fraction so that fl=1-fd and m are the exponents defining 
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the shape of the dose-effect curve. The prerequisite for experimental design was that each 
compound used in combination would show a dose-effect relationship (Chou and Talalay, 
1984). 
The CI values were automatically calculated using Calcusyn s (V2) (Biosoft, UK). According 
to Chou, r meaning linear correlation coefficient should be greater than 0.95 for the cell culture 
system (Chou, 2006). In summary, CI value less than 1 indicates synergism, equal to 1 indicates 
additiveness and greater than 1 indicates antagonism. 
 
2.8 Materials for DNA damage study  
 
The chemicals and instruments used during DNA damage study are listed in Table 2.5. 
Table 2.5: Chemicals and instruments used during DNA damage study 
 
2.9 Methodology for DNA damage study  
 
Since the platinum drug is considered to kill the cells through damaging DNA. This study is 
conducted to find out whether the synergism and antagonism obtained from combination study 
is related to interaction with DNA or not.  
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2.9.1 Addition of drugs and collection of cell pellets 
 
Initially, combination sets were selected for DNA damage study on the basis of 
synergism/antagonism observed in combination studies. Table 2.6 lists the chosen sets for 
DNA damage study. 
 
Table 2.6: Selected drugs for DNA-damage study (0.125 µL was considered as half dose) 
Caco-2 Cell lines  Lim-2405 cell lines 
Non treated cells  
(CA-Blank) 
Non treated cells  
(L24-Blank) 
Oxaliplatin alone  
(CA-Oxa) 
Oxaliplatin alone  
(L24-Oxa) 
Oxaliplatin and Quercetin  
(CA-Oxa + Quer, 0/0) 
Oxaliplatin and Quercetin  
(L24-Oxa + Quer, 0/0) 
Oxaliplatin and Quercetin  
(CA-Oxa + Quer, 0/4) 
Oxaliplatin and Quercetin  
(L24-Oxa + Quer, 0/4) 
Quercetin alone  
(CA-Quer) 
Oxaliplatin and Capsaicin  
(L24-Oxa + Cap, 0/0) 
 
The drugs (either alone or in combination) were added according to their IC50 values to Caco-
2 and Lim-2405 cell lines which were seeded 24 h before in prelabelled petri dishes. Table 2.7 
gives the final concentration of drugs used for DNA damage study. The treated cells were 
collected as cell pellets and stored at -20°C for further study following the procedure (Appendix 
II) established in the host laboratory.  
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Table 2.7: Final concentration of drug in DNA damage study 
Drug Concentration in single 
treatment (µM) 
Concentration in combined 
treatment (µM) 
Oxaliplatin 17.50 8.75 
Quercetin 15.68 7.84 
Capsaicin 7.0 3.5 
 
 
2.9.2 Extraction of DNA and Agarose gel 
electrophoresis 
 
Bowtell method was used to extract DNA through using EZ-10 spin column genomic DNA 
minipreps KIT (Bowtell, 1987a, Bowtell, 1987b). The amount of DNA of each sample was 
calculated according to its absorbance in 260 nm. The detail procedure is given in Appendix 
III. For agarose gel electrophoresis, firstly 100 mL 50 X TAE buffer is prepared by dissolving 
2 M Tris base (24.22 g), 2 M glacial acetic acid (5.71 mL), 50 mM EDTA (1.861 g) in 94.3 
mL of mQ water. Then 1% agarose gel was prepared by measuring 2 g agarose gel power and 
mixing with 200 mL of ready prepare 1 X TAE buffer. The mixture was boiled for 2 minutes 
in the microwave and gently stirred. 125 µL of ethidium bromide was added into the gel and 
dissolved by stirring. Later on the gel was gently transferred into the tray with comb placed in 
its proper place, kept at room temperature for 45 min for setting into solid (Stellwagen, 1998). 
250 µL of ethidium bromide was added in both sides of electrophoresis chamber. The gel was 
immersed into the electrophoresis chamber filled with TAE buffer.  
Few µL (calculated as equivalent to 0.2µg of DNA) of DNA sample was taken and added with 
few µL (calculated as to make the volume of 18 µL) of mQ water. 2 µL of chromatograph 
(0.25% bromophenol blue in 49% sucrose water prepared previously) dye was added to each 
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sample and then added to the respective well. Electrophoresis was conducted at 120 V for 2 
hours. The gel was taken out and placed in the UV lamp to visualize the bands. Photograph of 
these bands were taken by Kodak Gel Logic 100 imaging system (GL 100).   
 
2.10 Materials for cell uptake and DNA 
binding assay  
 
The chemicals and instruments used during cellular uptake and DNA binding study are listed 
in Table 2.8. 
Table 2.8: Chemicals and instruments for cellular uptake and DNA binding assay 
 
2.11 Methodology for cellular uptake 
study 
To identify the relationship between the observed synergism or antagonism and the cellular 
uptake, this study was conducted by following the modified method described by Blasi et al. 
(Di Blasi et al., 1998). It is assumed that the study may help to understand the mechanism 
underlying the combined drug action. 
2.11.1 Addition of drugs and collection of cell pellets 
For cellular uptake study drug combinations were selected depending on the observed 
combined drug action from combination studies. Against Caco-2 cell line Oxa + Quer (0/0) 
and Oxa + Quer (0/4) were chosen for investigation. But in Lim-2405 cell line Oxa + Cap 
 78 
(0/0), Oxa + Cap (0/4), Oxa + Quer (0/0) and Oxa + Quer (0/4) were chosen for the study. 
The drugs (either alone or in combination) were added according to their IC50 values to Caco-
2 and Lim-2405 cell lines which were seeded 24 h before in prelabelled petri dishes. The 
final concentration of drugs used in DNA damage study (Table: 2.7) was also used for cellular 
uptake study. The treated cells were collected as cell pellets and stored at -20°C for further 
study following the established procedure (Appendix II) of Cancer Research Group, 
Discipline of Biomedical Sciences, The University of Sydney.  
2.11.2 Determination of intracellular platinum 
contents 
 
Firstly, Triton-X100 was dissolved in mQ water followed by suspension of every cell pellet 
in 0.5 mL of 1% Triton-X100.  A sonicater was used for 30 min to lyse the cells (Farrell et 
al., 1992). The lysed cells were centrifuged for 3 min at 14000 rpm.  Supernatants (0.4 mL 
each) was assayed for intercellular platinum by graphite furnace AAS. The protocol for 
measurement of platinum is attached in Appendix IV. 
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2.12 Methodology for platinumDNA 
binding study 
 
Drugs were added to the cells and cells were collected as pellets by following the same protocol 
as described before in section 2.9.1. High molecular weight DNA was isolated from cell pellet 
using EZ-10 spin column genomic DNA minipreps KIT as per the modified protocol of Bowtell 
(Bowtell, 1987a, Bowtell, 1987b). The detail of the established procedure used in the host 
laboratory for extraction of DNA is supplied as Appendix III. Extracted DNA content was 
quantified by UV spectrophotometry (260 nm) (Varian Cary 1E UV-Visible with Varian Cary 
Temperature Controller). High purity of DNA was confirmed by A260/A280 ratios lying in 
between 1.75 and 1.8 (Holford et al., 2000), and the DNA concentration was calculated 
according to the equation: 
Concentration = Absorbance at 260 nm x 50 ng/μL. 
Platinum content was measured using graphite furnace AAS following the procedure described 
in section 2.11.2. 
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2.13 Materials for proteomics studies  
 
The chemicals and instruments used during proteomics study are listed in Table 2.9. 
Table 2.9: Chemicals and instruments for proteomics 
Name of chemical/instrument Source 
Protease inhibitor cocktail tablets (Complete, 
Mini, EDTA-free) 
Roche Applied Science, Australia 
1,4-Dithiothreitol (DTT), urea, glycerol, and 
thiourea 
Merck-Chemicals, Australia 
CHAPS (3[(3-Cholamidopropyl) 
dimethylammonio]-1-propanesulfonate 
Calbiochem, Germany 
2-D Quant kit GE Healthcare, Australia 
Phosphate buffered saline (PBS) powder,  
Sodium azide 
Sigma-Aldrich Pty Ltd, NSW, Australia 
DeStreak reagent GE Healthcare Bio-sciences AB, Sweden 
Glycerol and sodium dodecyl sulfate (SDS) MP Biomedicals, LLC, France 
Carrier ampholytes (163-1112), iodoacetamide,  
10 X tris/glycine buffer and mineral oil 
Bio-Rad, USA 
Bromophenol blue (161-0404), bovine serum 
albumin (BSA) (1.44 mg/mL), Bio-Rad protein 
assay standard II kit (500-0007), dye reagent 
concentrate (500-0006), protean plus overlay 
agarose, BioSafe coomasie G-250 Stain, wicks 
and gels for 1st dimensional electrophoresis 
[ReadyStrip IPG strip of 11 cm long, 3.3 mm 
wide, 3-10 NL (nonlinear) pH gradient and 0.5 
mm thick gel] 
Bio-Rad, Australia 
Criterion TGX Precast gel Bio-Rad, USA 
PROTEAN i12 IEF Cell for isoelectric focusing, 
Criterion Dodeca cell (Serial: 561BR 01908) for 
2nd-dimensional run, Power Pac Universal for 
proper power supply for 2D run and ChemiDoc 
XRS system (Serial: 720BR1508) for capturing 
gel picture 
Bio-Rad, Australia 
Melanie (version 7.0) Swiss Institute of Bioinformatics, 
Genebio, Switzerland 
 
  
 81 
2.14 Methodology of proteomics studies  
 
Proteomics studies are usually performed to get a comprehensive understanding of the 
expression, interaction, modifications and the regulation of proteins within the cells. In the 
current project, the objective of proteomics work was to investigate the effect of 
phytochemicals on expression of key proteins found associated with combined drug action in 
colorectal cancer cells Caco-2 and Lim-2405. In this study both 1-dimensional (1-D) and 2-
dimensional gel (2-D) electrophoresis was conducted to obtain protein expression. 2-D gel 
electrophoresis usually enables speed and accuracy in identification of proteins in complex 
mixtures (Patel et al., 2005). Melanie software (version 7.0) was used for analysis of 
differential protein expressions. The experimental protocol in proteomics using 2-D gel 
electrophoresis is given in Appendix- V. 
2.14.1 Addition of drugs into cells 
 
Caco-2 and LIM-2405 cells were seeded and cultured in 50 cm2 Petri dish. Caco-2 cells were 
treated with: Oxaliplatin alone, Quercetin alone, Capsaicin alone, Oxaliplatin + Quercetin (0/0 
h), Oxaliplatin and Capsaicin (0/0 h). On the other hand Lim-2405 cells were treated with 
Oxaliplatin alone, Capsaicin alone, Oxaliplatin + Capsaicin (0/4 h), Oxaliplatin and Capsaicin 
(0/0 h). 0.375 µL of drugs were added into the respective Petri dish according to their IC50 
values and appropriate sequence of administration. The Petri dishes were then incubated for 
24 h at 37°C in 5% CO2 incubator and each experiment was done in triplicate. 
 
2.14.2 Collection of cell pellets 
 
After 24 h incubation period, cells were collected from the Petri dishes. Sterilized cell scrappers 
were used to collect the cells by scraping the cells which was then relocated into 50 mL 
centrifugal tubes. Centrifugation was performed at 3500 rpm for 2 min at 4ºC. Then medium 
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was discarded, cells were washed with 5 mL PBS and centrifuged again as before. 1 mL of 
PBS was added. Finally, cells were transferred into a new 1.5 mL eppendorf tube and spun at 
14000 rpm for 2 min at 4ºC. After taking out the PBS from eppendorf tube, cell pellets were 
kept at -20ºC freezer until being lysed.  
2.14.3 Cell lysis and determination of protein 
concentration 
 
Before extracting the protein, the cells were lysed using lysis buffer following the method 
described by Maloney (Maloney et al., 2007b). Bradford dye-binding method  was used to 
determine the protein concentration using Bio-Rad Protein Assay (BIO-RAD, Australia) 
(Bradford, 1976). The details of the components of lysis buffer, cell lysis method and protein 
concentration determination protocol is given in Appendix V. 
2.14.4 Separation of proteins by gel electrophoresis 
 
Mixtures of proteins were separated in two dimensions which starts with first dimensional 
electrophoresis and then separate the molecules by a second property in 90° direction from the 
first. Isoelectric Focusing (IEF) represents the first dimension in which protein blot (200 µg) 
was loaded and proteins present were separated based on isoelectric points (pI) performed on 
immobilized pH gradient (IPG) strips, 11 cm pH 3-10NL. The second dimension of gel 
electrophoresis involved further separation of proteins according to their molecular mass using 
gradient polyacrylamide electrophoresis (PAGE) gels (Salvato et al., 2012). To improve the 
visualization of protein spots, coomasie blue was used for staining the gels and then preserved 
with 0.5% sodium azide solution for further analysis. 
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2.14.5 Analysis of protein spots on gel  
 
Melanie (version 7.0), Swiss Institute of Bioinformatics, Genebio, Switzerland was used for 
analysis of protein spots on 2D-gel. The detail of the analysis procedure is provided in 
Appendix V. In this study, eleven matched groups (Figure 2.3) were created in which each 
match group contained duplicate gel images. 
 
Figure 2.3: Classification of gels for proteomic studies 
Primarily, all the gel images were matched together and allocated matched IDs for each protein 
spot of respective cell line using the Melanie software. To simplify the matching process, two 
discrete spots were designated as markers to diminish errors in spot detection from one gel to 
the next. A total of 195 spots were identified by the automated spot detection software in Caco-
2 cell line. On the other hand, 137 spots were identified for Lim-2405 cells. Then the level of 
expression of each protein in drug treated cell line was compared with corresponding value 
observed in non-treated cell line. A protein spot was believed to show significant alterations in 
expression if the change in fold was more than 1.5 (Maloney et al., 2007c). Statistical 
Caco-2 Cells
Untreated
Oxaliplatin treated
Quercetin treated
Capsaicin treated
Oxaliplatin + Quercetin (0/0)
Oxaliplation + Capsaicin (0/0)
Lim-2405 cells
Untreated
Oxaliplatin treated
Capsaicin treated
Oxaliplatin + Capsaicin (0/0)
Oxaliplatin + Capsaicin (0/4)
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significance tests were carried out by using Analysis of variance (ANOVA) which detects the 
differences between experimental group means (P value=0.05) (Sawyer, 2009). 
2.14.6 Identification of protein  
 
15 protein spots which exhibited significant changes in expression (upregulation or 
downregulation) in treated cell line compared to the non-treated group were excised from 2D-
gels. All of the protein spots were forwarded to APAF (Australian Proteomic Analysis Facility) 
at Macquarie University for characterization and identification. MALDI-MS was performed 
with an Applied Biosystems 4800 Proteomics Analyser. Spectra were acquired in reflectron 
mode with mass range in between 700 to 3500 Da. Details are given in Appendix V. 
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CHAPTER THREE 
 
3 RESULTS 
 
The objective of the present study  is to identify sequenced binary combined action of platinum 
drugs cisplatin (Cis) and oxaliplatin (Oxa) with selected phytochemicals resveratrol (Res), 
thymoquinone (TQ), capsaicin(Cap) and quercetin (Quer) in four human colorectal tumour 
models (HT-29, Caco-2, Lim-1215 and Lim-2405 cell lines) with the aim of overcoming drug 
resistance and reducing the side effects. The results of the cytotoxicity study of compounds 
administered alone and in combination and mechanistic studies (cellular accumulation of 
platinum and PtDNA binding, DNA damage, and proteomics) are given in this chapter. 
3.1 Cytotoxicity of platinum drugs and 
phytochemicals against colorectal cancer 
cell lines (HT-29, Caco-2, Lim1215, and 
Lim2405) 
 
MTT reduction assay was used to determine the cytotoxicity of the compounds alone against 
the selected four colorectal human cancer cell lines. In every cell line, IC50 values for the 
selected phytochemicals were determined from the concentration versus cell survival fraction 
curves. Cisplatin and Oxaliplatin were used as reference compounds in all cases.  
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3.1.1  HT-29 cell line 
 
Figure 3.1 shows the plots applying to cell survival versus concentration for all compounds 
(Cis and Oxa, Res, TQ, Cap and Quer) as applied to the human colorectal cancer cell line HT-
29. It is evident from Figure 3.1 that Oxa showed highest cytotoxicity against HT-29 cell line 
followed by Cis. All of the phytochemicals were less active than the platinum compounds. But 
the activity of all phytochemicals was found to be increased with increase of concentration 
except Cap and Quer at very low concentrations. Among the phytochemicals TQ showed 
highest cytotoxicity followed by Res and then Quer. Cap was least active among all of the 
tested compounds. The structures of the compounds are given below the graphs: 
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Figure 3.1: Cell survival fractions plotted against added concentrations in HT-29 cell line 
followed by structures of compounds 
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3.1.2 Caco-2 cell line  
 
Figure 3.2 shows the plots applying to cell survival versus concentration for all compounds 
(Cis and Oxa, Res, TQ, Cap and Quer) as applied to the human colorectal cancer cell line Caco-
2. The structures of the compounds are given in Figure 3.1. It is apparent from Figure 3.2 that 
the activity of all tested compounds increased gradually with increase of concentration. Only 
in case of TQ the cell survival fractions did not decrease significantly from third to fourth 
concentration. Oxa showed highest cytotoxicity among all investigated compounds in Caco-2 
cell line. TQ showed higher activity than cisplatin but lower than oxaliplatin. The rest of the 
phytochemicals showed lower cytotoxicity than platinum compounds. 
 
Figure 3.2 Cell survival fractions plotted against added concentrations in Caco-2 cell line 
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3.1.3 Lim-1215 cell line  
 
Figure 3.3 shows the plots applying to cell survival versus concentration for all compounds 
(Cis and Oxa, Res, TQ, Cap and Quer) as applied to the human colorectal cancer cell line Lim-
1215. Cell survival fractions were observed to decrease with increase of the concentration of 
each investigated compounds. The pattern of cytotoxicity in Lim-1215 cell line for the tested 
platinum drugs and phytochemicals was similar to that observed in HT-29 cell line which is 
Oxa > Cis > TQ > Res> Quer> Cap. 
 
 
Figure 3.3: Cell survival fractions plotted against added concentrations in Lim-1215 cell line 
3.1.4 Lim-2405 cell line  
 
Figure 3.4 shows the plots applying to cell survival versus concentration for all compounds 
(Cis and Oxa, Res, TQ, Cap and Quer) as applied to the human colorectal cancer cell line Lim-
2405. Similar trend of cytotoxicity for the tested compounds was also observed in Lim-2405 
cell line with the increase of cell killing with the increase of drug concentration. Oxa gave 
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better activity than Cis; and among phytochemicals, TQ was best followed by Quer, Res and 
Cap. 
 
 
Figure 3.4: Cell survival fractions plotted against added concentrations in Lim-2405 cell line 
3.1.5 IC50 values  
 
The concentration of a particular compound required to kill 50% of treated cells is called its 
IC50 value. It is the primary determinant of the activity of a compound, the lower the value the 
more active is the compound. Determination of IC50 values is the prerequisite for drug 
combination study because it involves the addition of drugs at a constant ratio based on their 
IC50 values. The summary of IC50 values of the compounds used in this study is given in Table 
3.1. 
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Table 3.1: Summary of the IC50 values (μM) 
 IC50 (μM) 
Drugs HT29 Caco-2 Lim-1215 Lim-2405 
Cis 6.92 ± 0.34 26.02 ± 1.82 7.49 ± 0.31 5.33 ± 0.21 
Oxa 1.35 ± 0.05 1.21 ± 0.04 1.24 ± 0.05 1.44 ± 0.08 
Res 47.46 ± 2.96 40.57 ± 3.24 79.68 ± 1.39 51.19 ± 2.04 
TQ 12.03 ± 0.84 6.63 ± 0.38 16.12 ± 0.56 13.16 ± 0.59 
Cap 58.10 ± 2.61 75.38 ± 3.76 91.89 ± 4.58 74.76 ± 2.80 
Quer 50.65 ± 2.15 93.79 ± 3.51 65.79 ± 3.97 28.45 ± 1.13 
 
It can be seen from Table 3.1 that Oxa has a higher activity than cisplatin against all the four 
human colorectal cell lines. In general, all the phytochemicals (except TQ) have a lower 
activity than Cis and Oxa.  Among phytochemicals, TQ has the highest activity against all the 
colorectal cell lines whereas Cap is found to be least active.  
The order of activity for all compounds including platinum drugs and phytochemicals (from 
highest to lowest) against the four colorectal cancer cell lines were as follows: 
HT-29:  Oxa > Cis > TQ > Res > Quer > Cap 
Caco-2:  Oxa > TQ> Cis> Res > Cap > Quer 
Lim-1215:  Oxa > Cis > TQ > Quer > Res > Cap 
Lim-2405:  Oxa > Cis > TQ > Quer > Res > Cap. 
The more discussion on the activity of the compounds as a single drug is given in chapter four. 
3.2  Effects of Drugs in binary sequenced 
combination 
 
As stated earlier, the aim of drug combination study was to determine the nature of combined 
drug action. Precisely, binary combinations of Cis and Oxa with Res, TQ, Cap, and Quer were 
applied to human colorectal cancer cell lines (HT-29, Caco-2, Lim 1215 and Lim 2405), using 
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three different sequences of administration namely 0/0 h, 0/4 h, and 4/0 h. The combined drug 
action was evaluated using dose response curves and CI values. 
3.2.1 Dose response curves 
 
3.2.1.1 Combination of cisplatin (Cis) with phytochemicals 
(Res, TQ, Cap and Quer) 
 
3.2.1.1.1 HT-29 cell line 
 
Table 3.2 shows the dose effect values, fa (affected cell fraction) for three different 
concentrations of Cis and the phytochemicals (Res, TQ, Cap, and Quer) administered alone 
and in combination in HT-29 cell line. Results are expressed as mean ± SD where n is 5 or 
greater and SD stands for ‘standard deviation. Drugs were added using three sequences of 
administration (Cis/Phytochemicals): (0/0 h), (0/4 h) and (4/0 h). Corresponding dose-response 
curves are shown in Figure 3.5. 
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Table 3.2: Dose-response in terms of fa as applied to Cis and phytochemicals (Res, TQ, Cap 
and Quer) added alone and in combination to colorectal cancer cell line HT-29. In 
combination studies, the three doses were set at IC50, 5 x IC50, and 25 x IC50. 
Drug at different concentrations (μM) administered alone. 
Cis (μM) Effect   
1.11 0.25 ± 0.08 
5.54 0.65 ± 0.10 
27.68 0.89 ± 0.07 
Res (μM) Effect TQ (μM) Effect 
7.59 0.04 ± 0.07 1.92 0.04 ± 0.08 
37.97 0.17 ± 0.07 9.62 0.16 ± 0.09 
189.84 0.69 ± 0.11 48.12 0.79 ± 0.11 
Quer (μM) Effect Cap (μM) Effect 
8.10 0.06 ± 0.06 9.30  0.01 ± 0.07 
40.52 0.41 ± 0.07 46.48 0.23 ± 0.04 
202.60 0.84 ± 0.08  232.40 0.92 ± 0.01 
Drugs at different concentrations (μM) administered in combination 
      Concentration  Sequence and drug effect 
  (0/0 h) (0/4 h) (4/0 h) 
Cis Res Effect Effect Effect 
0.55 3.77 0.05 ± 0.03 0.09 ± 0.05 0.09 ± 0.05 
2.77 18.99 0.44 ± 0.09 0.50 ± 0.12 0.39 ± 0.10 
13.84 94.91 0.86 ± 0.09 0.87± 0.06 0.91 ± 0.07 
Cis TQ    
0.55 0.95 0.02 ± 0.04 0.02 ± 0.05 0.04 ± 0.06 
2.77 4.81 0.45 ± 0.07 0.51 ± 0.06 0.47 ± 0.06 
13.84 24.05 0.88 ± .010 0.87 ± 0.08 0.87 ± 0.16 
Cis Cap    
0.55 7.47 0.02 ± 0.13 0.10 ± 0.06 0.01 ± 0.05 
2.77 30.03 0.48 ± 0.09 0.50 ± 0.07 0.46 ± 0.08 
13.84 120.02 0.87 ± 0.10 0.87 ± 0.13 0.91 ± 0.09 
Cis Quer    
0.55 5.05 0.02 ± 0.10 0.14 ± 0.07 0.12 ± 0.05 
2.77 20.28 0.63 ± 0.11 0.68 ± 0.11 0.61 ± 0.15 
13.84 81.06 0.86 ± 0.07 0.85 ± 0.09 0.85 ± 0.08 
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Figure 3.5: Dose response plots for combinations of Cis with Res, TQ, Cap, and Quer as 
applied to HT-29 Colorectal cancer cell line. 
 
 
The results indicate that cell killing effect is generally greater with the (4/0) combination of 
cisplatin with phytochemicals than with other sequences of administration as applied to HT-29 
cell line. The only exception is combination of Cis with Quer where bolus administration has 
produced the highest cell killing effect. It is obvious from all dose response curves (Figure 3.5) 
that combination treatments are better in killing cancer cells than treatments with single drugs.  
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3.2.1.1.2 Caco-2 cell line 
 
Table 3.3 shows the dose effect values, fa (affected cell fraction) for three different 
concentrations of Cis and the phytochemicals (Res, TQ, Cap, and Quer) administered alone 
and in combination to Caco-2 cell line. Results are expressed as mean  ± SD where n is 5 or 
greater and SD stands for ‘standard deviation.' Drugs were added using three different 
sequences of administration (Cisplatin/Phytochemicals): (0/0 h), (0/4 h) and (4/0 h). 
Corresponding dose-response curves are shown in Figure 3.6. 
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Table 3.3: Dose-response in terms of fa as applied to Cis and phytochemicals (Res, TQ, Cap 
and Quer) added alone and in combination to colorectal cancer cell line Caco-2. In 
combination studies, the three doses were set at IC50, 5 x IC50, and 25 x IC50. 
Drug at different concentrations (μM) administered alone. 
Cis (μM) Effect    
  
  
  
  
  
  
  
  
  
  
  
4.16 0.22 ± 0.08 
20.82 0.62 ± 0.09 
104.08 0.87 ± 0.08 
Res(μM) Effect TQ (μM) Effect 
6.49 0.07 ± 0.02 1.06 0.01 ± 0.06 
32.46 0.13 ± 0.08 5.3 0.40 ± 0.13 
162.28 0.61 ± 0.13 26.52 0.84 ± 0.02 
Quer (μM) Effect Cap (μM) Effect 
15 0.09 ± 0.08 12.06 0.01 ± 0.05 
75 0.47 ± 0.06 60.3 0.48 ± 0.02 
375 0.85 ± 0.02 301.52 0.90 ± 0.07 
Drugs at different concentrations (μM) administered in combination   
      Sequence and drug effect 
    Concentration   (0/0 h) (0/4 h) (4/0 h) 
Cis Res Effect Effect Effect 
2.08 3.24 0.10 ± 0.06 0.12 ± 0.06 0.17 ± 0.06 
10.41 16.23 0.53 ± 0.11 0.48 ± 0.04 0.38 ± 0.02 
52.04 81.13 0.87 ± 0.05 0.87 ± 0.06 0.84 ± 0.08 
Cis TQ     
2.08 0.53 0.14 ± 0.06 0.11 ± 0.04 0.16 ± 0.08 
10.41 2.64 0.55 ± 0.05 0.53 ± 0.12 0.28 ± 0.06 
52.04 13.22 0.87 ± 0.12 0.85 ± 0.02 0.81 ± 0.06 
Cis Cap     
2.08 6.0216 0.38 ± 0.05 0.27 ± 0.05 0.15 ± 0.09 
10.41 30.108 0.56 ± 0.06 0.40 ± 0.10 0.56 ± 0.09 
52.04 150.54 0.89 ± 0.08 0.91 ± 0.09 0.91 ± 0.07 
Cis Quer     
2.08 7.4984 0.38 ± 0.11 0.31 ± 0.06 0.20 ± 0.12 
10.41 37.492 0.48 ± 0.04 0.54 ± 0.12  0.59 ± 0.08 
52.04 187.46 0.87 ± 0.05 0.86 ± 0.04 0.85 ± 0.08 
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Figure 3.6: Dose response plots for combinations of Cis with Res, TQ, Cap, and Quer as 
applied to Caco-2 Colorectal cancer cell line. 
The results indicate that combination of Cis with Cap added to colorectal cancer cell line Caco-
2 has produced greatest cell killing effect as compared to other combinations and also when 
the drugs are added alone. In contrast, combination of Cis with TQ is found to be least effective 
in producing cell killing effect. It will be seen later that the combination of Cis and TQ would 
be close being additive for all the three sequences of administration. 
Among the different sequences of administration, (4/0) sequence has produced the least cell 
kill whereas bolus treatment (0/0) has usually showed the greatest cell killing effect. 
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3.2.1.1.3 Lim-1215 cell line 
 
Table 3.4 shows the dose effect values, fa (affected cell fraction) for three different 
concentrations of Cis and the phytochemicals (Res, TQ, Cap, and Quer) administered alone 
and in combination in Lim-1215 cell line. Results are expressed as Mean ± SD where n is 5 or 
greater and SD stands for ‘standard deviation.' Drugs were added using three different 
sequences of administration (Cisplatin/Phytochemicals): (0/0 h), (0/4 h) and (4/0 h). 
Corresponding dose-response curves are shown in Figure 3.7. 
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Table 3.4: Dose-response in terms of fa as applied to Cis and phytochemicals (Res, TQ, Cap 
and Quer) added alone and in combination to colorectal cancer cell line Lim-1215. In 
combination studies, the three doses were set at IC50, 5 x IC50, and 25 x IC50. 
Drug at different concentrations (μM) administered alone. 
Cis (μM) Effect   
1.2 0.02 ± 0.05 
5.99 0.35 ± 0.08 
29.97 0.84 ± 0.08 
Res(μM) Effect TQ (μM) Effect 
12.72 0.07 ± 0.09 2.56 0.01 ± 0.01 
63.74 0.25 ± 0.06 12.8 0.40 ± 0.09 
318.72 0.87 ± 0.08 64 0.86 ± 0.05 
Quer (μM) Effect Cap (μM) Effect 
10.53 0.09 ± 0.08 14.7 0.03 ± 0.10 
52.63 0.18 ± 0.06 73.52 0.12 ± 0.09 
263.13 0.83 ± 0.09 367.6 0.87 ± 0.08 
Drugs at different concentrations (μM) administered in combination  
 Sequence and drug effect 
Concentration (0/0 h) (0/4 h) (4/0 h) 
Cis Res Effect Effect Effect 
0.6 6.36 0.09 ± 0.07 0.01 ± 0.04 0.07 ± 0.03 
3 31.87 0.30 ± 0.09 0.17 ± 0.08 0.24 ± 0.04 
14.99 159.36 0.86 ± 0.09 0.87 ± 0.06 0.87 ± 0.10 
Cis TQ    
0.6 1.28 0.01 ± 0.09 0.11 ± 0.03 0.05 ± 0.02 
3 6.39 0.28 ± 0.03 0.27 ± 0.06 0.34 ± 0.06 
14.99 31.93 0.87 ± 0.05 0.87 ± 0..02 0.85 ± 0.02 
Cis Cap    
0.6 7.35 0.15 ± 0.07 0.06 ± 0.09 0.02± 0.12 
3 36.76 0.23 ± 0.09 0.10 ± 0.02 0.13 ± 0.07 
14.99 183.8 0.84 ± 0.09 0.74 ± 0.07 0.85 ± 0.11 
Cis Quer    
0.6 5.26 0.12 ± 0.08 0.13 ± 0.13 0.03 ± 0.10 
3 26.31 0.42 ± 0.12 0.27± 0.06 0.24 ± 0.09 
14.99 131.56 0.82 ± 0.09 0.80 ± 0.07 0.84 ± 0.10 
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Figure 3.7: Dose response plots for combinations of Cis with Res, TQ, Cap, and Quer as 
applied to Lim-1215 Colorectal cancer cell line. 
. 
The results show that treatment with 0/4 sequenced combination of cisplatin with Res and bolus 
treatment have produced the greatest cell kill in human Lim-1215 colorectal cancer cell line 
where 4/0 sequence of administration has produced the least cell kill. As applied combination 
of Cis with TQ, 0/4 sequence of administration is most able to produce cell killing effect in 
human Lim-1215 colorectal cancer cell line whereas bolus administration is least able to do so. 
As applied combination of Cis with Cap, bolus administration is most able to produce cell 
killing effect in human Lim-1215 colorectal cancer cell line whereas administration using 0/4 
sequence is least able to do so. As applied combination of Cis with Quer, bolus administration 
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is most able to produce cell killing effect in human Lim-1215 colorectal cancer cell line 
whereas administration using 4/0 sequence is least able to do so. 
3.2.1.1.4 Lim-2405 cell line 
 
Table 3.5 shows the dose effect values, fa (affected cell fraction) for three different 
concentrations of Cis and the phytochemicals (Res, TQ, Cap, and Quer) administered alone 
and in combination in Lim-2405 cell. Results are expressed as Mean ± SD where n is 5 or 
greater and SD stands for ‘standard deviation.' Drugs were added using three different 
sequences of administration (Cisplatin/Phytochemicals): (0/0 h), (0/4 h) and (4/0 h). 
Corresponding dose-response curves are shown in Figure 3.8. 
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Table 3.5: Dose-response in terms of fa as applied to Cis and phytochemicals (Res, TQ, Cap 
and Quer) added alone and in combination to colorectal cancer cell line Lim-2405.  In 
combination studies, the three doses were set at IC50, 5 x IC50, and 25 x IC50. 
Drug at different concentrations (μM) administered alone 
Cis (μM) Effect    
  
  
  
  
  
  
  
  
  
  
  
  
0.85 0.04 ± 0.09 
4.26 0.27 ± 0.06 
21.32 0.92 ± 0.03 
Res(μM) Effect TQ (μM) Effect 
8.16 0.02 ± 0.10 2.08 0.08 ± 0.08 
40.8 0.41 ± 0.09 10.4 0.40 ± 0.10 
204 0.89 ± 0.08 52 0.94 ± 0.06 
Quer (μM) Effect Cap(μM) Effect 
4.55 0.04 ± 0.03 12 0.02 ± 0.09 
22.76 0.23 ± 0.07 60 0.26 ± 0.09 
113.8 0.84 ± 0.10 300 0.91 ± 0.05 
Drugs at different concentrations (μM) administered in combination 
 Sequence and drug effect 
 Concentration   (0/0 h) (0/4 h) (4/0 h) 
Cis Res Effect Effect Effect 
0.4 4.08 0.01 ± 0.10 0.07 ± 0.04 0.05 ± 0.06 
2 20.4 0.34 ± 0.07 0.30 ± 0.07 0.49 ± 0.05 
10 102 0.91 ± 0.06 0.92 ± 0.05 0.92 ± 0.14 
Cis TQ     
0.4 1.04 0.06 ± 0.07 0.13 ± 0.05 0.05 ± 0.10 
2 5.2 0.34 ± 0.08 0.22 ± 0.06 0.33 ± 0.06 
10 26 0.91 ± 0.05 0.91 ± 0.03 0.90 ± 0.04 
Cis Cap     
0.4 6 0.17 ± 0.04 0.05 ± 0.08 0.02 ± 0.08 
2 30 0.40 ± 0.06 0.31 ± 0.03 0.33 ± 0.03 
10 150 0.81 ± 0.04 0.85 ± 0.11 0.87 ± 0.05 
Cis Quer     
0.4 2.27 0.01 ± 0.11 0.06 ± 0.05 0.02 ± 0.10 
2 11.38 0.44 ± 0.10 0.47 ± 0.07 0.27 ± 0.08 
10 56.9 0.88 ± 0.13 0.91 ± 0.11 0.92 ± 0.11 
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Figure 3.8: Dose response plots for combinations of Cis with Res, TQ, Cap, and Quer as 
applied to Lim-2405 Colorectal cancer cell line. 
The results indicate that in treatment with sequenced combination of cisplatin with Res, 4/0 
sequence of administration has produced the greatest cell kill in human Lim-2405 colorectal 
cancer cell line whereas the bolus treatment has produced the least cell kill. As applied to 
combination of Cis with TQ, bolus administration is most able to produce cell killing effect in 
human Lim-2405 colorectal cancer cell line whereas 0/4 sequence of administration is least 
able to do so. As applied combination of Cis with Cap, bolus administration is most able to 
produce cell killing effect in human Lim-2405 colorectal cancer cell line whereas 
administration using 0/4 sequence is least able to do so. As applied combination of Cis with 
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Quer, 0/4 sequence of administration is most able to produce cell killing effect in human Lim-
2405 colorectal cancer cell line whereas bolus administration is least able to do so. 
3.2.1.2 Combination of oxaliplatin (Oxa) with phytochemicals 
(Res, TQ, Cap and Quer) 
3.2.1.2.1 HT-29 cell line 
 
Table 3.6 shows the dose effect values, fa (affected cell fraction) for three different 
concentrations of Oxa and the phytochemicals (Res, TQ, Cap, and Quer) administered alone 
and in combination in HT-29 cell line. Results obtained are expressed as Mean ± SD where n 
is 5 or greater and SD stands for ‘standard deviation.' Drugs were added using three different 
sequences of administration (Oxaliplatin/Phytochemicals h): (0/0 h), (0/4 h) and (4/0 h). 
Corresponding dose-response curves are shown in Figure 3.9. 
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Table 3.6: Dose-response in terms of fa as applied to Oxa and phytochemicals (Res, TQ, Cap 
and Quer) added alone and in combination to colorectal cancer cell line HT-29. In 
combination studies, the three doses were set at IC50, 5 x IC50, and 25 x IC50. 
Drug at different concentrations (μM) administered alone 
Oxa(μM) Effect    
  
  
  
  
  
  
  
  
  
  
0.22 0.20 ± 0.06 
1.08 0.48 ± 0.08 
5.39 0.64 ± 0.07 
Res(μM) Effect  TQ (μM) Effect  
7.59 0.05± 0.02 1.92 0.05 ± 0.06 
37.97 0.74 ± 0.19 9.62 0.83 ± 0.11 
189.84 0.82 ± 0.12 48.12 0.91 ± 0.12 
Cap (μM) Effect  Quer (μM) Effect  
9.30 0.08 ± 0.09 8.10 0.14 ± 0.08 
46.48 0.20 ± 0.07 40.52 0.32 ± 0.06 
232.40 0.88 ± 0.07 202.60 0.87 ± 0.08 
Drugs at different concentrations (μM) administered in combination 
 Sequence and drug effect  
Concentration   (0/0 h) (0/4 h) (4/0 h) 
Oxa Res Effect Effect Effect 
0.11 3.80 0.08 ± 0.08 0.08 ± 0.05 0.12 ± 0.07 
0.54 18.98 0.31 ± 0.05 0.34 ± 0.06 0.31 ± 0.07 
2.69 94.92 0.73 ± 0.08 0.67 ± 0.08 0.76 ± 0.06 
Oxa TQ     
0.11 0.96 0.10 ± 0.09 0.05 ± 0.06 0.10 ± 0.08 
0.54 4.81 0.53 ± 0.08 0.35 ± 0.08 0.37 ± 0.05 
2.69 24.06 0.80 ± 0.07 0.90 ± 0.12 0.90 ± 0.11 
Oxa Cap     
0.11 4.65 0.12 ± 0.08 0.11 ± 0.09 0.05 ± 0.07 
0.54 23.24 0.31 ± 0.09 0.32 ± 0.15 0.29 ± 0.13 
2.69 116.00 0.77 ± 0.17 0.69 ± 0.12 0.82 ± 0.09 
Oxa Quer     
0.11 4.05 0.08 ± 0.07 0.05 ± 0.08 0.12 ± 0.06 
0.54 20.26 0.33± 0.09 0.35 ± 0.09 0.32 ± 0.06 
2.70 101.30 0.68 ± 0.11 0.65 ± 0.09 0.73 ± 0.11 
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Figure 3.9: Dose response plots for combinations of Oxa with Res, TQ, Cap, and Quer as 
applied to HT-29 Colorectal cancer cell line. 
 
The results show that in treatment with sequenced combination of oxaliplatin with Res, 4/0 
sequence of administration has produced the greatest cell kill in human HT-29 colorectal cancer 
cell line where 0/4 sequence of administration has produced the least cell kill. As applied 
combination of Oxa with TQ, 4/0 sequence of administration is most able to produce cell killing 
effect in human HT-29 colorectal cancer cell line whereas bolus administration is least able to 
do so. As applied combination of Oxa with Cap, 4/0 sequence of administration is most able to 
produce cell killing effect in human HT-29 colorectal cancer cell line whereas administration 
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using 0/4 sequence is least able to do so. As applied combination of Oxa with Quer, 4/0 
sequence of administration is most able to produce cell killing effect in human HT-29 
colorectal cancer cell line whereas 0/4 sequence of administration administration is least able 
to do so. 
3.2.1.2.2 Caco-2 cell line 
 
Table 3.7 shows the dose effect values, fa (affected cell fraction) for three different 
concentrations of Oxa and the phytochemicals (Res, TQ, Cap, and Quer) administered alone 
and in combination in Caco-2 cell line. Results obtained are expressed as Mean ± SD where n 
is 5 or greater and SD stands for ‘standard deviation. Drugs were added using three different 
sequences of administration (Oxaliplatin/Phytochemicals h): (0/0 h), (0/4 h) and (4/0 h). 
Corresponding dose-response curves are shown in Figure 3.10. 
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Table 3.7: Dose-response in terms of fa as applied to Oxa and phytochemicals (Res, TQ, Cap 
and Quer) added alone and in combination to colorectal cancer cell line Caco-2. In 
combination studies, the three doses were set at IC50, 5 x IC50, and 25 x IC50. 
Drug at different concentrations (μM) administered alone 
Oxa (μM) Effect   
0.19 0.12 ± 0.09 
0.97 0.55 ± 0.08 
4.84 0.62 ± 0.10 
Res(μM) Effect TQ (μM) Effect 
6.49 0.07± 0.10 1.06 0.24 ± 0.05 
32.46 0.23 ± 0.03 5.30 0.82 ± 0.09 
162.28 0.65 ± 0.10 26.52 0.94 ± 0.06 
Cap (μM) Effect Quer (μM) Effect 
12.06 0.04 ± 0.05 15.01 0.06 ± 0.02 
60.30 0.26 ± 0.02 75.03 0.29 ± 0.05 
301.52 0.78 ± 0.10 375.16 0.70 ± 0.05 
Drugs at different concentrations (μM) administered in combination 
 Sequence and drug effect 
Concentration (0/0 h) (0/4 h) (4/0 h) 
Oxa Res Effect Effect Effect 
0.09 3.24 0.06 ± 0.05 0.10 ± 0.08 0.05 ± 0.07 
0.48 16.23 0.43 ± 0.08 0.34 ± 0.08 0.40 ± 0.09 
2.42 81.13 0.64 ± 0.10 0.62 ± 0.08 0.60 ± 0.03 
Oxa TQ    
0.11 0.53 0.13 ± 0.09 0.06 ± 0.09 0.12 ± 0.09 
0.54 2.65 0.46 ± 0.07 0.56 ± 0.04 0.47 ± 0.11 
2.69 13.26 0.91 ± 0.04 0.91 ± 0.06 0.93 ± 0.07 
Oxa Cap    
0.09 6.03 0.25 ± 0.03 0.15 ± 0.05 0.17 ± 0.07 
0.48 30.15 0.54 ± 0.10 0.42 ± 0.09 0.39 ± 0.05 
2.42 150.76 0.72 ± 0.06 0.65 ± 0.05 0.57 ± 0.02 
Oxa Quer    
0.09 7.50 0.30 ± 0.08 0.23± 0.04 0.28 ± 0.05 
0.48 37.52 0.52± 0.09 0.48 ± 0.04 0.52 ± 0.12 
2.42 187.58 0.76 ± 0.05 0.74 ± 0.06 0.72 ± 0.04 
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Figure 3.10: Dose response plots for combinations of Oxa with Res, TQ, Cap, and Quer as 
applied to Caco-2 Colorectal cancer cell line. 
 
The results show that in treatment with sequenced combination of oxaliplatin with Res, bolus 
administration has produced the greatest cell kill in human Caco-2 colorectal cancer cell line 
where 0/4 sequence of administration has produced the least cell kill. As applied combination 
of Oxa with TQ, 4/0 sequence of administration is most able to produce cell killing effect in 
human Caco-2 colorectal cancer cell line whereas bolus administration is least able to do so. 
As applied combination of Oxa with Cap, bolus administration is most able to produce cell 
killing effect in human Caco-2 colorectal cancer cell line whereas administration using 4/0 
sequence is least able to do so. As applied combination of Oxa with Quer, bolus administration 
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is most able to produce cell killing effect in human Caco-2 colorectal cancer cell line whereas 
4/0 sequence of administration is least able to do so. 
3.2.1.2.3 Lim-1215 cell line 
 
Table 3.8 shows the dose effect values, fa (affected cell fraction) for three different 
concentrations of Oxa and the phytochemicals (Res, TQ, Cap, and Quer) administered alone 
and in combination in Lim-1215 cell line. Results obtained are expressed as Mean ± SD where 
n is 5 or greater and SD stands for ‘standard deviation. Drugs were added using three different 
sequences of administration (Oxaliplatin/Phytochemicals h): (0/0 h), (0/4 h) and (4/0 h). 
Corresponding dose-response curves are shown in Figure 3.11. 
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Table 3.8: Dose-response in terms of fa as applied to Oxa and phytochemicals (Res, TQ, Cap 
and Quer) added alone and in combination to colorectal cancer cell line Lim-1215. In 
combination studies, the three doses were set at IC50, 5 x IC50, and 25 x IC50. 
Drug at different concentrations (μM) administered alone 
Oxa (μM) Effect   
0.2 0.13 ± 0.06 
1 0.38 ± 0.08 
5 0.61 ± 0.07 
Res(μM) Effect TQ (μM) Effect 
12.72 0.01± 0.09 2.56 0.01 ± 0.03 
63.74 0.08 ± 0.05    12.8 0.55 ± 0.11 
318.72 0.92 ± 0.06 64 0.91 ± 0.08 
Cap (μM) Effect Quer (μM) Effect 
14.7 0.09 ± 0.11 10.53 0.01 ± 0.05 
73.52 0.21 ± 0.05 52.64 0.27 ± 0.09 
367.6 0.89 ± 0.08 263.2 0.73 ± 0.01 
Drugs at different concentrations (μM) administered in combination   
 Sequence and drug effect 
 Concentration   (0/0 h) (0/4 h) (4/0 h) 
Oxa Res Effect Effect Effect 
0.10 6.36 0.02 ± 0.02 0.01 ± 0.09 0.01 ± 0.08 
0.50 31.87 0.30 ± 0.06 0.26 ± 0.08 0.40 ± 0.03 
2.50 159.36 0.60 ± 0.05 0.62 ± 0.08 0.64 ± 0.09 
Oxa TQ    
0.11 1.28 0.01 ± 0.01 0.02 ± 0.07 0.10 ± 0.06 
0.54 6.4 0.29 ± 0.07 0.23 ± 0.09 0.26 ± 0.03 
2.69 32 0.91 ± 0.03 0.63 ± 0.07 0.90 ± 0.03 
Oxa Cap    
0.10 7.35 0.11 ± 0.08 0.09 ± 0.07 0.04 ± 0.05 
0.50 36.76 0.25 ± 0.09 0.20 ± 0.10 0.36 ± 0.05 
2.50 183.80 0.69 ± 0.11 0.64 ± 0.11 0.75 ± 0.07 
Oxa Quer    
0.11 5.26 0.09 ± 0.08 0.01 ± 0.10 0.01 ± 0.04 
0.54 26.32 0.22± 0.06 0.20 ± 0.09 0.17 ± 0.01 
2.70 131.60 0.57 ± 0.09 0.59 ± 0.11 0.55 ± 0.07 
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Figure 3.11: Dose response plots for combinations of Oxa with Res, TQ, Cap, and Quer as 
applied to Lim-1215 Colorectal cancer cell line. 
The results show that in treatment with sequenced combination of oxaliplatin with Res, 4/0 
sequence of administration has produced the greatest cell kill in human Lim-1215 colorectal 
cancer cell line where 0/4 sequence of administration has produced the least cell kill. As applied 
combination of Oxa with TQ, bolus of administration is most able to produce cell killing effect 
in human Lim-1215 colorectal cancer cell line whereas 0/4 sequence of administration is least 
able to do so. As applied combination of Oxa with Cap, 4/0 sequence of administration is most 
able to produce cell killing effect in human Lim-1215 colorectal cancer cell line whereas 
administration using 0/4 sequence is least able to do so. As applied combination of Oxa with 
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Quer, 0/4 sequence of administration is most able to produce cell killing effect in human Lim-
1215 colorectal cancer cell line whereas bolus administration is least able to do so. 
3.2.1.2.4 Lim-2405 cell line 
 
Table 3.9 shows the dose effect values (affected cell fraction) at different three concentrations 
of Oxaliplatin, and selected phytochemicals (Res, TQ, Cap, and Quer) administered alone and 
in combination to Lim-2405 cell line. Results obtained are expressed as Mean ± SD where n is 
5 or greater and SD stands for ‘standard deviation'. Drugs were added using three different 
sequences of administration (Oxaliplatin/Phytochemicals h): (0/0 h), (0/4 h) and (4/0 h). 
Corresponding dose-response curves are shown in Figure 3.12. 
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Table 3.9: Dose-response in terms of fa as applied to Oxa and phytochemicals (Res, TQ, Cap 
and Quer) added alone and in combination to colorectal cancer cell line Lim-2405. In 
combination studies, the three doses were set at IC50, 5 x IC50, and 25 x IC50. 
Drug at different concentrations (μM) administered alone 
Oxa(μM) Effect   
0.23 0.12 ± 0.06 
1.15 0.50 ± 0.15 
5.76 0.65 ± 0.09 
Res(μM) Effect TQ (μM) Effect 
8.16 0.01± 0.07 2.08 0.01 ± 0.06 
40.8 0.38 ± 0.09 10.4 0.40 ± 0.05 
204 0.82 ± 0.11 52 0.92 ± 0.13 
Cap (μM) Effect Quer (μM) Effect 
12 0.06 ± 0.09 4.55 0.02 ± 0.05 
60 0.12 ± 0.02 22.77 0.23± 0.08 
300 0.93 ± 0.08 113.84 0.77 ± 0.05 
Drugs at different concentrations (μM) administered in combination   
 Sequence and drug effect 
Concentration (0/0 h) (0/4 h) (4/0 h) 
Oxa Res Effect Effect Effect 
0.72 4.08 0.06 ± 0.10 0.02 ± 0.13 0.01 ± 0.08 
0.58 20.4 0.37 ± 0.06 0.38 ± 0.08 0.39 ± 0.11 
2.88 102 0.77 ± 0.05 0.75 ± 0.07 0.72 ± 0.08 
Oxa TQ    
0.72 1.04 0.03 ± 0.12 0.10 ± 0.08 0.01 ± 0.06 
0.58 5.2 0.36 ± 0.05 0.48 ± 0.03 0.32 ± 0.08 
2.88 26 0.80 ± 0.06 0.79 ± 0.11 0.89 ± 0.10 
Oxa Cap    
0.72 6.25 0.10 ± 0.11 0.15 ± 0.05 0.03 ± 0.07 
0.58 30.21 0.17 ± 0.04 0.36 ± 0.08 0.29± 0.15 
2.88 149.99 0.92 ± 0.14 0.92 ± 0.15 0.93 ± 0.06 
Oxa Quer    
0.72 2.36 0.05 ± 0.07 0.05 ± 0.07 0.10 ± 0.12 
0.58 11.43 0.26± 0.11 0.34 ± 0.12 0.34 ± 0.11 
2.88 56.74 0.66 ± 0.15 0.64 ± 0.06 0.68 ± 0.07 
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Figure 3.12: Dose response plots for combinations of Oxa with Res, TQ, Cap, and Quer as 
applied to Lim-2405 Colorectal cancer cell line. 
 
The results show that in treatment with sequenced combination of oxaliplatin with Res, bolus 
administration has produced the greatest cell kill in human Lim-2405 colorectal cancer cell line 
where 4/0 sequence of administration has produced the least cell kill. As applied combination 
of Oxa with TQ, 4/0 sequence of administration is most able to produce cell killing effect in 
human Lim-2405 colorectal cancer cell line whereas bolus administration is least able to do so. 
As applied combination of Oxa with Cap, 0/4 sequence of administration is most able to 
produce cell killing effect in human Lim-2405 colorectal cancer cell line whereas bolus 
administration is least able to do so. As applied combination of Oxa with Quer, 4/0 sequence 
of administration is most able to produce cell killing effect in human Lim-2405 colorectal 
cancer cell line whereas bolus administration is least able to do so. 
0
0.5
1
0.1 1 10 100
F
ra
ct
io
n
 a
ff
ec
te
d
Concentration (µM)
Oxa
Res
Oxa + Res 0/0 h
Oxa + Res 0/4 h
Oxa + Res 4/0 h
0
0.5
1
0.1 1 10 100
F
ra
ct
io
n
 a
ff
ec
te
d
Concentration (µM)
Oxa
TQ
Oxa + TQ 0/0
Oxa + TQ 0/4
Oxa + TQ 4/0
0
0.5
1
0.1 1 10 100
F
ra
ct
io
n
 a
ff
ec
te
d
Concentration (µM)
Oxa
Cap
Oxa + Cap ( 0/0)
Oxa + Cap ( 0/4)
Oxa + cap ( 4/0)
0
0.5
1
0.1 1 10 100
F
ra
ct
io
n
 a
ff
ec
te
d
Concentration (µM)
Oxa
Quer
Oxa + Quer ( 0/0)
Oxa + Quer ( 0/4)
Oxa + Quer ( 4/0)
 116 
3.2.2 Combination Indices(CI) 
 
The combination index (CI) is a calculated quantity that provides a quantitative measure of 
combined drug action. A CI value greater than 1 indicates that the combined drug action is 
antagonistic; equal one means it is additive and less than one means it is synergistic. It is 
defined as the total of concentration ratios for the component drugs, where the concentration 
ratio for each component drug is the ratio of concentration in combination to that when the 
drug is present alone, needed for a defined action (say 50% cell kill). In this study, Calcusyn 
(Biosoft) was used to determine CI values.  
3.2.2.1  Combination of cisplatin (Cis) with 
phytochemicals (Res, TQ, Cap and Quer) 
3.2.2.1.1 HT-29 cell line 
 
Table 3.10 gives the calculated combination indices (CIs) at at different concentrations 
applying to sequential binary combinations of Cis and selected Phytochemicals  (Res, TQ, Cap 
and Quer) for the three modes of administration: (0/0 h), (0/4 h) and (4/0 h) in human colorectal 
cancer cell line HT-29. Figure 3.13 gives the graphical representation of combination indices 
(CIs) at ED50 (the median effective dose) in HT-29 cell line for selected combinations. 
  
 117 
Table 3.10: CI values at three different effect levels relating to combinations of Cis and 
selected phytochemicals applying to different sequences in HT-29 (Dm is the medium effect 
dose, m defines shape of the curve, and r denotes the reliability coefficient)  
Drug Sequence (h) Molar Ratio CI Values at  
   ED50 ED75 ED90 Dm m r 
Cis  (1:6.85) NA NA NA 3.22 0.99 1.00 
Res  NA NA NA 110.59 1.24 0.99 
Cis + Res 0/0 1.40 1.01 0.74 3.76 1.48 1.00 
Cis + Res 0/4 1.14 0.91 0.73 3.07 1.31 1.00 
Cis + Res 4/0 1.25 0.97 0.77 3.35 1.33 1.00 
Cis  (1:1.73) NA NA NA 3.22 0.99 1.00 
TQ  NA NA NA 20.23 1.40 1.00 
Cis + TQ 0/0 1.52 1.04 0.73 3.85 1.70 0.99 
Cis + TQ 0/4 1.49 1.03 0.72 3.75 1.67 0.98 
Cis + TQ 4/0 1.47 1.05 0.77 3.71 1.57 0.99 
Cis  
 
NA NA NA 1.95 0.91 0.99 
Cap  (1:8.37) NA NA NA 77.60 2.19 1.00 
Cis + Cap 0/0 2.52 1.63 1.17 4.07 1.81 0.98 
Cis + Cap 0/4 1.86 1.55 1.43 3.00 1.28 1.00 
Cis + Cap 4/0 2.51 1.48 0.96 4.06 2.15 0.99 
Cis  (1:7.29) NA NA NA 1.95 0.91 0.99 
Quer  NA NA NA 57.76 1.37 1.00 
Cis + Quer 0/0 2.37 1.44 0.92 3.71 1.78 0.95 
Cis + Quer 0/4 1.45 1.28 1.18 2.27 1.11 0.97 
Cis + Quer 4/0 1.72 1.46 1.27 2.70 1.16 0.99 
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Figure 3.13: Combination indices (CIs) at medium effect dose (ED50) applying to sequenced 
binary combinations of Cis and selected phytochemicals in HT-29 cell line 
 
The results show that in HT-29 cell line, all administered sequences have shown antagonism 
at lower concentration (ED50). Additive to synergistic effect is observed at higher 
concentrations. Synergism is observed for all sequences at ED90 as applied to (Cis + Res) and 
(Cis + TQ) combinations. On the other hand (Cis + Cap) and (Cis + Quer) combinations, 
combined drug action is almost antagonistic for all administered sequences and concentrations.   
3.2.2.1.2 Caco-2 cell line 
 
Table 3.11 provides the calculated combination indices (CIs) at different concentrations 
applying to sequential binary combinations of Cis and selected Phytochemicals  (Res, TQ, Cap 
and Quer) for the three modes of administration: (0/0 h), (0/4 h) and (4/0 h) in human colorectal 
cancer cell line Caco-2. Figure 3.14 gives the graphical representation of combination indices 
(CIs) at ED50 (the median effective dose) in Caco-2 cell line for selected combinations. 
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Table 3.11: CI values at three different effect levels relating to combinations of Cis and 
selected phytochemicals applying to different sequences in Caco-2 (Dm is the medium effect 
dose, m defines shape of the curve, and r denotes the reliability coefficient) 
Drug Sequence (h) Molar Ratio CI Values at   
   
   ED50 ED75 ED90 Dm m r 
Cis  (1:1.55) NA NA NA 13.64 0.97 1.00 
Res  NA NA NA 135.48 0.94 0.95 
Cis + Res 0/0 0.92 0.70 0.53 10.90 1.27 1.00 
Cis + Res 0/4 0.92 0.73 0.58 10.91 1.21 1.00 
Cis + Res 4/0 1.03 0.98 0.93 12.12 1.01 0.98 
Cis  (1:0.25) NA NA NA 13.64 0.97 1.00 
TQ  NA NA NA 9.41 1.94 0.98 
Cis + TQ 0/0 0.96 0.96 1.04 9.58 1.15 1.00 
Cis + TQ 0/4 1.11 1.08 1.14 11.12 1.19 1.00 
Cis + TQ 4/0 1.55 1.87 2.43 15.49 0.97 0.95 
Cis  (1:2.89) NA NA NA 8.36 0.87 0.99 
Cap  NA NA NA 77.97 1.76 0.99 
Cis + Cap 0/0 0.76 1.02 1.52 2.42 0.80 0.97 
Cis + Cap 0/4 1.21 1.21 1.33 3.87 1.03 0.94 
Cis + Cap 4/0 1.31 1.08 0.97 4.18 1.26 1.00 
Cis  (1:3.6) NA NA NA 8.36 0.87 0.99 
Quer  NA NA NA 90.31 1.26 1.00 
Cis + Quer 0/0 0.91 1.27 1.82 2.86 0.74 0.93 
Cis + Quer 0/4 1.02 1.25 1.58 3.21 0.81 0.99 
Cis + Quer 4/0 1.30 1.28 1.30 4.07 0.97 1.00 
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Figure 3.14: Combination indices (CIs) at medium effect dose (ED50) applying to sequenced 
binary combinations of Cis and selected phytochemicals in Caco-2 cell line 
 
The results show that all combinations of selected phytochemicals with Cis when administered 
as a bolus has produced slight synergism in Caco-2 cell line. Combination of (Cis + Res) is 
found to produce synergistic effect at almost all concentrations and sequences of administration 
with the degree of synergism increasing with the increase of concentration. The combinations 
(Cis + TQ), (Cis + Cap) and (Cis + Quer) have given rise to synergism only at lower 
concentrations and for (0/0) sequence. At higher concentrations and for other sequences, the 
combined action is found to be antagonistic for (Cis + TQ), (Cis + Cap) and (Cis + Quer) in 
Caco-2 cell line. 
3.2.2.1.3 Lim-1215 cell line 
 
Table 3.12 provides the calculated combination indices (CIs) at different concentrations 
applying to sequential binary combinations of Cis and selected Phytochemicals  (Res, TQ, Cap 
and Quer) for the three modes of administration: (0/0 h), (0/4 h) and (4/0 h) in human colorectal 
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cancer cell line Lim-1215. Figure 3.15 gives the graphical representation of combination 
indices (CIs) at ED50 (the median effective dose). 
Table 3.12: CI values at three different effect levels relating to combinations of Cis and 
selected phytochemicals applying to different sequences in Lim-1215 (Dm is the medium 
effect dose, m defines shape of the curve, and r denotes the reliability coefficient) 
Drug Sequence (h) Molar Ratio CI Values at   
 
      Dm m r 
Cis  (1:10.81) NA NA NA 10.40 1.72 0.99 
Res  NA NA NA 99.28 1.39 0.98 
Cis + Res 0/0 0.87 1.01 1.17 4.25 1.28 0.99 
Cis + Res 0/4 1.25 1.05 0.89 6.08 2.02 1.00 
Cis + Res 4/0 2.75 3.44 4.30 4.65 1.39 0.98 
Cis  (1:2.13) NA NA NA 10.40 1.72 0.99 
TQ  NA NA NA 21.81 1.99 0.98 
Cis + TQ 0/0 1.06 1.01 0.96 5.47 2.02 1.00 
Cis + TQ 0/4 0.80 1.07 1.44 4.12 1.24 0.97 
Cis + TQ 4/0 0.89 1.05 1.24 4.61 1.45 1.00 
Cis  (1:8.78) NA NA NA 7.07 0.89 1.00 
Cap  NA NA NA 149.82 1.67 0.97 
Cis + Cap 0/0 0.92 0.93 1.02 4.58 1.05 0.92 
Cis + Cap 0/4 1.81 1.63 1.60 9.03 1.18 0.93 
Cis + Cap 4/0 1.30 0.87 0.63 6.50 1.75 0.99 
Cis  (1:6.13) NA NA NA 7.07 0.89 1.00 
Quer  NA NA NA 97.62 1.21 0.95 
Cis + Quer 0/0 0.78 0.70 0.63 3.83 1.09 1.00 
Cis + Quer 0/4 1.00 0.95 0.93 4.91 1.02 0.97 
Cis + Quer 4/0 1.14 0.74 0.49 5.58 1.60 1.00 
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Figure 3.15: Combination indices (CIs) at medium effect dose (ED50) applying to sequenced 
binary combinations of Cis and selected phytochemicals in Lim-1215 cell line 
 
It is evident from Figure 3.15 that, bolus administration at lower concentration has produced 
synergism for all treatments in Lim-1215 cell line except (Cis +TQ). Similarly, all combined 
treatments at lower concentration have produced antagonism as applied to (0/4) or (4/0) 
sequences except that (Cis +TQ). (Cis + Quer) at bolus administration have produced 
synergistic effect at all concentrations where the degree of synergism is found to increase with 
the increase of concentration. The combination (Cis + Quer) when administered using (0/4) or 
(4/0) sequences, synergism is observed only at higher concentrations (ED75 and ED90). In the 
case of (Cis + Cap), synergistic effect is observed at higher concentrations when administered 
using (4/0) sequence. 
3.2.2.1.4 Lim-2405 cell line 
 
Table 3.13 gives the calculated combination indices (CIs) at different concentrations applying 
to sequential binary combinations of Cis and selected Phytochemicals  (Res, TQ, Cap and 
Quer) for the three modes of administration: (0/0 h), (0/4 h) and (4/0 h) in human colorectal 
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cancer cell line Lim-2405. Figure 3.16 gives the graphical representation of combination 
indices (CIs) at ED50 (the median effective dose). 
Table 3.13: CI values at three different effect levels relating to combinations of Cis and 
selected phytochemicals applying to different sequences in Lim-2405 (Dm is the medium 
effect dose, m defines shape of the curve, and r denotes the reliability coefficient) 
Drug Sequence (h) Molar Ratio CI Values at  
Dm 
 
m 
 
r 
ED50 ED75 ED90 
Cis  (1:10.2) NA NA NA 5.57 1.75 0.99 
Res  NA NA NA 57.16 1.73 1.00 
Cis + Res 0/0 1.06 0.99 0.93 2.95 1.93 1.00 
Cis + Res 0/4 0.89 0.95 1.02 2.47 1.56 0.98 
Cis + Res 4/0 0.80 0.82 0.84 2.23 1.67 1.00 
Cis  (1:2.6) NA NA NA 5.57 1.75 0.99 
TQ  NA NA NA 10.08 1.67 0.99 
Cis + TQ 0/0 1.09 1.15 1.21 2.50 1.57 1.00 
Cis + TQ 0/4 1.10 1.31 1.56 2.53 1.34 0.93 
Cis + TQ 4/0 1.18 1.23 1.28 2.71 1.60 1.00 
Cis  (1:15) NA NA NA 4.93 1.48 0.98 
Cap  NA NA NA 94.45 1.93 1.00 
Cis + Cap 0/0 0.88 1.45 2.40 2.42 0.94 0.99 
Cis + Cap 0/4 1.15 1.26 1.39 3.17 1.45 1.00 
Cis + Cap 4/0 1.20 1.14 1.09 3.33 1.80 1.00 
Cis  (1:5.68) NA NA NA 4.93 1.48 0.98 
Quer  NA NA NA 41.68 1.50 0.99 
Cis + Quer 0/0 1.08 0.88 0.72 3.18 2.05 0.98 
Cis + Quer 0/4 0.76 0.73 0.70 2.25 1.57 1.00 
Cis + Quer 4/0 1.10 0.87 0.68 3.23 2.19 1.00 
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Figure 3.16: Combination indices (CIs) at medium effect dose (ED50) applying to sequenced 
binary combinations of Cis and selected phytochemicals in Lim-2405 cell line 
 
Among the all combination treatments in the Lim-2405 cell line; (Cis + Quer) is found to 
produce greatest synergism as applied to all sequences of administration. The sequence (0/4) 
has shown synergistic effect at all concentrations where the degree of synergism is found to 
increase with the increase of concentration. As applied to (0/0) or (4/0) sequences, synergistic 
effect is also observed at higher concentrations (ED75 and ED90). However, at ED50, 
additiveness to slight antagonism is observed for (0/0) or (4/0) sequences as applied to the 
combination (Cis + Quer).  
The combination (Cis + Res) is found to be second best in terms of synergistic combined drug 
action in Lim-2405 cell line. The (4/0) sequence of administration as applied to (Cis +Res) 
showed synergism at all different concentrations. In the case of (0/4) sequence of 
administration, synergism is observed at ED50 and ED75 level, but additiveness is found at ED90. 
For the combinations (Cis +TQ) and (Cis + Cap), combined drug treatment is found to be 
mostly antagonistic for all sequences of administration. 
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3.2.2.2  Combination of cisplatin (Cis) with 
phytochemicals (Res, TQ, Cap and Quer) 
3.2.2.2.1 HT-29 cell line 
 
Table 3.14 gives the calculated combination indices (CIs) at different concentrations applying 
to sequential binary combinations of Oxa and selected Phytochemicals  (Res, TQ, Cap and 
Quer) for the three modes of administration: (0/0 h), (0/4 h) and (4/0 h) in human colorectal 
cancer cell line HT-29. Figure 3.17 gives the graphical representation of combination indices 
(CIs) at ED50 (the median effective dose). 
  
 126 
Table 3.14: CI values at three different effect levels relating to combinations of Oxa and 
selected phytochemicals applying to different sequences in HT-29 (Dm is the medium effect 
dose, m defines shape of the curve, and r denotes the reliability coefficient) 
Drug Sequence (h) Molar Ratio CI Values at   
   
   ED50 ED75 ED90 Dm m r 
Oxa  (1:35.25) NA NA NA 1.76 0.61 0.98 
Res  NA NA NA 38.60 1.35 0.91 
Oxa + Res 0/0 1.57 1.52 1.72 1.06 1.03 1.00 
Oxa + Res 0/4 1.81 1.86 2.21 1.22 0.99 1.00 
Oxa + Res 4/0 1.40 1.44 1.71 0.95 0.98 0.99 
Oxa  (1:8.93) NA NA NA 1.76 0.61 0.98 
TQ  NA NA NA 7.91 1.63 0.92 
Oxa + TQ 0/0 1.13 1.19 1.47 0.67 1.12 0.99 
Oxa + TQ 0/4 1.22 0.96 0.87 0.72 1.61 1.00 
Oxa + TQ 4/0 1.05 0.92 0.94 0.62 1.38 0.99 
Oxa  (1:42.27) NA NA NA 1.28 0.66 0.97 
Cap  NA NA NA 72.48 1.38 0.96 
Oxa + Cap 0/0 1.26 1.14 1.22 0.92 1.00 0.99 
Oxa + Cap 0/4 1.58 1.61 1.93 1.16 0.90 1.00 
Oxa + Cap 4/0 1.29 0.86 0.67 0.95 1.39 1.00 
Oxa  (1:36.9) NA NA NA 1.28 0.66 0.97 
Quer  NA NA NA 49.13 1.15 0.97 
Oxa + Quer 0/0 1.85 1.60 1.53 1.21 1.00 1.00 
Oxa + Quer 0/4 2.01 1.55 1.33 1.31 1.11 0.98 
Oxa + Quer 4/0 1.53 1.42 1.48 1.00 0.93 1.00 
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Figure 3.17: Combination indices (CIs) at medium effect dose (ED50) applying to sequenced 
binary combinations of Oxa and selected phytochemicals in HT-29 cell line 
 
From the above, it is apparent that all the combinations of Oxa with selected phytochemicals 
are antagonistic in outcome at lower concentrations irrespective of sequences. But at ED75 and 
ED90 levels, additiveness to slight synergism is observed in some cases. For example, the 
combination (Oxa + TQ) administered using (0/4) or (4/0) sequences is found to produce 
synergism. Similar trend is observed for the combination (Oxa +Cap) when administered using 
(4/0) sequence. 
3.2.2.2.2 Caco-2 cell line 
 
Table 3.15 gives the calculated combination indices (CIs) at different concentrations applying 
to sequential binary combinations of Oxa and selected Phytochemicals  (Res, TQ, Cap and 
Quer) for the three modes of administration: (0/0 h), (0/4 h) and (4/0 h) in human colorectal 
cancer cell line Caco-2. Figure 3.18 gives the graphical representation of combination indices 
(CIs) at ED50 (the median effective dose). 
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Table 3.15: CI values at three different effect levels relating to combinations of Oxa and 
selected phytochemicals applying to different sequences in Caco-2(Dm is the medium effect 
dose, m defines shape of the curve, and r denotes the reliability coefficient) 
Drug Sequence (h) Molar Ratio CI Values at   
  
   ED50 ED75 ED90 Dm m r 
Oxa  (1:58.82) NA NA NA 1.14 0.80 0.92 
Res  NA NA NA 110.78 1.18 1.00 
Oxa+ Res 0/0 1.11 0.87 0.71 0.79 1.17 0.96 
Oxa + Res 0/4 1.26 1.43 1.69 0.89 0.84 1.00 
Oxa + Res 4/0 1.23 1.08 0.99 0.88 1.05 0.96 
Oxa  (1:6.12) NA NA NA 1.14 0.80 0.92 
TQ  NA NA NA 1.76 1.21 0.98 
Oxa + TQ 0/0 1.36 1.17 1.03 0.31 1.32 1.00 
Oxa + TQ 0/4 1.50 1.10 0.83 0.35 1.63 0.99 
Oxa+ TQ 4/0 1.24 0.97 0.78 0.28 1.49 1.00 
Oxa  (1:62.28) NA NA NA 1.12 0.58 0.95 
Cap  NA NA NA 123.1 1.38 1.00 
Oxa + Cap 0/0 0.68 0.98 1.85 0.49 0.64 0.99 
Oxa + Cap 0/4 1.31 1.50 2.26 0.93 0.74 0.99 
Oxa + Cap 4/0 1.85 3.13 6.94 1.32 0.59 0.99 
Oxa  (1:77.49) NA NA NA 1.12 0.58 0.95 
Quer  NA NA NA 163.06 1.15 1.00 
Oxa + Quer 0/0 0.54 0.73 1.20 0.40 0.63 1.00 
Oxa + Quer 0/4 0.75 0.82 1.11 0.55 0.71 1.00 
Oxa + Quer 4/0 0.64 0.94 1.73 0.47 0.59 0.99 
 
 129 
  
Figure 3.18: Combination indices (CIs) at medium effect dose (ED50) applying to sequenced 
binary combinations of Oxa and selected phytochemicals in Caco-2 cell line 
 
The above results show that the combination (Oxa + Quer) produces greater synergistic 
outcomes as compared to other combination treatments in Caco-2 cell line. Strongest synergism 
is observed at higher concentrations when administered as a bolus. Oxa + Cap with bolus 
addition synergism only at lower concentrations. All other combined treatments of selected 
phytochemicals with oxaliplatin have shown additiveness to antagonism in general irrespective 
of sequences and concentrations. However the combination (Oxa + TQ) has produced 
synergism at ED90 when administered using (4/0) sequence. 
3.2.2.2.3 Lim-1215 cell line 
 
Table 3.16 gives the calculated combination indices (CIs) at different concentrations applying 
to sequential binary combinations of Oxa and selected Phytochemicals (Res, TQ, Cap and 
Quer) for the three modes of administration: (0/0 h), (0/4 h) and (4/0 h) in human colorectal 
cancer cell line Lim-1215. Figure 3.19 gives the graphical representation of combination 
indices (CIs) at ED50 (the median effective dose). 
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Table 3.16: CI values at three different effect levels relating to combinations of Oxa and 
selected phytochemicals applying to different sequences in Lim-1215 (Dm is the medium 
effect dose, m defines shape of the curve, and r denotes the reliability coefficient) 
Drug Sequence (h) Molar Ratio CI Values at 
 
 
Dm 
ED50 ED75 ED90 Dm m r 
Oxa  (1:46.81) NA NA NA 1.91 1.00 0.94 
Res   NA NA NA 113.38 2.19 1.00 
Oxa+ Res 0/0  1.46 1.36 1.39 1.56 1.52 0.96 
Oxa + Res 0/4  1.60 1.72 1.99 1.46 1.35 0.98 
Oxa + Res 4/0  1.28 1.65 2.32 1.16 1.09 0.97 
Oxa  (1:12.8) NA NA NA 1.91 1.00 0.94 
TQ   NA NA NA 21.34 2.86 0.95 
Oxa + TQ 0/0  0.73 0.71 0.77 0.65 1.75 1.00 
Oxa + TQ 0/4  0.86 0.80 0.82 0.76 1.89 1.00 
Oxa+ TQ 4/0  1.08 0.82 0.70 0.96 2.83 0.98 
Oxa  (1:73.5) NA NA NA 2.20 0.77 1.00 
Cap   NA NA NA 107.19 1.37 0.95 
Oxa + Cap 0/0  1.38 1.72 2.30 1.21 0.90 0.98 
Oxa + Cap 0/4  1.82 2.26 3.02 1.60 0.90 0.98 
Oxa + Cap 4/0  1.11 0.93 0.83 0.97 1.33 0.99 
Oxa  (1:52.65) NA NA NA 2.20 0.77 1.00 
Quer   NA NA NA 127.17 1.74 0.99 
Oxa + Quer 0/0  1.70 2.51 4.26 1.95 0.81 0.99 
Oxa + Quer 0/4  1.40 0.86 0.61 1.61 2.26 0.96 
Oxa + Quer 4/0  1.52 0.95 0.68 1.75 2.21 0.96 
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Figure 3.19: Combination indices (CIs) at medium effect dose (ED50) applying to sequenced 
binary combinations of Oxa and selected phytochemicals in Lim-1215 cell line 
It is evident from Table 3.16 and Figure 3.19 that the combination (Oxa + TQ) has produced 
the greatest synergistic outcome as compared to all other combinations of oxaliplatin with 
selected phytochemicals in Lim-1215 cell line, which showed synergism at all concentrations 
and for all sequences except at ED50 administered using (4/0) sequence. Greatest synergism is  
observed with bolus administration of (Oxa + TQ). The combination (Oxa + Quer) 
administered using (0/4) and (4/0) sequences has shown synergism at higher concentrations. 
The combination (Oxa + Cap) has produced antagonistic effect except at the highest 
concentration when administered (4/0) sequence. On the other hand, the combination (Oxa + 
Res) has shown antagonism at all concentrations irrespective of the sequence of administration. 
3.2.2.2.4 Lim-2405 cell line 
 
Table 3.17 gives the calculated combination indices (CIs) at different concentrations applying 
to sequential binary combinations of Oxa and selected Phytochemicals  (Res, TQ, Cap and 
Quer) for the three modes of administration: (0/0 h), (0/4 h) and (4/0 h) in human colorectal 
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cancer cell line Lim-2405. Figure 3.20 gives the graphical representation of combination 
indices (CIs) at ED50 (the median effective dose). 
Table 3.17: CI values at three different effect levels relating to combinations of Oxa and 
selected phytochemicals applying to different sequences in Lim-2405(Dm is the medium 
effect dose, m defines shape of the curve, and r denotes the reliability coefficient) 
Drug Sequence (h) Molar Ratio CI Values at 
 
ED50    ED75   ED90 
Dm m r 
Oxa  (1:35.47) NA NA NA 2.12 1.08 0.95 
Res  NA NA NA 76.34 1.90 0.98 
Oxa+ Res 0/0 0.95 1.06 1.24 1.01 1.24 0.99 
Oxa + Res 0/4 1.10 1.02 0.99 1.17 1.58 0.98 
Oxa + Res 4/0 1.20 1.04 0.94 1.28 1.75 0.96 
Oxa  (1:9.04) NA NA NA 2.12 1.08 0.95 
TQ  NA NA NA 15.79 2.15 0.99 
Oxa + TQ 0/0 1.12 1.13 1.21 1.50 1.52 0.99 
Oxa + TQ 0/4 0.82 1.08 1.50 0.77 1.12 0.99 
Oxa+ TQ 4/0 0.97 0.85 0.74 0.98 2.12 0.99 
Oxa  (1:52.08) NA NA NA 2.02 0.81 0.96 
Cap  NA NA NA 92.57 1.66 0.92 
Oxa + Cap 0/0 0.84 0.70 0.65 0.79 1.46 0.92 
Oxa + Cap 0/4 0.59 0.54 0.55 0.57 1.32 0.97 
Oxa + Cap 4/0 0.84 0.59 0.46 0.80 1.91 1.00 
Oxa  (1:19.7) NA NA NA 2.02 0.81 0.96 
Quer  NA NA NA 51.63 1.58 1.00 
Oxa + Quer 0/0 1.36 1.30 1.38 1.55 1.14 1.00 
Oxa + Quer 0/4 1.28 1.25 1.36 1.46 1.11 0.98 
Oxa + Quer 4/0 1.07 1.27 1.66 1.25 0.93 1.00 
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Figure 3.20: Combination indices (CIs) at medium effect dose (ED50) applying to sequenced 
binary combinations of Oxa and selected phytochemicals in Lim-2405 cell line 
 
The above results show that the combination (Oxa + Cap) is the best in synergistic outcome as 
compared to all other combinations in the Lim-2405 cell line. Synergism is observed for all 
sequences of administration and at all concentrations for the combination (Oxa + Cap) where 
CI values are generally found to decrease with the increase of concentration. The combination 
(Oxa + TQ) follows the same trend but only for the (4/0) sequence of administration. On the 
other hand, the combinations (Oxa + Res) and (Oxa + Quer) have generally produced additive 
to antagonistic effects. Figure 3.20 depicts that the combinations (Oxa + Cap) and (Oxa + TQ) 
have produced synergism for all sequences of administration but only at a lower concentration. 
While the combinations (Oxa + Res) and (Oxa + Quer) are seen to be antagonistic in outcome.  
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3.3  Studies on DNA damages 
 
This study was carried out to obtain qualitative information on DNA damage to be seen in 
increase in mobility and/or change in intensity of the band. It is a well-established fact that 
platinum drugs exhibit their cytotoxicity through their binding with nucleobases in DNA and 
hence causing DNA damage. The study was extended to interaction of DNA with drug 
combinations to determine whether there was any correlation on nature of drug combination  
synergistic or antagonistic – and DNA damage.  
Two synergistic combination treatments of Caco-2 cell line were selected and compared with 
the single drug treatment as well as non-treated cells. Similarly, two antagonistic and one 
synergistic treatments applying to Lim-2405 were also selected for DNA damage study. 
3.3.1 DNA damage in Caco-2 (CA) cell line 
 
Figure 3.21 illustrates the DNA bands obtained from agarose gel electrophoresis of DNA 
extracted from Caco-2 cells. Table 3.18 provides DNA bands mobility and intensity and Figure 
3.22 and Figure 3.23 give visual representations of the DNA bands mobility and intensity, 
respectively. 
                 1                     2                      3                    4                     5                   6 
 
Figure 3.21: Electrophoretograms obtained from Caco-2 cell line DNA damage study. Where 
lane 1: control, lane 2: Oxa, lane 3: Oxa+Quer (0/0 h), lane 4: Oxa+Quer (0/4 h), lane 5: Quer, 
lane 6: control 
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Table 3.18: DNA mobility and total intensity on Caco-2 (CA) cell line 
Cell line/drugs Combined Effect Mobility (mm) Total Intensity 
1. CA-Blank -- 3.87 30662.8 
2. CA-Oxa -- 3.95 28008 
3. CA-Oxa+Quer (0/0) Synergistic 3.78 20513.1 
4. CA-Oxa+Quer (0/4) Synergistic 3.87 12592 
5. CA-Quer -- 4.04 8032.4 
 
 
 
Figure 3.22: Graphical display of the DNA bands mobility applying to Caco-2 cell line. 
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Figure 3.23: Visual representations of the DNA bands intensity found in Caco-2 cell line 
 
The above results show that there was no detectable change in the mobility of the DNA band. 
However, when the total intensity values of DNA band are compared, interaction with Oxa and 
Quer alone, combinations of Oxa and Quer (0/0 and 0/4), it is found that while treatment with 
Oxa alone did not cause any damage to DNA, all other treatments were able to cause damage 
to cellular DNA. Greatest damage to DNA is found to be caused by Quer alone. In fact, some 
streaking of DNA band can be seen in treatment with Quer. 
3.3.2 DNA damage in Lim-2405 (L24) cell line 
 
Figure 3.24 illustrates bands applying to DNA extracted from Lim-2405 cells. Table 3.19 
demonstrates DNA bands mobility and intensity and Figure 3.25 and Figure 3.26 give visual 
representations of bands mobility and intensity. 
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Table 3.19: Mobility and sum intensity on Lim-2405 (L24)  
Cell line/drugs Combined Effect Mobility (mm) Sum Intensity 
1. L24-Blank -- 5.54 29461.8 
2. L24-Oxa -- 5.54 27187.3 
3. L24-Oxa+Quer (0/0) Antagonistic 5.63 48259.7 
4. L24-Oxa+Quer (0/4) Antagonistic 5.88 10930 
5. L24-Oxa+Cap (0/0) Synergistic 5.54 24292 
 
 
 
Figure 3.24: Electrophoretrograms obtained from Lim-2405 cell line DNA damage study. 
Where lane 1: control, lane 2: Oxa, lane 3: Oxa+Quer (0/0 h), lane 4: Oxa+Quer (0/4 h) and 
lane 5: Oxa+Cap (0/0 h) 
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Figure 3.25: Graphical display of the DNA bands mobility observed in Lim-2405 cell line 
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Figure 3.26: Visual representations of the DNA bands intensity found in Lim-2405 cell line 
 
The above results show that (Oxa + Quer, 0/4 sequence) is most damaging to DNA in Lim-
2405 cell line followed by treatments with (Oxa + Cap, 0/0) and Oxa alone. Antagonistic 
combination (Oxa + Quer, 0/0) is found to be least damaging to DNA.   
3.4  Studies on DNA Binding and Cellular 
Accumulation 
 
Cellular accumulation of oxaliplatin and PtDNA binding level were determined to find out 
whether any correlation existed between intracellular platinum accumulation or level of 
platinum DNA binding and the combined drug action. Two synergistic treatments associated 
with Caco-2 cell line; two synergistic, one additive and one antagonistic treatments associated 
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with Lim-2405 cell line were selected for the study. Platinum uptake and PtDNA binding 
from treatment with Oxa alone were also determined. 
3.4.1 Cellular accumulation of platinum  
 
Table 3.20 provides cellular accumulation of Pt expressed as nmol Pt per 5x106 cells in 
colorectal cancer Caco-2 (CA) and Lim-2405 (L24) cell lines for oxaliplatin alone and its 
selected combinations with capsaicin and quercetin. Figure 3.27 shows graphical 
representations. 
Table 3.20: Cellular platinum uptake of Oxa alone and from its selected combinations  
Sample (DNA binding) Combined Effect Cellular Accumulation of Platinum 
(nmol Pt per 5x106 cells) 
CA-Oxa -- 0.33 ± 0.07 
CA-Oxa + Quer (0/0) Synergistic 0.29 ± 0.06 
CA-Oxa + Quer (0/4) Synergistic 0.23 ± 0.02 
L24-Oxa -- 0.12 ± 0.08 
L24-Oxa + Quer (0/0) Antagonistic   0.08 ± 0.02 
L24-Oxa + Quer(0/4) Antagonistic   0.09 ± 0.01 
L24-Oxa + Cap (0/0) Synergistic 0.16 ± 0.03 
L24-Oxa + Cap (0/4) Synergistic 0.09 ± 0.03 
 
 
 
Figure 3.27: Graphical display of the results obtained from cellular accumulation study 
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Table 3.20 and Figure 3.27 indicate that in Caco-2 cell line highest accumulation of platinum 
was observed from treatment with Oxa alone followed by treatments with (Oxa + Quer, 0/0) 
and then (Oxa + Quer, 0/4). In Lim-2405 cell line, the highest platinum accumulation was 
shown by treatment with synergistic combination (Oxa + Cap, 0/0) followed by that with Oxa 
alone. The least platinum accumulation was shown in treatment with antagonistic (Oxa + Quer, 
0/0) combination. 
3.4.2  PtDNA binding 
 
Table 3.21 provides the levels of PtDNA binding, expressed as nmol Pt per mg of DNA, in 
the colorectal cancer cell lines Lim-2405 and Caco-2, after treatment with Oxa alone and its 
selected combinations with Cap and Quer. Figure 3.28 shows the corresponding graphical 
representations. 
Table 3.21 : Pt−DNA binding levels from Oxa alone and selected combinations in the 
colorectal cancer Lim-2405 and Caco-2 cell lines 
Sample (DNA binding) Combined effect Pt(nmol)/DNA(mg) 
CA-Oxa -- 0.13 ± 0.03 
CA-Oxa + Quer (0/0) Synergistic 0.26 ± 0.13 
CA-Oxa + Quer (0/4) Synergistic 0.48 ± 0.15 
L24-Oxa -- 0.67 ± 0.08 
L24-Oxa + Quer (0/0) Antagonistic  0.36 ± 0.08 
L24-Oxa + Quer (0/4) Antagonistic 0.52 ± 0.01 
L24-Oxa + Cap (0/0) Synergistic 0.82 ± 0.05 
L24-Oxa + Cap (0/4) Synergistic 0.81 ± 0.35 
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Figure 3.28: Graphical display of the results obtained from Pt-DNA binding study 
It can be seen from the above results that treatment with synergistic combinations were 
associated with higher PtDNA binding levels than that due to Oxa alone. Treatments with 
antagonistic and additive combinations exhibited lower PtDNA binding levels compared to 
treatment with Oxa alone. In Caco-2 cell line, maximum PtDNA binding level was shown by 
treatment with (Oxa + Quer, 0/4) combination whereas in Lim-2405 treatment with (Oxa + 
Cap, 0/0) combination produced the highest PtDNA binding level. 
3.5  Proteomics studies 
 
 Recently proteomics have been used to identify the potential biomarkers for developing cancer 
(Sallam, 2015). Proteomics is also now being utilized for characterizing the differentially 
expressed proteins in various cancers (Myers et al., 2017). The objective of proteomics was to 
quantify changes in expression of proteins in Caco-2 and Lim-2405 cells after treatment with 
Oxa and its combinations with phytochemicals Cap and Quer. 
Eleven (11) matched groups were generated for all the gels using Melanie Software and then 
pooled in two classes. The first class included non-treated Caco-2 cell lines, Caco-2 cell line 
0.00
0.40
0.80
1.20
1.60
P
t(
n
m
o
l)
/D
N
A
(m
g
)
Platinum-DNA Binding 
 143 
treated alone with Oxa, Cap and Quer, combination of (Oxa + Cap, 0/0)  and combination of 
(Oxa + Quer, 0/0). The second class includes non-treated Lim-2405 cell line, Lim-2405 treated 
alone with Oxa and Cap, combinations of Oxa and Cap (0/0) and (0/4). Based on Melanie 
software, a total of 195 spots were identified in Caco-2 cell line and 137 spots were identified 
in Lim-2405 cells. All of the spots were given common ID number among all gels grouped in 
respective class. Expression of each of the protein spots in non-treated cell lines was compared 
with corresponding value in drug treated cell line. Decision was made whether a protein 
underwent differential expression or not, on the basis of difference between folds of non-treated 
and treated cells. Fold difference greater than 1.5 was considered significant (Maloney et al., 
2007a).  
3.5.1 Expression of proteins according to spot intensity 
in Caco-2 cell line 
 
Among 195 spots detected in Caco-2 cell line, only 20 spots were found to undergo significant 
changes in expression. Of them eight spots were excised and chosen for further analysis by 
MALDI mass spectrometry combined with Swiss-Prot Database was used for protein 
identification. This is because some spots were not in detectable amount/position and some 
were overlapping. Figure 3.29-Figure 3.32 give the 2-D protein gel images of non-treated and 
treated groups. It should be noted that each spot in the 2-D gel image represents a unique protein  
defined by its molecular mass and isoelectric point value. Figure 3.33 visualizes the 2D-Gel 
protein profile of untreated Caco-2 cell line with annotated protein spots which have changed 
in expression after single drug treatment and that with selected combinations. Table 3.22 
summarizes changes in expression of protein spots (up regulated or down regulated) as a result 
of drug treatments. Up-regulated indicates that the protein spot in the treatment group has been 
shown more expression compared to the non-treated blank cell where the fold is greater than 
1.5. The converse is true for down-regulated.  
 144 
 
Figure 3.29:  Protein gel image of Caco-2 (Untreated) cells 
 
Figure 3.30: Protein gel image of Caco-2 (Oxa treated) cells 
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Figure 3.31:  Protein gel image of Caco-2 (Quer treated) cells 
 
 
Figure 3.32:  Protein gel image of Caco-2 (Oxa + Cap treated) cells 
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Figure 3.33: Annotated 2D-Gel profile of untreated Caco-2 cells showing significant changes 
in expression following treatment with selected drugs 
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Table 3.22: Changes in expression of proteins in Caco-2 line before and after treatment with 
oxa, cap, quer and their combination with drugs alone and in combination (‘Down Regulated’ 
and ‘Up Regulated’ are with respect to the blank) 
Keys: DR – Down regulated, UR – Up regulated 
The details of the identified proteins observed in Caco-2 cell line using (MALDI) mass 
spectrometry combined with Swiss-Prot Database is tabulated in Table 3.23. The protein 
accession number, alternative names, genes, and function of each protein are not shown in the 
table but provided as Appendix –V. 
  
Match ID Effect of treatment on Caco-2 cell  
Oxa Cap Quer Oxa + Cap 
(0/0 h) 
Oxa + Quer 
(0/0 h) 
4 DR DR DR DR DR 
7 UR DR DR UR DR 
10 DR DR DR DR DR 
15= 2 
(Marker)  
DR DR DR DR DR 
47 UR UR UR UR UR 
148 UR - UR UR UR 
174 DR - UR UR No change 
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Table 3.23: Basic information related to the proteins identified from Caco-2 cell line 
Match 
ID 
ID Full name MALDI Location  
(Subcellular) 
4 H2B1C_HUMAN Histone  H2B type 1-
C/E/F/G/I 
Score: 183 
Mass: 13898 
pI: 10.31 
Coverage: 37% 
Nucleus and 
chromosome 
7 H4_HUMAN 
 
Histone H4 Score: 140 
Mass: 11360 
pI: 11.36 
coverage: 29% 
Nucleus and 
chromosome 
10 COF1_HUMAN Cofilin-1 
 
Score: 62 
Mass: 18491 
pI: 8.22 
coverage: 24 % 
Nucleus 
matrix. 
Cytoplasm. 
 
15=2 
(Marker) 
GSTP1_HUMAN Glutathione S-
transferase P 
 
Score: 732 
Mass: 23341 
pI: 5.43 
coverage: 57 % 
Cytoplasm, 
mitochondrio
n, 
nucleus 
47 PROF1_HUMAN Profilin-1 
 
Score: 67 
Mass: 15045 
pI: 8.44 
coverage: 25 % 
Cytoplasm › 
cytoskeleton 
148 PRDX1_HUMAN Peroxiredoxin-1 
 
Score: 176 
Mass: 22096 
pI: 8.27 
coverage: 42 % 
Cytoplasm, 
Melanosome 
174 AGR2_HUMAN Anterior gradient 
protein 2 
 
Score: 130 
Mass: 19967 
pI: 9.03 
coverage: 32 % 
Endoplasmic 
reticulum 
 
3.5.2 Expression of proteins according to spot intensity 
in Lim-2405 cell line 
 
Among 137 spots detected in Lim-2405 non treated cell line, only nine spots were identified 
which underwent significant change in expression. But only eight spots were excised and 
chosen for further analysis by Matrix-assisted laser desorption/ionization (MALDI) mass 
spectrometry combined with Swiss-Prot Database was used for protein identification. This is  
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because some spots were not in detectable amount/position and some were overlapping. Figure 
3.34 – Figure 3.38 give the 2-D protein gel images of non-treated and treated groups. Figure 
3.39 visualizes the 2D-Gel protein profile of untreated Lim-2405 cell line with annotated 
protein spots which have changed in expression after treatment with single drug and selected 
drug combinations. Table 3.24 summarizes changes in expression of protein spots (up regulated 
or down regulated) as a result of drug treatments. Up-regulated indicates that the protein spot 
in the treatment group has been shown more expression compared to the non-treated blank cell 
where the fold is greater than 1.5. The converse is true for down-regulated.  
 
Figure 3.34:  Protein gel image of Lim-2405 (Untreated) cells 
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Figure 3.35 :  Protein gel image of Lim-2405 (Oxa treated) cells 
 
 
Figure 3.36: Protein gel image of Lim-2405 (Cap treated) cells 
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Figure 3.37: Protein gel image of Lim-2405 (Oxa + Cap, 0/0 treated) cells 
 
 
Figure 3.38: Protein gel image of Lim-2405 (Oxa + Cap, 0/4 treated) cells 
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Figure 3.39: Annotated 2D-Gel profile of untreated Lim-2405 cells showing significant 
changes in expression following treatment with selected drugs  
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Table 3.24: Changes in expression of proteins in Lim-2405 line before and after treatment 
with oxa, cap and their combination with drugs alone and in combination (‘Down Regulated’ 
and ‘Up Regulated’ are with respect to the blank) 
Keys: DR – Down regulated, UR – Up regulated 
The details of the identified proteins observed in Lim-2405 cell line using (MALDI) mass 
spectrometry combined with Swiss-Prot Database is tabulated in Table 3.25. The protein 
accession number, alternative names, genes and function of each protein are not shown in the 
table but provided as Appendix –VI. 
  
 
 
Match ID 
Effect of treatment on Lim2405 cell 
Oxa Cap Oxa + Cap 
(0/0 h)  
Oxa +cap 
(0/4 h)  
 3 DR UR DR - 
4 DR - - - 
10=2 (Marker) DR UR DR UR 
11 DR UR - UR 
35 UR UR UR - 
48 UR UR UR - 
72 UR - UR - 
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Table 3.25: Basic information related to the proteins identified from Lim-2405 cell line 
 
Match 
ID 
ID Full name  MALDI Location  
(Subcellular)  
3  GSTP1_HUMAN  Glutathione S-
transferase P 
 Score: 154 
Mass: 23341 
pI: 5.43 
coverage: 31%  
 Cytoplasm, 
Mitochondrion, 
Nucleus  
4  THIO_HUMAN  Thioredoxin  Score: 59 
Mass: 11730 
pI: 4.82 
coverage: 33% 
 Nucleus, 
Cytoplasm 
10= 2 
(Marker) 
 GSTP1_HUMAN  Glutathione S-
transferase P 
 Score: 140 
Mass: 23341 
pI: 5.43 
coverage: 39%  
 Cytoplasm, 
Mitochondrion, 
Nucleus 
11  PRDX6_HUMAN  Peroxiredoxin
-6 
 Score: 60 
Mass: 25019 
pI: 6.00 
coverage:19 % 
  Cytoplasm, 
Lysosome 
35  ATPB_HUMAN  ATP synthase 
subunit beta, 
mitochondrial 
 Score: 67 
Mass: 56525 
pI: 5.26 
coverage: 11 
% 
 Mitochondrion 
inner membrane 
48  HSP7C_HUMAN  Heat shock 
cognate 71 
kDa protein 
 Score: 228 
Mass: 70854 
pI: 5.37 
coverage: 24 
% 
 Cytoplasm, 
Melanosome, 
Nucleus › 
nucleolus,  
Cell membrane 
72  CH60_HUMAN  60 kDa heat 
shock protein, 
mitochondrial 
 Score: 80 
Mass: 61016 
pI: 5.70 
coverage: 18 
% 
 Mitochondrion 
matrix 
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3.5.3  Expression of proteins and Mass spectral analysis 
for Caco-2 cell line 
 
3.5.3.1 H2B1C_HUMAN 
 
The protein corresponding to spot 4 (H2B1C_HUMAN) was found to be down-regulated in Caco-
2 cell line following all selected treatments as compared to the level found in untreated cells (Table 
3.22). The protein sequence obtained from the Swiss Prot Database (UniProtKB/Swiss-Prot) of 
the protein matched well with Histone H2B type 1-C/E/F/G/I OS, (H2B1C_HUMAN) (Figure 
3.40).  
 
Figure 3.40: Matched peptides sequence in H2B1C_HUMAN protein sequence obtained from 
library search  
 
Masses of peptides from MS scan using MALDI are given in Figure 3.41. 
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Figure 3.41: Spectrum of H2B1C_HUMAN 
obtained from Mass spectrometer 
 
The sequence coverage was 37%, nominal mass (Mr) was 13898 Da and the calculated pI was 
10.31. The protein accession number is P62807. Figure 3.42 shows mascot score histogram 
where protein mascot scores of (H2B1C) is 183 and significant (P value <0.05).  
 
Figure 3.42: Summary of mascot score histogram for H2B1C_HUMAN 
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3.5.3.2 H4_HUMAN 
 
The expression of protein identified as spot 7 (H4_HUMAN) was found to be downregulated in 
treatment with Cap, Quer and Oxa +Quer (0/4) in Caco-2 cell line. However, the same protein 
was upregulated with the treatment of Oxa and Oxa +Cap (0/0) when compared with the 
expression in the non-treated Caco-2 cell line (Table 3.22). The resulting masses were then 
exported to Mascot for the identification and detection of the corresponding protein. The 
arrangement of the protein sequences obtained from the Swiss- Prot Database of protein in spot 
7 was found to greatly matched with Histone H4 ( Figure 3.43) 
 
Figure 3.43: Matched peptides sequence in H4_HUMAN protein sequence obtained from 
library search 
 
 
Masses of peptides from MS scan using MALDI are given in Figure 3.44. 
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Figure 3.44: Mass spectrum of H4_HUMAN 
The sequence coverage was 29%, nominal mass (Mr) was 11360 Da and the calculated pI was 
11.36. The protein accession number is P62805. Figure 3.45shows mascot score histogram of 
H4_HUMAN where protein mascot score is 140 and significant (P-value <0.05).  
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Figure 3.45: Summary of mascot score histogram of H4_HUMAN protein 
3.5.3.3 COF1_HUMAN 
 
The expression of protein identified as spot 10 (COF1_HUMAN) was found to be downregulated 
in all selected treatment groups added either as single or in combination drugs in Caco-2 cell line 
(Table 3.22). The resulting masses were then exported to Mascot for the identification and detection 
of the corresponding protein. The arrangement of the protein sequence obtained from 
(UniProtKB/Swiss-Prot) the Swiss- Prot Database of protein in spot 10 was found to greatly 
matched with Cofilin-1 OS, (COF1_HUMAN) (Figure 3.46).  
 
Figure 3.46: Matched peptides sequence in COF1_HUMAN protein sequence obtained from 
library search 
 
 
Masses of peptides from MS scan using MALDI are given in Figure 3.47. 
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Figure 3.47: Spectrum of COF1_HUMAN obtained from Mass spectrometer 
The sequence coverage was 62%, nominal mass (Mr) was 18491 Da and the calculated pI was 
8.22. The protein accession number is (P23528). Figure 3.48 shows mascot score histogram of 
(COF1_HUMAN) where mascot score is 62 and significant (P value <0.05).  
 
 
Figure 3.48: Summary of mascot score histogram of COF1_HUMAN protein 
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3.5.3.4 GSTP1_HUMAN 
 
The expression of protein identified as spot 15 (GSTP1_HUMAN) was found to be down 
regulated in response to all selected treatment of the drugs in comparison with non-treated 
Caco-2 cell line  (Table 3.22). This was used as marker 2 during matching of the spots using 
Melanie software. The resulting masses of spot 15 (marker 2) were then exported to Mascot 
for the identification and detection of corresponding protein. The arrangement of the protein 
sequence obtained from (UniProtKB/Swiss-Prot) the Swiss- Prot Database of protein in spot 
15 was found to greatly matched with Glutathione S-transferase P OS, (GSTP1_HUMAN) 
(Figure 3.49).  
 
Figure 3.49: Matched peptides sequence in GSTP1_HUMAN protein sequence obtained from 
library search. 
 
Masses of peptides from MS scan using MALDI are given in Figure 3.50. 
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Figure 3.50: Mass spectrum of GSTP1_HUMAN 
 
The sequence coverage was 57%, nominal mass (Mr) was 23341 Da and the calculated pI was 
5.43. The protein accession number is (P09211). Figure 3.51 shows mascot score histogram of 
GSTP1_HUMAN where the mascot score is 732 and significant (P-value <0.05).  
 
Figure 3.51: Summary of mascot score histogram of GSTP1_HUMAN protein 
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3.5.3.5 PPIB_HUMAN 
 
The expression of protein in Caco-2 cell line identified as spot 47 (PPIB_HUMAN) was found 
to be upregulated with the treatment of all selected drugs either alone or in combination (Table 
3.22). The protein sequence obtained from the Swiss Prot Database (UniProtKB/Swiss-Prot) of 
the protein well matched with Peptidyl-prolyl cis-trans isomerase B, (PPIB_HUMAN) (Figure 
3.52).  
 
Figure 3.52: Matched peptides sequence in PPIB_HUMAN protein sequence obtained from 
library search 
 
Masses of peptides from MS scan using MALDI are given in Figure 3.53. 
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Figure 3.53: Mass spectrum of PPIB_HUMAN 
 
The sequence coverage was 37%; nominal mass (Mr) was 23728 Da and  the calculated pI 
was 9.42. The protein accession is P23284. Figure 3.54 shows mascot score histogram of 
PPIB_HUMAN where the mascot score is 136 and significant (P-value <0.05). 
 
Figure 3.54: Summary of mascot score histogram of PPIB 
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3.5.3.6 PRDX1_HUMAN 
 
The expression of protein in Caco-2 cell line identified as spot 148 (PRDX1_HUMAN) was 
found to be upregulated in single drug treatment of Oxa and Quer, and combinations treatment 
with (Oxa + Cap, 0/0)  and (Oxa + Quer, 0/0). But in single drug treatment with Cap the protein 
did not express at all (Table 3.22). The resulting masses were then exported to Mascot for the 
identification and detection of the corresponding protein. The arrangement of the protein 
sequence obtained from (UniProtKB/Swiss-Prot) the Swiss- Prot Database of protein in spot 
148 was found to greatly matched with Peroxiredoxin-1 PRDX1_HUMAN (Figure 3.55).  
 
Figure 3.55: Matched peptides sequence in PRDX1_HUMAN protein sequence obtained 
from library search. 
. 
 
Masses of peptides from MS scan using MALDI are given in Figure 3.56 
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Figure 3.56: Mass spectrum of PRDX1_HUMAN 
The sequence coverage was 42%; nominal mass (Mr) was 22096 Da and the calculated pI was 
8.27. The protein accession number is (Q06830). Figure 3.57 shows mascot score histogram of 
PRDX1_HUMAN where the mascot score is 176 and significant (P value <0.05).  
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Figure 3.57: Summary of mascot score histogram of PRDX1_HUMAN protein  
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3.5.3.7 AGR2_HUMAN 
 
The expression of protein in Caco-2 cell line identified as spot 174 (AGR2_HUMAN) 
was found to be downregulated with the treatment of Oxa, upregulated with the 
treatment of Quer and (Oxa + Cap, 0/0). But the expression of protein remained same 
with the treatment of (Oxa +Quer, 0/0). Interestingly the spot disappeared with the 
treatment of Cap (Table 3.22). The protein sequence obtained from the Swiss Prot 
Database (UniProtKB/Swiss-Prot) of the protein matched well with Anterior gradient 
protein 2 homolog, (AGR2_HUMAN) (Figure 3.58).  
 
 
Figure 3.58: Matched peptides sequence in AGR2 protein sequence obtained from 
library search. 
 
Masses of peptides from MS scan using MALDI are given in figure 3.59. 
 169 
 
Figure 3.59: Mass spectrum of AGR2_HUMAN 
The sequence overage was 32%; nominal mass (Mr) was 19967 Da and the calculated 
pI was 9.03. The protein accession number is O95994. Figure 3.60 shows mascot score 
histogram of AGR2_HUMAN where the mascot score is 130 and significant (P value 
<0.05).  
 
Figure 3.60: Summary of mascot score histogram of AGR2_HUMAN 
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3.5.4  Expression of proteins and Mass spectral 
analysis for Lim-2405 cell line 
3.5.4.1 GSTP1_HUMAN 
 
The expression of protein in Lim-2405 cell line identified as spot 3 (GSTP1_HUMAN) 
was found to be downregulated in treatment with Oxa alone and the combination of 
(Oxa + Cap, 0/0) as compared to the level found in untreated control. However, Cap 
alone treatment leaded to upregulation of the protein. Interestingly, combination of 
(Oxa + Cap, 0/4) treatment did not express the protein at all. The resulting masses were 
then exported to Mascot for the identification and detection of the corresponding 
protein. The arrangement of the protein sequence obtained from (UniProtKB/Swiss-
Prot) the Swiss Prot Database of protein in spot 3 was found to greatly matched with 
Glutathione S-transferase P,  (GSTP1_HUMAN) (Figure 3.61).  
 
Figure 3.61: Matched peptides sequence in GSTP1 protein sequence obtained from 
library search. 
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Masses of peptides from MS scan using MALDI are given in Figure 3.62. 
 
Figure 3.62: Mass spectrum of GSTP1_HUMAN 
The sequence coverage was 31%; Nominal mass (Mr) was 23341 Da and the calculated 
pI was 5.43. The protein accession is P09211. Figure 3.63 shows mascot score 
histogram of GSTP1_HUMAN where the mascot score is 154 and significant (P value 
<0.05).   
 
Figure 3.63: Summary of mascot score histogram of GSTP1_HUMAN protein 
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3.5.4.2 THIO_HUMAN 
 
The expression of protein in Lim-2405 cell line identified as spot 4 (THIO_HUMAN) 
was found to be down-regulated in treatment with Oxa alone as compared to the level 
found in untreated control group. The protein was disappeared in case of other treatment 
groups  (Table 3.24). The resulting masses were then exported to Mascot for the 
identification and detection of the corresponding protein. The arrangement of the 
protein sequence obtained from (UniProtKB/Swiss-Prot) the Swiss Prot Database of 
protein in spot 4 was found to greatly matched with Thioredoxin (THIO_HUMAN) 
(Figure 3.64).  
 
Figure 3.64: Matched peptides sequence in THIO protein sequence obtained from 
library search. 
 
Masses of peptides from MS scan using MALDI are given in Figure 3.65. 
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Figure 3.65: Spectrum of THIO_HUMAN obtained from Mass spectrometer 
 
The sequence coverage was 33 %, nominal mass (Mr) was 11730 Da and the calculated 
pI was 4.82. The protein accession number is P10599. Figure 3.66 shows mascot score 
histogram of THIO_HUMAN where the mascot score is 59 and significant (P value 
<0.05). 
 
 
Figure 3.66: Summary of mascot score histogram of THIO_HUMAN protein 
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3.5.4.3 GSTP1_HUMAN 
 
Spot 10 is in fact marker 2 of Lim-2405 cell line. The expression of protein in Lim-
2405 cell line identified as spot 10 (GSTP1_HUMAN) was found to be downregulated 
in treatment with Oxa alone and in combination with Cap at 0//0 h sequence. Whereas, 
the expression of the protein with the treatment of Cap alone and its combination with 
Oxa at 0/4 sequence was found to be upregulated (Table 3.24). The resulting masses 
were then exported to Mascot for the identification and detection of the corresponding 
protein. The arrangement of the protein sequence obtained from (UniProtKB/Swiss-
Prot) the Swiss Prot Database of protein in spot 10 was found to greatly matched with 
(GSTP1_HUMAN) (Figure 3.67).  
 
 
Figure 3.67: Matched peptides sequence in GSTP1 protein sequence obtained from 
library search. 
. 
Masses of peptides from MS scan using MALDI are given in Figure 3.68. 
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Figure 3.68: Spectrum of GSTP1_HUMAN obtained from Mass spectrometer 
The sequence coverage was 39 %; nominal mass (Mr) was 23341 Da and the calculated 
pI was 5.43. The protein accession is Q8NDQ6. Figure 3.69 shows mascot score 
histogram of GSTP1_HUMAN where the mascot score is 140 and significant (P value 
<0.05). 
 
Figure 3.69: Summary of mascot score histogram of GSTP1_HUMAN protein 
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3.5.4.4  PRDX6_HUMAN 
 
The expression of protein in Lim-2405 cell line identified as spot 11 
(PRDX6_HUMAN) was found to be down-regulated in treatment with Oxa alone,  
upregulated with Cap alone and its combination with Oxa at 0/4 sequence (Table 3.24). 
But the expression of the protein was not observed in combined treatment of (Oxa + 
Cap, 0/0 h). The resulting masses were then exported to Mascot for the identification 
and detection of the corresponding protein. The arrangement of the protein sequence 
obtained from (UniProtKB/Swiss-Prot) the Swiss Prot Database of protein in spot 11 
was found to greatly matched with (PRDX6_HUMAN) (Figure 3.70).  
 
 
Figure 3.70: Matched peptides sequence in PRDX6 protein sequence obtained from 
library search. 
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Masses of peptides from MS scan using MALDI are given Figure 3.71. 
 
Figure 3.71: Spectrum of PRDX6_HUMAN obtained from Mass spectrometer 
The sequence coverage was 19 %; nominal mass (Mr) was 25019 Da and the calculated 
pI was 6.00. The protein accession number is Q8NDQ6. Figure 3.72 shows mascot 
score histogram of PRDX6_HUMAN where the mascot score is 60 and significant (P-
value <0.05).  
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Figure 3.72: Summary of mascot score histogram of PRDX6_HUMAN protein 
3.5.4.5 ATPB_HUMAN 
 
The expression of protein in Lim-2405 cell line identified as spot 35 (ATPB_HUMAN) 
was found to be upregulated with all of the treatment group except combination 
treatment of (Oxa + Cap, 0/0) where the expression of the protein was not observed 
(Table 3.24). The resulting masses were then exported to Mascot for the identification 
and detection of the corresponding protein. The arrangement of the protein sequence 
obtained from (UniProtKB/Swiss-Prot) the Swiss Prot Database of protein in spot 35 
was found to greatly matched with ATP synthase subunit beta, (ATPB_HUMAN) 
(Figure 3.73).  
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Figure 3.73: Matched peptides sequence in ATPB protein sequence obtained from 
library search. 
Masses of peptides from MS scan using MALDI are given in Figure 3.74. 
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Figure 3.74: Spectrum of ATPB_HUMAN obtained from Mass spectrometer 
 
The sequence coverage was 11 %; nominal mass (Mr) was 56525 Da and the calculated 
pI was 5.26. The protein accession was P06576 (Table 3.25). Figure 3.75 shows mascot 
score histogram of ATPB_HUMAN where the mascot score is 67 and significant (P 
value <0.05).  
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Figure 3.75: Summary of mascot score histogram of ATPB_HUMAN protein 
 
3.5.4.6 HSP7C_HUMAN 
 
The expression of protein in Lim-2405 cell line identified as spot 48 
(HSP7C_HUMAN) was found to be upregulated in all treatment treatment groups 
except (Oxa + Cap, 0/0). The later treatment did not allow to express the protein at all 
in Lim-2405 cell (Table 3.24).  The resulting masses were then exported to Mascot for 
the identification and detection of the corresponding protein. The arrangement of the 
protein sequence obtained from (UniProtKB/Swiss-Prot) the Swiss Prot Database of 
protein in spot 48 was found to greatly matched with Heat shock cognate 71 kDa 
protein, (HSP7C_HUMAN) (Figure 3.76).  
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Figure 3.76: Matched peptides sequence in HSP7C protein sequence obtained from 
library search. 
 
Masses of peptides from MS scan using MALDI are given in in Figure 3.77. 
 
Figure 3.77: Spectrum of HSP7C_HUMAN obtained from Mass spectrometer 
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The sequence coverage was 24 %; nominal mass (Mr) was 70854 Da and the calculated 
pI was 5.37. The protein accession number is P11142 (Table 3.25). Figure 3.78 shows 
mascot score histogram of HSP7C_HUMAN where the mascot score is 228 and 
significant (P-value <0.05).  
 
Figure 3.78: Summary of mascot score histogram of HSP7C_HUMAN protein 
3.5.4.7 CH60_HUMAN 
 
The expression of protein in Lim-2405 cell line identified as spot 72 (CH60_HUMAN) 
was found to be upregulated in treatment with Oxa alone and 0/0 h combination of Oxa 
+ Cap. On the other hand, Cap alone and 0/4 h combination of Oxa + Cap did not 
express that protein (Table 3.24). The resulting masses were then exported to Mascot 
for the identification and detection of the corresponding protein. The arrangement of 
the protein sequence obtained from (UniProtKB/Swiss-Prot) the Swiss Prot Database 
of protein in spot 72 was found to greatly matched with 60 kDa heat shock protein, 
mitochondrial,  (CH60_HUMAN) (Figure 3.79).  
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Figure 3.79: Matched peptides sequence in HSP7C protein sequence obtained from 
library search. 
 
Masses of peptides from MS scan using MALDI are given in Figure 3.80. 
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Figure 3.80:  Mass spectrum of CH60_HUMAN 
The sequence coverage was 18%; nominal mass (Mr) was 61016 Da and the calculated 
pI was 5.70. The protein accession number is P10809. Figure 3.81 shows mascot score 
histogram of CH60_HUMAN where the mascot score is 80 and significant (P-value 
<0.05).  
 
Figure 3.81: Summary of mascot score histogram of CH60_HUMAN protein 
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CHAPTER FOUR 
4  DISCUSSION 
 
Improvement in survival rate in colorectal cancer has been made in the past few decades 
due to advancement in diagnosis and treatment methods (Siegel et al., 2016). However, 
the patients undergoing chemotherapy would face a number of dose-related side effects 
of chemotherapeutic drugs. To reduce these adverse effects and to increase 
effectiveness of chemotherapy, researchers have focused on natural plant products to 
be administered mainly in  combination with targeted therapy (Porcelli et al., 2017). As 
stated earlier, the present study was designed to explore drug action from the 
combination of platinum drugs: cisplatin (Cis) and oxaliplatin (Oxa) and 
phytochemicals: resveratrol (Res), thymoquinone (TQ), capsaicin (Cap) and quercetin 
(Quer) against colorectal cancer. The results of the study were given in chapter three. 
This chapter provides a thorough discussion of the results in terms of current state of 
knowledge including ideas and concepts.  
4.1  Cytotoxicity of single drugs and 
phytochemicals 
 
Antitumour activity of platinum drugs and selected phytochemicals was first 
determined using MTT reduction assay (Wu et al., 2008). Human colorectal cancer cell 
lines used in the study were HT-29, Caco-2, Lim-1215 and Lim-2405.  
The IC50 values of the platinum drugs and selected phytochemicals were given in Table 
3.1. It is clear that all of the phytochemicals were less active than the platinum drugs in 
all the four colorectal cancer cell lines. Oxaliplatin showed higher cytotoxicity than 
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cisplatin against the four colorectal cancer cell lines (with similar IC50 values in all the 
cell lines). However, the activity of cisplatin was three to five times less in Caco-2 cell 
line compared to other three cell lines. Higher activity of oxaliplatin than cisplatin has 
been reported earlier against six different colorectal cancer cell lines including HT-29 
(Arnould et al., 2003). Similar finding has been described by Virag et al. as applied to 
Colo-320 and HT-29 cell lines (Virag et al., 2012). However, Virag et al. found lower 
IC50 value for cisplatin than oxaliplatin against Caco-2 cell line in conflict with the 
result from the present study. The reason remains unclear unless the cell line used in 
the study (Caco-2) developed different characteristics. It is thought that bulkier and 
hydrophobic groups present in oxaliplatin might be responsible for higher cytotoxicity 
of the compound (Seetharam et al., 2009). 
Among the phytochemicals, thymoquinone was found to have the highest activity as 
compared to other phytochemicals. The observed trend for cytotoxicity for 
thymoquinone as well as other phytochemicals was: TQ > Res ≈ Quer > Cap. Similar 
trend of cytotoxicity profile was also observed for resveratrol, thymoquinone, capsaicin 
and quercetin against A2780, A2780cisR and A2780ZDO473R ovarian tumour models 
(Nessa et al., 2011, Nessa et al., 2012, Arzuman et al., 2016). Like oxaliplatin, 
thymoquinone showed greater activity against Caco-2 cell line than other tested cell 
lines. In earlier findings, it was also observed that TQ was most sensitive against Caco-
2 cell line among five different colorectal cell lines (Caco-2, HCT-116, LoVo, DLD-1 
and HT-29) (El-Najjar et al., 2010). IC50 value for TQ found in the study against HT-
29 cell line was 12.03 μM after 72 h incubation which is smaller than earlier reported 
values of 28.2 μM after 24 h incubation period (Abdelazeem et al., 2017) and that is to 
be expected because the two studies differed in the period of incubation. In another 
study, the IC50 value of TQ after 72 h incubation was reported to be 1.4 times greater 
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than cisplatin in agreement with findings of the present study (Rooney and Ryan, 2005). 
The IC50 values of TQ against Caco-2 cell line found in other studies (12.5 µM and 8 
µg/mL) (Norsharina et al., 2011, El-Najjar et al., 2010)  can be seen to be similar to the 
values from the present study. No report could be found regarding IC50 values of TQ 
against Lim-1215 and Lim-2405 cell line.  
Antiproliferative effects of TQ have been linked with mitogen-activated protein kinase 
(MAPK) and protein kinase B (AKT/PKB) signalling pathways. In DLD-1 colorectal 
cancer cell line, TQ has been found to activate the c-Jun N-terminal kinase (JNK) and 
extracellular-signal-regulated kinases (ERKs) proteins of the MAPK family (El-Najjar 
et al., 2010). Other studies also provide support to the idea (Koka et al., 2010, Torres et 
al., 2010). However, in myeloma and squamous cell carcinomas, the pathways are 
found to be inhibited by TQ (Badr et al., 2011, Das et al., 2012). 
Resveratrol is found to be the second most active phytochemical after thymoquinone 
against all tested cell lines except Lim-2405. Res is found to be most sensitive against 
Caco-2 cell line followed by HT-29, Lim-2405 and Lim-1215 cell lines. Other studies 
also showed that IC50 value of Res was lower against Caco-2 cell line than HT-29 cell 
line (González-Sarrías et al., 2011, Li et al., 2009a). However, the reported IC50 
values of Res against HT-29 and Caco-2 cells are about two times greater than the 
values observed in the present study (Sgambato et al., 2001, De Maria et al., 2013, Li 
et al., 2009b, González-Sarrías et al., 2011).  
In the study of Carew et al., IC50 value of Res against Caco-2 cell line was found to be 
half of that observed in the present study. The reasons behind the variation of IC50 
values of Res from different studies might be due to the duration differences in the 
incubation period (24 h, 48 h, 72 h and 96 h) and differences in experimental 
conditions and growth characteristics of cells.  
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Moreover, biphasic pattern of activity was observed for Res in Caco-2 and HT-29 cell 
line (Fig 3.1 and Fig 3.2) showing wide variation in activity with the change in 
concentration. Limited cell kill at lower doses and greater cell kill at higher doses for 
Res were also reported by Peiro et al (San Hipólito-Luengo et al., 2017). Interestingly, 
biphasic pattern was not observed in Lim-1215 and Lim-2405 cell lines. Activity of Res 
in any of the tested Lim cell lines was not reported earlier. The cell death mechanism 
mediated by Res has been described in terms of extrinsic and intrinsic apoptotic 
pathways as applied to colorectal cancer cell lines (Miki et al., 2012, Liu et al., 2014, 
Fouad et al., 2013). 
Unlike thymoquinone and resveratrol, quercetin caused greater kill of HT-29 cells than 
that caused in Caco-2 cell line (Table 3.1). However, the trend of antitumour activity 
of quercetin as observed in the present study can be seen to match with the reported 
results with little differences in IC50 values against HT-29 and Caco-2 cell lines (Kuo, 
1996, Wenzel et al., 2004, Delgado et al., 2014, Yang et al., 2016, Shedid et al., 2017, 
Atashpour et al., 2015). However, the present study is the first to report anticancer 
activity of Quer against Lim-1215 and Lim-2405 cell lines.  
Quer is believed to bring about apoptosis with the involvement of different proteins 
including PKC, cdc25 phosphatase, PI3K, protein kinase-B phosphorylated, DNA 
topoisomerase II and JNK. Additionally, Quer inhibits p53 gene by blocking G2-M 
phase of cell cycle (Filipa Brito et al., 2015). 
Among the four phytochemicals, capsaicin was found to be least cytotoxic against the 
tested cancer cell lines although in Caco-2 cell line Cap had lower IC50 value than Quer 
(Table 3.1). When the activity of Cap against the tested cell lines are compared, Cap is 
found to be most sensitive against HT-29 cell line, equally sensitive against Caco-2 and 
Lim-2405 cell lines, least active against Lim-1215 cell line. Only one report could be 
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on the antiproliferative activity of Cap against HT-29 cell line where the IC50 value of 
Cap was found to lie between 100 to 200 µM after 24 h incubation (Kim et al., 2007). 
In the present study, Cap is found to have an IC50 value of 58.1 µM (after 72 h of 
incubation) which is somewhat lower than the reported value. No report could be found 
on the IC50 values for Cap against Caco-2, Lim1215 and Lim-2405 cell lines. Studies 
in mice bearing colorectal tumour xenografts showed that Cap significantly reduced 
tumour progression by activating caspase-3, caspase-8, caspase-9, Bax, Fas and 
reducing Bcl-2 (Lu et al., 2010). 
4.2  Drugs in Combination 
 
Combination of dietary phytochemicals having antioxidant attributes with currently 
used chemotherapy is actively considered to provide a better means to combat cancer 
(Ho and Cheung, 2014). However, selection of appropriate phytochemicals, right dose 
and appropriate sequence of administration are considered to be critical determinants. 
Usually, combination therapy is divided into two types - vertical and horizontal. In 
vertical combination, combined drugs would target the same pathway individually at 
two different points. In horizontal combination, selected drugs would target different 
intracellular signalling pathways (Lombardo et al., 2012). In this study, a combination 
of cisplatin and oxaliplatin with phytochemicals would fall under the classification of 
a horizontal combination strategy. The idea is that a number of phytochemicals 
including those in the present study can sensitize tumour cells towards platinum drugs 
by modulating different pathways.  
The effect of a change in concentration and sequence of addition has been studied by 
combining the drugs at equipotent ratios. Nature of combined drug action in terms of 
synergism, additiveness and antagonism have been determined from dose response 
 191 
curves and combination index values. Each of the combination sets (Cis+Res, Cis+TQ, 
Cis+Cap, Cis+Quer, Oxa+Res, Oxa+TQ, Oxa+Cap and Oxa+Quer) have been 
investigated in four different colorectal cancer cell lines. The results of the combined 
drug action from the combination of cisplatin and oxaliplatin with selected 
phytochemicals have been shown as dose response curves (Figure 3.5 to Fig 3.12) and 
combination indices (Table 3.10 to Table 3.17). It has been observed that among the 
selected combination sets, only in few cases mild synergistic to additive effect was 
found. In general, the greater synergistic effect was observed at higher concentrations 
(ED90 and ED75). However, no clear-cut evidence could be found as applied to the 
association between cell kill and sequence of administration (0/0, 0/4 and 4/0). 
The greatest synergism was observed from the combination of Cis and Res as compared 
to all other combination sets in all of the four tested colorectal cell lines irrespective of 
sequence of addition. Generally, greater synergism was observed at a higher 
concentration than at lower concentrations. The combined drug action was found to 
vary from one cell line to another. In Caco-2 and Lim-2405 cell lines, the combination 
Cis+Res produced synergistic outcomes at all concentrations and for all sequences of 
administration, with the greatest synergism being found in Caco-2 cell line at ED90 
level. However, the combination of Cis and Res produced concentration dependent 
antagonistic outcome in Lim-1215 cell line as applied to 4/0 sequence of administration 
(meaning Res was added first and Cis 4 h later) but in HT-29 cell line antagonism was 
observed at ED50 level for all sequences of administration.  In contrast, a combination 
of Res with Oxa produced synergism in Caco-2, and Lim-2405 cell lines at higher 
concentrations but predominantly antagonistic outcomes were produced in HT-29 and 
Lim-1215 cell lines. The changes in combined drug effect with the change in nature of 
the cancer cell lines, was also observed in ovarian cancer model where combination of 
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oxaliplatin and resveratrol showed synergism against A2780 and A2780cisR but 
antagonism against A2780ZD0473R cell line (Nessa et al., 2012).  
Chemo-sensitizing activity of Res has been described for different tumour models as 
applied to different drug i.e. cisplatin and doxorubicin in ovarian, lung and uterine 
cancer (Rezk et al., 2006, Ma et al., 2015, Hu et al., 2016), 5-fluorouracil in colorectal 
cancer (Buhrmann et al., 2015), and paclitaxel in lung cancer (Kong et al., 2017). In 
vitro and nude mice xenograft model studies have shown that resveratrol gives 
synergistic effect against colorectal cancer by upregulating miR-34c-KITLG (Yang et 
al., 2015). The proposed molecular mechanism for the synergistic anticancer effect of 
Res obtained from the present study is presented in Figure 4.1. 
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Figure 4.1: Molecular mechanism of Res that could be responsible for synergism 
Thymoquinone in combination with cisplatin produced weak synergism to additiveness 
against all tested cell lines except Lim-2405. In HT-29 cell line, greater synergism was 
observed at higher concentrations, but the converse was true for Lim-1215 and Caco-2 
cell lines. Unlike resveratrol, TQ displayed greater synergism in combination with 
oxaliplatin than that observed in combination with cisplatin. The combination Oxa+TQ 
showed synergism against all the four tested cell lines. However, greater synergism was 
found against Lim-1215 cell line from treatment with the combination of Oxa and TQ 
than that with the combination of Cis and TQ. Combination of Oxa and TQ produced 
synergistic outcomes with 0/0 and 0/4 All sequences of administration but not with 4/0 
sequence at ED50 level where additiveness was observed. Bolus administration of Oxa 
and TQ exhibited mainly antagonism compared to administrations with 4h time gaps.  
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The results of combined drug action observed in the present study can be seen to be 
similar to that obtained in ovarian tumour models as applied to the combinations 
Cis+TQ and Oxa+TQ where synergism was found in most of the cases especially for 
the sequenced administration of the drugs (Huq et al., 2014). TQ in combination also 
enhanced anticancer activity of paclitaxel in triple negative breast cancer (Şakalar et 
al., 2016), topotecan in colorectal cancer and leukemia (Khalife et al., 2016, Khalife et 
al., 2014), cisplatin in animal model of lung cancer and ovarian cancer (Jafri et al., 
2010, Wilson et al., 2015), gemcitabine and oxaliplatin in pancreatic cancer (Banerjee 
et al., 2009) and 5-fluorouracil in gastric cancer (Lei et al., 2012). In several instances, 
it has been shown that bolus administration of TQ and chemotherapeutic drugs would 
minimize toxicity (El-Ashmawy et al., 2017, Badary, 1999). Key signalling pathways 
modulated by TQ that confers observed synergistic activity in this and other reported 
study are summarized in Figure 4.2. 
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Figure 4.2: Molecular mechanism of TQ that could be responsible for synergism 
 
Among the four phytochemicals, capsaicin was found to be least effective in cell kill 
when combined with cisplatin. The combination Cis+Cap produced antagonism in most 
of the cases in all cell lines. Antagonism was greatest for 0/4 sequence of administration 
of Cis+Cap. 4/0 sequence of Cis and Cap also showed antagonism except at ED90 level 
in Lim-1215 and HT-29 cell lines where mild synergism and additiveness were 
observed. On the other hand, bolus administration of Cis+Cap produced a mild 
synergistic effect at ED50 against all tested cell lines except HT-29. Combination 
treatment of Oxa and Cap produced high synergism against Lim-2405 cell line for all 
sequences of administration and at all concentrations. In Lim-2405 cell line, the degree 
of synergism was found to increase with the increase in concentration. However, in all 
other cell lines, generally, antagonism was observed except with 4/0 sequence at higher 
concentration. From the literature review, no report could be found regarding the 
synergistic or antagonistic outcomes from combinations: Cis+Cap or Oxa+Cap as 
applied to any of the colorectal models. Cap in combination with Cis produced 
synergistic outcomes against gastric cancer cell lines believed to be caused by 
degradation of cisplatin-inducible aurora-A protein (Huh et al., 2011). Another report 
suggests that capsaicin in combination with camptothecin produces synergistic cell kill 
in lung cancers via calpain pathway (Friedman et al., 2017). Studies on ovarian tumour 
models carried out in the host laboratory, showed sequence and concentration 
dependent synergism from a combination of Cap with Cis and Oxa (Huq et al., 2014). 
However, at low-concentration, capsaicin is reported to promote colorectal cancer 
metastasis by actuating ROS production, up-regulating expression of MMP-2 and 
activating Akt/mTOR and STAT-3 pathways (Yang et al., 2012). Antagonistic outcome 
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observed in the present study may be associated with low concentration of Cap used in 
combination study. Several studies reported that Cap did not show any antitumour 
activity when given at lower concentration (Lu et al., 2010, Yang et al., 2012, Lin et 
al., 2013).  
The reason behind the synergistic outcome from treatment with the combination 
Oxa+Cap for all sequences of administration and at all concentrations as observed in 
Lim-2405 cell line is not well clear but may be due to the nature of the cell line itself. 
Lim-2405 represents adherent, poorly differentiated (aggressive) primary tumour 
whereas Lim-1215 is moderately differentiated and metastatic tumour (Sethi et al., 
2013). Caco-2 cells can differentiate spontaneously in vitro under standard culture 
conditions whereas HT-29 cells cannot differentiate spontaneously in vitro under 
standard conditions, representing undifferentiated colonic epithelial cells (Lenaerts et 
al., 2007). These differences in the inherent nature of the cell lines might lead to varied 
response against the same drug.  
Combination Cis+Quer produced significant synergism in Lim-1215 and Lim-2405 cell 
lines for all sequences of administration and at all concentrations. The observed 
synergism did not show any variation with the change in the sequence of administration. 
In HT-29 and Caco-2 cell lines, the combination Cis+Quer was mostly antagonistic in 
action. The combination Oxa+Quer showed a synergistic effect against HT-29 cell line 
at all concentrations and for all the 0/4 and 4/0 sequences of administration. Quer is 
reported to have displayed chemosensitizing effects when administered as a bolus along 
with cisplatin in ovarian, nasopharyngeal, head and neck cancer (Scambia et al., 1990, 
Daker et al., 2012, Sharma et al., 2005, Kuhar et al., 2007). Oxa is also reported to 
produce synergistic outcome in combination with Quer against ovarian cancer (Nessa 
et al., 2011). Quer in combination with doxorubicin was reported to enhance 
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cytotoxicity and apoptosis in ovarian tumour models (Atashpour et al., 2015). 
Synergistic outcome associated with the combination of Quer with platinum against 
colorectal cancer can be mediated by the inhibition of PI3K/Akt/mTOR, induction of 
JNK/JUN pathways, binding with CB1 receptor and modulation of β-catenin pathways, 
blocking GLUT-I, inhibition of shock proteins and PTKs activity, blocking G2-M 
phase of cell cycle, generation of ROS and activation of AMPK followed by increased 
Sestrin 2 expression (Refolo et al., 2015, Brito et al., 2015, Shedid et al., 2017, Raja et 
al., 2017, Kim et al., 2013). 
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4.3  Mechanistic information from 
DNA damage study 
 
This study provided qualitative information on DNA conformational change and 
damage to DNA resulting from the interaction with the compounds. Altered nature of 
formed DNA adducts following entry of the platinum drug into the nucleus, subsequent 
differences in protein recognition and downstream processes in the cell cycle may 
ultimately cause apoptotic cell death. As mentioned earlier, treatment of Caco-2 cell 
line with two synergistic combinations, treatment of Lim-2405 cell line with two 
synergistic and one antagonistic combination, were selected for this study to find out 
whether there was any correlation between DNA damage and the combined drug effect. 
Results of DNA damage study showed that in Caco-2 cell line Quer was most damaging 
to DNA followed by Oxa (Figure 3.21-Figure 3.23). The findings are in agreement with 
reported results (Srivastava et al., 2016b). Although Oxa is more cytotoxic than Quer, 
the latter is more damaging to DNA in Caco-2 cell line. This is due to the fact that cell 
death does not depend only on the binding with DNA or damage of DNA but the mode 
of binding that cause greater disruption of DNA structure is more important. Another 
possibility is that the cell death mechanism involves targets other than DNA such as 
intervention with protein function may play a bigger role in the effects of Oxa than 
Quer (Ta et al., 2006). Synergistic combinations of Oxa and Quer were found to be 
more damaging to DNA than Oxa but less than Quer in Caco-2 cell line. The lesser 
damage from treatment with the synergistic combination compared to that with Quer 
alone could be due to reduced concentration of Quer in the combination than when Quer 
is added as a single drug. The converse would be true when DNA damage of Oxa is 
compared with that from synergistic combinations: Oxa+Quer (0/0) and Oxa+Quer 
(0/4) in Caco-2 cell line. 
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As applied to DNA damage in Lim-2405 cell line, it has been observed that treatment 
with synergistic combination Oxa+Cap (0/0) is more damaging than that due to Oxa 
alone and treatment with antagonistic combination Oxa+Quer (0/0) produces the 
converse effect. Although the results are as expected, why treatment with the other 
antagonistic combination Oxa+Quer (0/4) shows the highest DNA damage is not clear. 
However, it is clear from the DNA study that damage to the DNA varies with the change 
in the sequence of drug administration in the combined drug treatments. For example, 
Oxa+Quer, when given as a bolus, produced the least damage to DNA but when 
administered using 0/4 sequence, DNA damage was highest.  
4.4  Cellular uptake of Platinum and 
PtDNA binding 
 
Entry into cells is a prerequisite for platinum drugs to bind with DNA before exerting 
their anticancer properties. DNA binding and recognition of altered DNA are the 
important processes responsible for their antitumour activity of platinum drugs (Brabec 
et al., 2017). A higher level of intracellular platinum accumulation may result into a 
greater level of platinumDNA binding although not necessarily so as platinum drugs 
may experience deactivation due to binding with cellular glutathione and 
metallothionein before binding with DNA. Cell death mediated by platinums after 
binding with DNA is dependent on (i) nature and structure of the DNA lesion induced; 
(ii) conformational alterations induced in DNA by these lesions; and (iii) various 
cellular signalling pathways initiated by platinum-DNA damage (Brabec et al., 2017).   
As noted earlier, DNA binding study was carried out to explore the link between 
combined drug action and cellular accumulation of platinum as well as the level of 
platinumDNA binding. Since drugs were added into the cells at their IC50 
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concentrations, only few combination sets were selected for this study that shows clear 
synergism or antagonism at ED50 level during combination study. Based on the CI 
values at ED50 level two synergistic combination treatments from Caco-2 cell line; two 
synergistic, and two antagonistic combination treatments from Lim-2405 cell line were 
chosen for this study. It was found that treatments with synergistic combination showed 
increased cellular accumulation of platinum than that with single in Lim-2405 cell line 
(Table 3.20) whereas antagonistic treatment caused decreased the cellular accumulation 
of platinum in Lim-2405 cell line. The results can be seen to indicate that the order of 
cellular accumulation is in agreement with the order of the observed synergism which 
was also reported in case of ovarian cancer model (Nessa et al., 2011, Arzuman et al., 
2014). It should, however, be noted that in Caco-2 cell line, treatment with synergistic 
combination did not result in increased cellular accumulation of platinum.  
In contrast, level of PtDNA binding was found to be increased in treatment with 
synergistic combinations in both Caco-2 and Lim-2405 cell lines (Table 3.21). 
Likewise, level of PtDNA binding was found to be reduced in treatment with 
antagonistic combinations in Caco-2 and Lim-2405 cell lines. Hence synergism 
produced from the combination treatment can be related to increased PtDNA binding 
so aided by the presence of phytochemicals used in combination. Conversely, in 
treatment with antagonistic combinations, the phytochemicals may be inhibiting the 
binding of platinum with DNA in agreement with the previous findings (Nessa et al., 
2011, Arzuman et al., 2014).       
4.5  Proteomics studies 
 
Proteomics provides a growing research arena which can be used to gather a functional 
understanding of the proteins that are differentially expressed in tumour cells. 
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Currently, mass spectrometry based proteomics study is being extensively employed in 
many research areas including biomarker- related research and opened a unique 
window into biological perturbation (Deng et al., 2016). This technique gives additional 
insights into the molecular mechanisms that relate to carcinogenesis of a particular 
cancer and its chemoresistance mechanism (Chaiyawat et al., 2017). In this research, 
proteomic studies were carried out to determine further changes in expression of the 
identified proteins in the drug-treated cell compared to untreated colorectal cancer cell 
lines Caco-2 and Lim-2405.  
A total of 195 spots were identified in Caco-2 cell line, and 137 spots were identified 
in Lim-2405 cell line before they any drug treatment. Expression of each of the protein 
spots in Caco-2 cell line was compared with the corresponding value found in before 
and after treatments with the selected drugs administered alone and in the following 
combinations: Oxa, Cap, Quer, (Oxa + Cap, 0/0)  and (Oxa + Quer, 0/0) (Table 3.22). 
Twenty spots were found to be significantly altered in expression (up- or down-
regulated) in Caco-2 cell line due to one or more of the treatments. Among these 20 
spots, only 7 spots could be identified successfully. In some cases MS data were 
insufficient for protein identification of the selected spot. On the other hand in Lim-
2405 cell line, only 7 spots could be identified properly from total of 9 differentially 
expressed proteins. GSTP1_HUMAN protein spot was identified as two different spots 
(Spot 3 and Spot 10). The appearance of different spots of the same protein as multiple 
isoforms with changed pIs, suggest the presence of different post-translationally 
modified forms of the same protein. This scenario is not unlikely in 2-D gel 
electrophoresis-based proteomics and observed in previous studies conducted in the 
host laboratory and elsewhere (Al-Eisawi et al., 2016, Schlüter et al., 2009, Takenawa 
et al., 2013).  
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Information from UniPort database and existing reported works were used to group the 
finally identified proteins in terms of the localization and cellular functions. Most of 
the differentially expressed proteins in Caco-2 cell line were found to be located in 
Nucleus and chromosome (43%), followed by cytoplasm (29%) and endoplasmic 
reticulum and mitochondria (Figure 4.3). However, some of the proteins found to share 
different locations. For example, GSTP1_HUMAN is usually present in the cytoplasm, 
mitochondria and nucleus; PROF1_HUMAN is localized at cytoplasm and 
cytoskeleton. Thus the choice of the location of an individual protein is arbitrary. Figure 
4.4 represents the subcellular location and percentage distribution of differentially 
expressed proteins after treatment in Lim-2405 cell line where it can be seen that highest 
number of differentially expressed proteins are localized in mitochondria (50%) 
followed by cytoplasm (33%) and nucleus (17%). The selection of the located position 
of each protein in Lim-2405 cell line is also arbitrary because few proteins were found 
in many different organelles. For example- HSP7C_HUMAN locates in the cytoplasm, 
melanosome, nucleus and cell membrane. 
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Figure 4.3: Main subcellular location and percentage distribution of differentially 
expressed proteins after treatment in Caco-2 cell line 
 
Figure 4.4: Main subcellular location and percentage distribution of differentially 
expressed proteins after treatment in Lim-2405 cell line 
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From the view of functional classification, the highest percentage of the differentially 
expressed proteins in Caco-2 cell line belongs to transcription regulation class (29%) 
and cytoskeleton organization class (29%). The rest of them belong to proto-oncogene 
(14%), drug detoxification (14%) and redox regulation (14%) classes. On the other 
hand in Lim-2405 cell line, chaperon class constitutes 33% of all differentially 
expressed proteins, redox regulation class also contains 33% proteins. The other 
differentially expressed proteins fell into drug detoxification class (17%) and ATPase 
activity class (17%). The pictorial presentation is given in Figure 4.5 and Figure 4.6. 
 
Figure 4.5: Functional classification as a percentage of the identified proteins 
differentially expressed in Caco-2 cell line 
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Figure 4.6: Functional classification as a percentage of the identified proteins 
differentially expressed in Lim-2405 cell line 
4.5.1 H2B1C_HUMAN 
 
Genomic DNA in eukaryotic cells is organized into nucleosomes which are the 
fundamental repeating units of chromatin. Each nucleosome unit is composed 
of four core histone proteins, H2A, H2B, H3 and H4 that form an octamer 
around which a segment of DNA winds with 147 base pairs in 1.7 left-handed 
superhelical turns (Talbert and Henikoff, 2014). Mutations meaning deletions 
or altered expression profiles alter the function of several histone-modifying 
proteins contribute to colorectal carcinogenesis (Gargalionis et al., 2012). 
Recently a new terminology “histo-oncomodifications”, has been coined to 
describe the histone covalent alterations that are linked to cancer (Füllgrabe et 
al., 2011). All of the above mentioned histone proteins have multiple isoforms 
except H4. Among the 16 isoforms of H2B protein, H2B1C is the most common 
(Molden et al., 2015).  
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In a recent study, H2B1C_HUMAN was found to be upregulated in arsenic 
mediated carcinogenesis when ovarian Hela cells underwent epithelial to 
mesenchymal transition (EMT) (Rea et al., 2016). The result of the study is 
corroborated with the earlier findings in three breast cancer cell lines (Pärssinen 
et al., 2008). In a study on colon cancer model, it has also been observed that 
H2B1C protein was upregulated in colorectal cancer tissues compared to that of 
normal mucosa (Karczmarski et al., 2014). FOLFOX treated colorectal cancer 
cells also displayed upregulation of H2B1C protein in a chemoresistant group 
than sensitive group (Unger et al., 2014). Furthermore, down regulation of the 
protein has been observed during telomere inhibited senescence (Biniossek et 
al., 2013) and DNA damage in cancer cells (Su et al., 2004). Although, 
signalling mechanism (activating Wnt-pathway and inhibiting tumour 
suppressor genes, e.g. NDRG1, Cyclin D1, E-cadherin) through which histones 
have been associated with cancer has been explored, but little has been 
mentioned specifically about the signalling mechanism of H2B1C (Gargalionis 
et al., 2012).  
In the present study, H2B1C is found to be downregulated in all treatment 
groups compared to the non-treated Caco-2 human colorectal cancer cells. 
Among the treated groups Oxa has produced a highest change in the fold factor 
(2.63), and Cap did the least. Treatment with combination of Oxa with Quer 
(0,0) and Oxa with Cap (0,4) is also found to downregulate the protein by 2.26 
fold. The change in downregulation of H2B1C protein due to treatment with 
Quer is found to be greater than due to Cap but less than that due to Oxa and 
synergistic combinations of Oxa with Quer. From above, it may be concluded 
that H2B1C protein is an anti-apoptotic in action and anticancer effects of the 
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investigated drugs alone or in combination is associated with the 
downregulation of the protein.  
4.5.2  H4_HUMAN 
 
H4_HUMAN or Histone H4 is also a core protein of nucleosome found in 
combination with H2A, H2B, H3 forms chromatin. This is why any 
modification in Histone H4 protein in response to various stimuli, have a direct 
effect on the accessibility of chromatin to transcription factors and, 
consequently, gene expression (Jaskelioff and Peterson, 2003). Histone H4 can 
undergo a number of posttranslational modifications-e.g. acetylation at K5, K8, 
K12, and K16 and methylation at R3, K5 and K20 in transcriptional regulation, 
and phosphorylation at S1 during mitosis (Chou et al., 2014). It was reported 
that in leukaemia, cancer cells had a loss of monoacetylated and trimethylated 
forms of histone H4 compared to normal cells. Predominant loss was observed 
in acetylated Lys16 and trimethylated Lys20 residues of H4_HUMAN and was 
associated with the hypomethylation of DNA repetitive sequences (Fraga et al., 
2005). Commonly, the hyperacetylation of the protein opens the chromatin and 
leads forward for transcriptional activation (Struhl, 1998). On the other hand 
histone deacetylases were found to upregulate in various types of cancer (West 
and Johnstone, 2014). Recently few inhibitors of histone deacetylases have been 
considered as candidates for cancer therapy and entered into clinical trial (Dung 
et al., 2017) . However histone deacetylases also have targets other than histones 
such as p53, E2F, GATA1, TFIIE and TFIIF. This might explain the ability of 
histone deacetylases to regulate gene expression by a mechanism that is distinct 
from their effects on chromatin (Marks et al., 2001). And also methylation at 
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K5 H4_HUMAN has been identified and is speculated to play a role in 
neoplastic process. No report was found in the literature regarding the 
expression of the H4_HUMAN protein itself in cancer cell. Similarly no one 
reported the effect of any anticancer drug on the expression of the protein. 
In the present study, upregulation of H4_HUMAN was observed due to 
treatment with Oxa alone and that with combination of Oxa with Cap (bolus) in 
Caco-2 human colorectal cancer cell line. On the other hand, the same protein 
was downregulated due to treatment with Quer, Cap alone and that with 
synergistic combination Oxa+Quer (0,0). Due to the mixed result - upregulation 
and downregulation on the expression of H4_HUMAN from different 
treatments - it cannot concluded precisely whether the protein is proapoptotic 
or antiapoptotic in action. It may be also possible that the protein can function 
as either a proto-oncogene or a tumour suppressor depending on its expression 
and gene dosage which is not uncommon (Grisendi et al., 2006). Further 
investigation would be required to make decisive comments on the role of 
H4_HUMAN in colorectal cancer. 
4.5.3  COF1_HUMAN 
 
Cofilin/Actin depolymerizing factor (ADF) family has three members (cofilin-
1, a muscle-specific isoform cofilin-2 and destrin) which are responsible for 
enhancing the turnover rate (thus creating new free pointed ends) and to 
depolymerize filaments at their barbed ends (Estornes et al., 2007). Cofilin can 
be controlled through upstream effectors such as. LIM 1 and 2, and TES 1 and 
2 kinases phosphorylate cofilin on the serine 3 residue, and make it inactive. It 
can be reactivated through dephosphorylation by type 1, 2A, 2B, slingshot, and 
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chronophin phosphatases (DesMarais et al., 2005, Yang et al., 1998, Niwa et 
al., 2002, Yamaguchi and Condeelis, 2007). Morphological changes 
accompanied by cytoskeleton arrangement are considered as hallmark of 
apoptotic cell death and are also implicated in cell-cycle arrest (Ndozangue-
Touriguine et al., 2008, Buell et al., 1976). COF1_HUMAN plays a key role in 
free barbed end generation at the leading edge and in lamellipodium formation 
required applying to mammary cancer cells (Mouneimne et al., 2004). There is 
little doubt that Cofilin-1 is an essential regulator of cancer cell motility and 
invasion. COF1_HUMAN is over expressed in C6 rat glioblastoma cell line 
(Gunnersen et al., 2000), and amount of inactive form is reduced in cell lines 
derived from T-lymphoma and carcinomas from colon, cervix, kidney and liver 
(Nebl et al., 1996).  
Recently, COF1_HUMAN has been proposed to be potential diagnostic, 
prognostic and therapeutic targets due to its overexpression in various cancers. 
In pulmonary adenocarcinoma, significant upregulation of the protein has been 
observed compared to normal lung cells. Moreover, the shRNA expressing 
plasmid targeting cofilin-1 inhibited metastases and prolonged survival in LL/2 
metastatic model (Peng et al., 2011). Similar upregulation of the protein is also 
observed in chemoresistant pancreatic, gastric, head & neck and colorectal 
cancer (Wang et al., 2011, Tang et al., 2014, Dowling et al., 2008, Zhao et al., 
2007, Sinha et al., 1999). Moreover, anticancer drugs found to downregulate 
COF1_HUMAN during apoptotic cancer cell death (Lee et al., 2017, Yao et al., 
2009). In this study, all treatments with single and combination drug 
combinations are found to downregulate the protein in Caco-2 cell line, with the 
greatest change being observed with Oxa+Cap (bolus). Cap alone produced 
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second highest change in the expression followed by Oxa+Quer (0,0). Quer 
alone did cause the least change. So it can be concluded that Coflin-1 is 
antiapoptotic in action and could be targeted in developing novel anticancer 
drugs.  
4.5.4   GSTP1_HUMAN 
 
GSTP1_HUMAN or Glutathione S-transferase P belongs to Glutathione S-
transferase super family of Phase-II enzyme that catalyses conjugation of 
glutathione (GSH) with a wide range of different structures and functionalities, 
resulting in the formation of corresponding GSH conjugates to facilitate 
elimination. GSTP1 isozyme shows at least two functional polymorphisms 
(GSTP1-1 and GSTP-2), makes into four allelic variants: *A, *B, *C and *D. 
Various transcription factors such as specificity protein1 (SP1), 
activatorprotein1 (AP- 1), nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) and GATA1 were thought to play an important role 
in regulating GSTP1expression (Schnekenburger et al., 2014). The protein is 
also involved in cell death regulation, interaction with apoptotic signalling 
pathways (Ruscoe et al., 2001, Wu et al., 2006b). Role of GSTP1-1 in cell 
signalling process is shown in Figure 4.7.  
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Figure 4.7: GSTP1-1 cell signalling mechanism [Adapted from (Laborde, 2010)] 
 
GSTP1_HUMAN was found to be the predominant isoenzyme in all but 2 of 60 
tumour cell lines investigated by National Cancer Institute (NCI). A range of 
human cancers including of breast, colon, kidney, lung, head and neck, stomach, 
bladder, soft tissue sarcoma, testicular embryonic carcinoma, meningioma, 
glioma and ovarian carcinoma usually express high levels of GSTP1 compared 
with the peritumoral tissues (Howells et al., 2004, Schnekenburger et al., 2014). 
In a recent study, increased expression of GSTP1 has also been observed in 
colorectal aberrant crypt foci (Muguruma et al., 2017). Presently increased 
expression of Glutathione S-transferase P has been considered to be a marker 
for cancer development (Laborde, 2010). Over expression of the protein has 
been associated not only with advancement of tumour but also with acquired 
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drug resistance in patients undertaking chemotherapy. In a study of ovarian 
tumour model, knockdown of GSTP1 selectively influenced cisplatin and 
carboplatin chemosensitivity (2.3- and 4.83-fold decrease in IC50, respectively). 
It was reported that cell cycle progression was unaffected but cell invasion and 
migration were significantly reduced (Sawers et al., 2014). 
In the present study, the expression of GSTP1_HUMAN was found to be 
significantly changed in both Caco-2 and Lim-2405 colorectal cell lines upon 
treatment. In Lim-2405 cell line, the protein was appeared as two different spots 
(Spot 3 and Spot 10). The spreading of the same protein in 2-DE as different 
spots is not uncommon and may happen for isoforms of the protein or due to 
post-translational modifications including phosphorylation, glycosylation and 
others (Deng et al., 2012).  GSTP1 protein was found to downregulate in Caco-
2 human colorectal cell line with all treatment groups. Bolus combination 
treatments with (Oxa+Cap) and (Oxa +Quer) produced higher change in folds 
of downregulation than the drugs alone. However, in Lim-2405 cell line the 
protein was downregulated by treatment with Oxa alone and the combination 
Oxa+Cap (bolus), upregulated by treatment with Cap. Bolus administration of 
Oxa in combination with Cap did not express the protein at all possibly due to 
extreme downregulation of the protein. From the above results it can be 
concluded that GSTP1_HUMAN is an antiapoptotic protein and can be a 
potential therapeutic tool against cancer. Novel inhibitors of the protein could 
bring benefit when co-administered with other anticancer drugs in overcoming 
drug resistance (Laborde, 2010). 
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4.5.5  PROF1_HUMAN 
 
Profilins belong to a family of small G-actin-binding proteins comprising of 
four members: PROF1 (universally expressed in almost all cell types). PROF2 
is mainly found in nervous system in vertebrates), PROF3 and PROF4 are 
expressed only in kidney and testis) (Zou et al., 2010). PROF1 is one of the first 
actin-binding proteins to be discovered and found to show significant 
contribution in a number of cellular processes i.e. membrane transport, GTPase 
signalling pathways, RNA splicing, pathogenesis of neurological diseases, and 
tumorigenesis (Gieni and Hendzel, 2009, Liu et al., 2013). Moreover, 
upregulation of the protein would impair cell motility and promote apoptosis 
(Janke et al., 2000, Yao et al., 2014, Adami et al., 2017). PROF1 is 
downregulated in breast, pancreatic, laryngeal, bladder cancers and oral 
squamous cell carcinoma (Grønborg et al., 2006, Wu et al., 2006a, Zoidakis et 
al., 2012, Adami et al., 2017, Chan et al., 2008). Although PROF1 showed 
tumour suppressor potential in various cancer, few studies reported upregulation 
of the protein in pancreatic and colorectal cancer (Chen et al., 2005, Almeida et 
al., 2017). In a recent in vitro and in vivo study using triple-negative breast 
cancer cells, it was suggested that balanced level of PROF1 promotes stemness 
and tumour initiating potential of cancer cells (Jiang et al., 2017). 
In the present study in Caco-2 colorectal cell line, the protein was found to be 
upregulated with all drug treatments, strengthening the argument that PROF1 
has tumour suppressor potential. Combination treatment of Oxa with Cap given 
as bolus has produced largest change in upregulation (by a factor of 3.88) 
followed by treatment with combination of Oxa with Quer (2.67). Single drug 
treatments also upregulated the protein but the fold change was lower than 
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combined treatments. The results indicate that the protein is involved in 
apoptotic cell death. Tumour suppressive mechanism for PROF1 has been 
reported via up-regulation of PTEN and p27kip1, suppression of AKT 
activation and involvement of Ena/VASP proteins.  
4.5.6  AGR2_HUMAN 
 
Anterior gradient homolog 2 (AGR2), also known as hAG-2 or Gob-4 consists 
of 175 amino acids with a molecular weight of approximately 20 kDa. AGR2 
along with AGR1 and AGR3 belong to protein disulfide isomerase (PDI) family 
which is part of thioredoxin (TRX) superfamily. AGR2 and AGR3 subfamilies 
are present in amniotes, while members of AGR1 subfamily are present only in 
lower vertebrates (Obacz et al., 2015). AGR2 is highly expressed in the lung, 
stomach, colon, prostate and small intestine tissues that contain mucus secreting 
cells and/or function as endocrine organs (Shih et al., 2007). The protein is 
believed to play a significant role in the entire process of carcinogenesis: 
initiation, development and metastasis (Gao et al., 2013). The link between 
AGR2 and cancer was first recognized in a study concentrated on differentially 
expressed genes in estrogen receptor–positive breast cancers. Increased AGR2 
expression in the ovarian, esophagus, gastrointestinal, pancreas, lung, breast and 
prostate cancer was detected in a number of studies (Thompson and Weigel, 
1998, Lowe et al., 2007, Liu et al., 2005, Hao et al., 2006, Valladares-Ayerbes 
et al., 2008, Zhang et al., 2007, Edgell et al., 2010). But in colorectal cancer 
contradictory observations have been made regarding the expression of AGR2 
protein. Elevated expression of mRNA of AGR2 protein was reported as a 
circulating tumour cell biomarker in colorectal cancer in earlier studies 
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(Smirnov et al., 2005, Valladares-Ayerbes et al., 2008). Comprehensive 
analysis of AGR2 expression in 1068 samples colorectal carcinomas revealed 
that the protein is frequently lost in colorectal carcinomas while the normal cells 
expressed the protein significantly (Riener et al., 2014).  
In the present study, it is found that bolus combination of Oxa with Cap causes 
about four fold upregulation of AGR2 while treatment with Quer alone is found 
to upregulate by a factor of two in Caco-2 colorectal cell line. On the other hand 
single treatment with Oxa is found to cause downregulation of the protein by a 
factor of two and treatment with Cap (alone) did not have the protein expressed 
at all. Downregulation of the protein by Oxa might be countered by the 
upregulation effect of Quer and vice versa when the drugs are combined 
together. Disappearance of the protein spot in the gel by Cap alone treatment 
could be explained that AGR2 is highly downregulated by the treatment. 
However, spot could have be missed in the gels due to staining errors, mean 
volume factors of the spot or incorrect gel alignment (Grove et al., 2006). The 
role of AGR2 in colorectal cancer remains unclear as per the present study. 
4.5.7  PRDX1_HUMAN 
 
Six isoforms of mammalian peroxiredoxins are classified into three major 
groups based on their number of conserved cysteine residues and catalytic 
mechanism. These are typical 2-cysteine PRDXS (PRDX1-4), atypical 2-
cysteine (PRDX5) and 1-cysterine PRDX (PRDX6). PRDX1 contains a 
conserved Cys52 at the N-terminal and a conserved Cys173 at the C-terminal 
(Rhee et al., 2001). Structurally it is a homodimer in which C terminus of one 
subunit reaches beyond dimer interface to interact with other subunit (Neumann 
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et al., 2009). Functionally it is an important endogenous antioxidant, protecting 
cells from oxidative damage by reducing H2O2 and ONO2 and scavenging thiyl 
radicals (Netto and Antunes, 2016). Moreover, PRDX1 is implicated in 
regulation of numerous biological processes including cell differentiation, 
proliferation, and apoptosis (Kim et al., 2012).  The protein has been reported 
as a tumour-suppressor in earlier studies as Prdx1-knockout mice that showed a 
decreased life span due to the development of cancer (Neumann et al., 2003). In 
another study PRDX1 was found to inhibit activation of oncogenes such as c-
Abl and c-myc. The authors proposed that PRDX1 might also prevent lipid 
phosphatase activity of PTEN, which is essential for its tumour-suppressive 
function (Cao et al., 2009). But oncogenic activity of the protein in terms of 
elevated expression has been demonstrated in a variety of cancers including 
esophageal squamous cell carcinoma, lung cancer, cholangiocarcinoma, 
prostate cancer, hepatocellular carcinoma and bladder cancer (Zhang et al., 
2011, Kim et al., 2008, Yonglitthipagon et al., 2012, Li et al., 2013, Riddell et 
al., 2011, Sun et al., 2014). In a study involving nine different cancer cell lines, 
mixed expression of PRDX1 was observed suggesting that the role of the 
protein in cancer is not well defined (Ren et al., 2013). Most of the studies 
conducted in colorectal cancer showed upregulation of PRDX1 (Rho et al., 
2008, Luo et al., 2013). One study reported that the protein was upregulated in 
primary tumour samples relative to normal colon, but were downregulated in 
metastases (Lin et al., 2007). 
In the current study in Caco-2 colorectal cancer cell line, all the treatments 
upregulated the protein except single drug treatment with Cap where the spot 
was not detected. Similar to our findings upregulation of PRDX1 in colorectal 
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cancer followed by the treatment of oxaliplatin was also evidenced in a recent 
study (Jiao et al., 2016). It can be said that anticancer activity of the investigated 
compounds either alone or in combination might not be related with the change 
in expression of PRDX1. Because the protein is upregulated in colorectal 
malignancy, combination treatments with Oxa+Quer (bolus), Oxa+Cap (bolus), 
single drug treatments with Oxa and Quer would be seen to downregulate the 
protein, the results can be seen to fit with the idea PRDX1 is associated with 
carcinogenesis, metastasis, and resistance to chemotherapy (He et al., 2014). 
Further research is needed to get clearer picture on the role of PRDX1 in 
colorectal cancer and to exploit the inhibitor of the protein as anticancer drugs. 
4.5.8  THIO_HUMAN 
 
THIO_HUMAN or Thioredoxin (Trx), is a 12 kDA protein consisting of 105 
amino acids and that has multiple biological functions. Between two isoforms 
of the protein, Trx-1 is more common and existing in the cytosol, whereas Trx-
2 is a mitochondria-specific (Spyrou et al., 1997). Trx-1 plays important role in 
the first step of DNA synthesis and regulates the activity of transcription factors 
that ultimately control cell growth (Noike et al., 2008). The protein provides 
antioxidant defence by either direct neutralization of reactive oxygen species or 
by indirect effects through recycling small-molecule antioxidants such as DHA, 
LA, ebselen, and UQ. Trx can have bifacial role in the development and 
propagation of cancer depending on its stage. During initiation of cancer, the 
protein serves beneficial role by preventing normal cells to become malignant 
by bringing into play other antioxidant enzymes such as peroxiredoxin (Prx) 
family and methionine sulfoxide reductase (Msr) isoenzymes (Zhang et al., 
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2017). However, in later stage the higher level of Trx may advance tumour 
development and metastasis owing to their growth-promoting, apoptosis-
resisting, and angiogenesis-supporting functions (Schumacker, 2006). 
Increased expression of the protein was reported in many human primary 
cancers including gastric, hepatic, pancreatic, lung, breast, lymphoma, 
squamous cell carcinoma and cervical cancers. (Grogan et al., 2000, Rubartelli 
et al., 1995, Nakamura et al., 1999, Soini et al., 2001, Matsutani et al., 2001, 
Noike et al., 2008, Wakita et al., 1992, Zhu et al., 2011, Powis et al., 2000). A 
very recent study corroborated the earlier reports of the association of colorectal 
cancer with elevated expression of Trx and confirms that upregulation of the 
protein is a prognostic factor in colorectal cancer (Raffel et al., 2003, Lou et al., 
2017).  
The protein is reported to inhibit apoptosis in the cytoplasm via redox regulation 
of ASK-1 and inhibition of Iκβ degradation by scavenging reactive oxygen 
species. In response to oxidative stress, Trx moves to the nucleus and increases 
the DNA binding activity of NF-κβ via reduction of its cysteine residue. The 
protein also regulates other transcription factors such as AP-1 and HIF-1 
(Karlenius and Tonissen, 2010).  Possible antiapoptotic mechanism for Trx that 
promote cancer cell proliferation is presented that leads to in Figure 4.8. 
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Figure 4.8: Antiapoptotic signalling mechanism of THIO_HUMAN (Trx) [Adapted 
from (Kaimul et al., 2007)] 
In the present study, single treatment with Oxa downregulated the protein in Lim-2405 
cell line. The spot could not be detected after other single and combination treatments 
believed to be due to extreme downregulation. Hence the protein is considered to have 
a direct relationship with the anticancer mechanism of the investigated drugs. Hence 
there is potential of designing anticancer drugs that can inhibit THIO_HUMAN. Indeed 
some natural and synthetic inhibitors of THIO_HUMAN have already been reported in 
literature (Zhang et al., 2017).  
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4.5.9  PRDX6_HUMAN 
 
PRDX6 protein belongs to peroxiredoxins family that serve as antioxidant by reducing 
wide variety of cellular substrates including aqueous and lipid peroxides. In contrast to 
other antioxidants such as superoxide dismutase and catalase, peroxiredoxins do not 
require any cofactors for their enzymatic activity instead use internal active site cysteine 
residues for target reduction (Goncalves et al., 2012). Different from the other members 
of peroxiredoxins family, PRDX6 has a single conserved cysteine residue as Cys47 in 
protein monomer and has been called a 1-Cys PRDX (Fisher, 2011). Other 
distinguishing features that make it special than other mammalian peroxiredoxins are: 
heterodimerization of the oxidized protein with πGST as part of the redox cycle, 
glutathionylation rather than disulfide formation with another (identical) monomer, and 
the requirement for GSH rather than thioredoxin to complete the catalytic cycle and to 
regenerate the active enzyme (Zhou et al., 2016). PRDX6 is a bifunctional protein with 
both GSH peroxidase and PLA2 activities where Cys47 is responsible for peroxidase 
activity and Ser32 for PLA2 activity (Chen et al., 2000). Elevated expression of PRDX6 
has been linked with various neoplastic diseases including ovarian carcinoma (Pak et 
al., 2011), malignant mesothelioma (Kinnula et al., 2002), lung cancer (Zhang et al., 
2009), gastric cancer (Choi et al., 2011), gingivo-buccal cancer (Shukla et al., 2009), 
bladder cancer (Quan et al., 2006), liver cancer (Eismann et al., 2009) and breast cancer. 
It has been proposed that the peroxidase activity of PRDX6 promotes cancer growth 
whereas the PLA2 activity facilitates invasiveness through the upregulation of the AP-
1 and JNK pathways (Ho et al., 2010, Jo et al., 2013). However, in colorectal cancer a 
different scenario has been reported with downregulation of PRDX6 in stage I of 
carcinogenesis (Peng et al., 2012). Another study demonstrated that the protein was 
uniformly under expressed in all 8 colorectal cancer patients (Piepoli et al., 2009). 
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In the current study, single drug treatment with Cap and combination treatment of Oxa 
with Cap using 0/4 sequence have produced upregulation of PRDX6 in Lim-2405 cell 
line. On the other hand, treatment with Oxa alone has shown downregulation of the 
protein while bolus combination of Oxa and Cap does not show any expression of the 
protein. Although combination of Oxa with Cap using different sequences is 
synergistic, the difference in expression of PRDX6 in response to treatment is not well 
understood.  
4.5.10 ATPB _HUMAN 
 
ATP synthase is the last enzyme in the oxidative phosphorylation and is responsible for 
catalysing the synthesis of ATP from ADP and inorganic phosphate. The enzyme 
consists of two well defined protein entities: the F1 sector and Fo sector. F1 is the 
soluble portion situated in the mitochondrial matrix while the Fo sector is bound to the 
inner mitochondrial membrane. F1 is composed of three α subunits and there β subunits 
and constitute the core of ATP synthase enzyme (Jonckheere et al., 2012). Other than 
the mitochondria, ATP synthase can also be found in extracellular surface of endothelial 
cells in some cancer tissues (Yamamoto et al., 2007).  ATP synthase play a vital role in 
multiple biological processes such as metabolism of lipid formation, hypertension (Das 
et al., 1994), angiogenesis (Chi et al., 2007), regulation of the proliferation and 
differentiation in endothelial cells, and innate immunity (Moser et al., 2001, Vantourout 
et al., 2008). Downregulation of ATPB (β subunit of ATP synthase) has been reported 
in liver, kidney, squamous oesophageal carcinoma, lung carcinomas, breast and gastric 
adenocarcinomas (Isidoro et al., 2004, Cuezva et al., 2004, Shin et al., 2005). Studies 
on colorectal cancer also revealed that ATPB was downregulated (Klein et al., 2013) 
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and this downregulation might be responsible for resistance to chemotherapy (Shin et 
al., 2005). 
In the present study, the protein was upregulated due to treatment with Oxa alone, Cap 
alone and combination of Oxa with Cap (bolus). It is suggested that ATPB might act as 
proapoptotic protein in colorectal cancer and can be considered to design the analogues 
of the protein as anticancer drug against colorectal cancer.  
4.5.11 HSP7C_HUMAN 
 
Heat shock proteins (HSPs) are extremely conserved molecular chaperones that are 
synthesized and expressed by the cell during stress conditions (Wu et al., 2016). HSPs 
are present in all living kingdoms including archaea to higher mammals. The main role 
of HSPs is to facilitate covalent folding of proteins as well as maintenance of natural 
structures and functions of other proteins when cells are exposed to homeostatic 
challenges such as high temperature, anoxia or hypoxia, metabolic stress, cytokines, 
nitrogen oxides, heavy metals, drugs, or other chemical agents (Macario and De 
Macario, 2007). Nomenclature and classification of HSPs have been done on the basis 
of their molecular weight e.g. HSP27, HSP40, HSP60, HSP70, HSP90, and large HSPs 
(HSP110 and glucose regulated protein 170, GRP170). High molecular weight HSPs 
require ATP for their functioning, whereas small HSPs act in an ATP-independent 
fashion (Jego et al., 2013). The human genome contains at least 12 genes encoding 14 
proteins of the HSP70 family. Heat shock cognate 71 kDa protein (HSP7C or HSP73 
or HSC70) is one of the four major members of HSP70 family (Kampinga et al., 2009). 
HSP7C has a profound effect on promoting membrane protein folding and polypeptide 
translocation; promotion and aggregation of phosphatidylserine liposomes (Liu et al., 
2012). The function of HSP7C requires some co-chaperones and other partner proteins 
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such as. J-domain proteins (Liu et al., 2012). The protein may also affect the balance 
between cell differentiation, proliferation and apoptosis by interactions with: BAG-1, 
p53, cell-cycle kinases and pRB (Rusin et al., 2004). Like other HSPs, HSP7C was also 
reported to be overexpressed in tumour cells compared to normal cells in lung, gastric, 
pancreatic, breast, cervical and endometrial cancer models (Maeda et al., 2000, Liu et 
al., 2012). Increased expression of the protein with co-chaperone HOP was also 
observed colorectal cancer model (Kubota et al., 2010). 
In the current study, all treatments have caused upregulation of HSP7C in Lim-2405 
colorectal cancer cell line except that with combination of Oxa with Cap using (0/4) 
sequence. Highest upregulation of the protein was caused by treatment with Cap alone 
(2.7 fold) followed by Oxa alone (2.3). Combined treatment of Oxa with Cap 
administered as a bolus produced 2 fold upregulation of the protein. The results indicate 
that anticancer action of the investigated drugs may be associated with the upregulation 
of the protein HSP7C which acts as inhibitor of N-myristoyltransferase enzyme. The 
enzyme is highly expressed in colorectal cancer and catalyzes myristoylation of many 
proteins and promotes carcinogenesis (Shrivastav et al., 2005). Since HSP7C 
negatively regulates N-myristoyltransferase, further development of the analogues of 
the protein may lead towards gene-based therapy of colorectal cancer (Shrivastav et al., 
2008).  
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4.5.12 CH60_HUMAN 
 
CH60 or 60 kDa heat shock protein (HSP60) is also a molecular chaperone which is 
typically found in mitochondria. It is also observed in cytosol, cell surface, extra-
cellular space and in the peripheral blood (Cappello et al., 2008). In addition to its 
recognized role in protein folding, CH60 serves a vital role in intracellular protein 
trafficking, and in peptide-hormone (Deocaris et al., 2006, Czarnecka et al., 2006). 
Moreover, the protein can interfere with the functions of various endogenous and 
exogenous proteins (Cappello et al., 2008). Depending on the cellular circumstances 
both mitochondrial or cytosolic CH60 can act as proapoptotic or antiapoptotic protein 
(Chandra et al., 2007). Several studies showed that expression of CH60 was elevated 
due to neoplasia e.g. acute leukaemia (Thomas et al., 2005), oesophageal squamous 
carcinoma (Kawahara et al., 1999), hepatocellular carcinoma (Kuramitsu and 
Nakamura, 2005), prostate adenocarcinoma (Johansson et al., 2006) and ovarian 
carcinoma (Castle et al., 2005). Evidence regarding downregulation of the protein also 
exists in literature such as glioblastoma (Khalil, 2007), bronchial adenocarcinoma 
(Cappello et al., 2006) and carcinosarcoma of urinary bladder (Kamishima et al., 1997). 
A number of other studies displayed no significant changes of the expression of CH60 
in cancerous cell compared to normal cells i.e. lymphoblastic leukaemia (Wehner et al., 
2003), pancreatic ductal adenocarcinoma (Qi et al., 2008) and endocrine 
chondrosarcoma (Trieb et al., 2000). In case of colorectal cancer, the expression of 
CH60 was elevated compared to non-cancerous colonic cells (Cappello et al., 2003, 
Hamelin et al., 2011, Aldea et al., 2011). 
In the present study, varied expression of the protein was observed from single and 
combined treatment of drugs in Lim-2405 colorectal cancer cell line. Treatment with 
Oxa alone and bolus combination of Oxa with Cap displayed upregulation while 
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treatment with Cap alone and combination Oxa with Cap using 0/4 sequence resulted 
in absence of the protein. The absence of the protein spot might be due to extreme 
downregulation of CH60. However, diverse outcome on the expression of the protein 
from single and synergistic combination treatments rendered uncertainty of the role of 
CH60 in colorectal cancer. More research needs to be done on CH60 to obtain more 
precise concept.  
4.6 Summary from proteomics study  
 
From the results presented in chapter 3 (Table 3.22; 3.24) and discussion made above 
(section 4.5) it is obvious that only a very few proteins underwent significant changes 
in expression due to drug treatment of Caco-2 and Lim-2405 colorectal cancer cell 
lines. Three proteins namely H2B1C, COF1 and GSTP1 underwent downregulation in 
Caco-2 cell line indicating that they would be antiapoptotic in nature. Earlier findings 
also support the idea that downregulation of the proteins would have an impact in 
cancer treatment. On the other hand, PROF1 and PRDX1 underwent upregulation due 
to synergistic treatments in Caco-2 cell line suggesting that the proteins could be pro-
apoptotic in action. However, no report could be found suggesting that upregulation of 
PRDX1 could have beneficial against cancer development. Probable mechanism by 
which treatment with Oxa, Quer and Cap administered alone, and combinations of Oxa 
with Cap and Oxa with Quer can bring about cell death in Caco-2 colorectal cancer cell 
line is given in figure 4.9.  
In this study ATPB and HSP7C proteins were found to be upregulated in Lim-2405 cell 
line due to treatment with the selected drug combinations except Oxa+Cap (0/4). No 
clear cut trend could be seen was perceived for other proteins identified in the study. 
Both ATPB and HSP7C might play key roles in the antitumour activity of Oxa and Cap 
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as wells the combinations: Oxa+Cap(0/0) and Oxa+Cap(0/4). However the possible 
molecular mechanism could not be ascertained from the existing knowledge and 
literature.  
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Figure 4.9: Molecular mechanism for antitumour activity of selected drugs in Caco-2 
cell line 
 
The major limitation of this study was the little number of proteins which were 
successfully identified through MALDI-MS. As stated earlier, only twelve spots were 
chosen to be excised from Caco-2 cell line, and nine spots from Lim-2405 cell line for 
MALDI-MS characterization. The reason behind choosing few numbers was the 
inability of protein spots to match the selection criteria of displaying significant changes 
in expression over three different treatments. Moreover few spots which showed 
significant changes in expression over multiple treatments but unable to cut due to their 
unsuitable position in the gel. The number of identified proteins reduced further when 
different spots appeared with isoforms of same protein. For example Match ID 3 and 
Match ID 10 of Lim-2405 cell line was identified as GSTP1. Match ID 15 of Caco-2 
cell line was also recognized as GSTP1 and thus reduced the total number of identified 
proteins again. In addition to these Match ID 6 of Lim-2405 cell line was identified as 
ZN540 but displayed insignificant mascot score and finally discarded from this study. 
Further identification of other proteins which were significantly expressed after 
individual treatment with selected drugs alone or in combination would clarify the exact 
phenomenon. 
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CHAPTER FIVE  
5 CONCLUSION 
 
Global burden of colorectal cancer is expected to follow current trend of cumulative 
incidence due to the adoption of westernized behaviours and lifestyle throughout the 
world. Improved diagnostic and treatment methods have served to increase overall 
survival rates in colorectal cancer patients. Chemotherapy has played an important role 
in treatment against colorectal cancer especially in the forms of drugs given in 
combination. Intake of dietary phytochemicals in the forms of fruits and vegetables has 
shown inverse relationship with the incidence of colorectal cancer. In the present study, 
a number of commonly known phytochemicals (resveratrol, thymoquinone, capsaicin 
and quercetin) have been administered in combination with oxaliplatin and cisplatin to 
colorectal tumour models (HT-29, Caco-2, Lim-1215 and Lim-2405 cell line). The 
mechanistic information of the combined drug effects have been investigated through 
studies on DNA damage, cellular accumulation of platinum, level of platinumDNA 
binding and proteomics. 
Before conducting combination studies, IC50 values of each phytochemical and 
platinum drug were determined through MTT reduction assay. Oxaliplatin showed 
lowest IC50 values against all tested human colorectal cancer cell lines. Thymoquinone 
has displayed greater anticancer activity among the selected phytochemicals as it had 
lowest IC50 values against four investigated colorectal cancer cell lines. The observed 
trend for cytotoxicity for the phytochemicals against colorectal cancer model was: 
thymoquinone > resveratrol ≈ quercetin > capsaicin. 
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Combination studies showed that combination of cisplatin with resveratrol was best in 
terms of synergistic outcome than all other phytochemicals administered in 
combination with cisplatin. Synergistic outcome was found to be more dependent on 
concentration than sequence of addition. Although thymoquinone had the lowest IC50 
values among the selected phytochemicals, combination of cisplatin with 
thymoquinone did not produce desired synergistic outcome with mild synergism being 
observed only at higher concentration in HT-29 cell line and at lower concentration in 
Lim-1215 cell line (when thymoquinone was added in combination with cisplatin at 
different sequences). Combination of cisplatin with capsaicin produced mostly 
antagonistic outcomes against all colorectal cell lines irrespective of concentration and 
sequence of administration. Another selected phytochemical quercetin in combination 
with cisplatin produced synergistic outcome in Lim-1215 and Lim-2405 cell lines only 
while antagonistic outcome was predominant in HT-29 and Caco-2 cell lines (when 
administered in combination with cisplatin). 
When selected phytochemicals were combined with oxaliplatin, better synergism was 
observed against the tested human colorectal cancer cell lines. Capsaicin in 
combination with oxaliplatin gave synergistic outcome at all concentrations and 
sequences of administration in Lim2405 cell line. Bolus addition of oxaliplatin with 
capsaicin also produced significant synergism at lower concentration in Caco-2 cell line 
while quercetin in combination with oxaliplatin showed stronger synergism at ED50 and 
ED75 level in the same cell line. Oxaliplatin in combination with thymoquinone 
displayed mild synergistic effect at almost all added concentrations and sequences of 
administration in Lim-1215 cell line. But resveratrol in combination with oxaliplatin 
resulted in additive to antagonistic effect against all tested cell lines.  
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The following mechanistic studies were conducted to obtain information underlying 
combined drug actions. DNA damage study revealed that all the investigated drugs 
administered either alone or in combination caused DNA damage and their combined 
antitumour action could be correlated with interactions with DNA. In Lim-2405 cell 
line, combined treatment of oxaliplatin with quercetin using 0/4 sequence of 
administration showed highest DNA damage. Cellular platinum accumulation study 
showed that there was a positive correlation between synergistic effect and platinum 
accumulation in Lim-2405 cell line. However no such trend was observed as applied to 
platinumDNA binding level.  
Proteomics study was conducted to identify key proapoptotic and antiapoptotic proteins 
in Caco-2 and Lim-2405 colorectal cancer cell lines. A number of proteins showed 
significant changes in expression after treatment with drugs either alone or in 
combination compared to the levels found in untreated Caco-2 cell line. Among those 
proteins PROF1, PRDX1 H2B1C, COF1 and GSTP1 were identified as key proteins 
mediating combined drug actions. H2B1C, COF1 and GSTP1 were downregulated after 
all treatments and were recognized as antiapoptotic in action. PROF1 and PRDX1 
demonstrated upregulation following all treatments in Caco-2 cell line compared to 
untreated cell. On the other hand in Lim-2405 cell line, very few proteins underwent 
significant changes in expression following drug treatments. Among those undergoing 
changes in expression, only ATPB and HSP7C were considered to be important in 
relation to antitumour activity of the investigated compounds alone or in combination. 
Both were upregulated in the treatment groups compared to untreated Lim-2405 cell 
line. 
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Future directions  
It is understood that many phytochemicals can sensitize cancer cells towards 
chemotherapeutic drugs using diverse molecular pathways. Search for phytochemicals 
that may give synergistic combined action with clinically used chemotherapeutic drugs 
may be continued. The study can be extended with other phytochemicals and other 
chemotherapeutic drugs e.g. 5-fluorouracil. In vivo animal model studies can be carried 
out to confirm the combined drug actions obtained from this study. 
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7 Appendices 
7.1 APPENDIX I Synthesis of Cisplatin 
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7.2 APPENDIX II Extraction of DNA 
 
 
 The working protocol was prepared based on the booklet obtained with EZ-10 
spin column genomic DNA minipreps Kit.  
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7.3 APPENDIX III Platinum Content 
Determination 
 
 
The working procedure was prepared according to the published article 
[Huq, F., Abdullah, A., Beale, P., Yu, J., Zhang, M., 2006. Studies on the synthesis, 
characterization and binding with DNA of cis-bis (2,3-diaminopyridine) 
diiodoplatinum (II): A compound with high cell uptake and drug-DNA binding 
but very little activity. International Journal of Pure and Applied Chemistry, 1(2), 
205-211] from our group. 
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7.4 APPENDIX IV Proteomics protocol 
details 
 
7.4.1 Cell lysis Buffer constituents & cell lysis 
method 
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7.4.2 Determination of protein concentration 
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7.4.3Isoelectric Focusing (IEF) 
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7.4.4Preparation for second dimension gel 
electrophoresis 
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7.4.5 Running the gels for 2-D electrophoresis 
 
 
 
 271 
. 
7.4.6 Gel staining 
 
 
7.4.7Gel preservation 
 
 
  
 272 
7.4.8Analysis of 2D-gel 
 
   
 273 
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The working procedure for proteomics was prepared on the basis of previously 
reported article from our group [Al-Eisawi, Z., Beale, P., Chan, C. Yu, J and 
Huq, F., 2016, BMC Cancer,16: 688].
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7.5 APPENDIX-V Protein details identified from Caco-2 cells 
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7.6 APPENDIX-VI Protein details identified from Lim-2405 cells 
 
